About Lymphoma | Advocacy | Art | CAM | Clinical trials | Doctors - Experts - Centers | Guidelines at Diagnosis | News
Risk Factors | Side Effects | Statistics | Support | Symptoms | Tests | Treatments | Types of Lymphoma

Search Site         Guidelines at Diagnosis | About Clinical Trials            How to Help!

Patients Against Lymphoma

 


Current News >  Archived News Items
 

ARCHIVE

Some links to outside sources
may be discontinued by the provider
over time

 

 

Tuesday, February 11

Select "lymphomation" items posted by Anjou, Carol, and Karl for Patients Against Lymphoma - sometimes with comment.
Please feel free to share items of interest -- or your questions -- by sending an email to support.

*  JCO, 2010:
Second Malignant Neoplasms in Survivors of Pediatric Hodgkin's Lymphoma Treated With Low-Dose Radiation and Chemotherapy http://bit.ly/1m33v6f

Cumulative incidence of first second malignant neoplasms (SMN) was 17% (95% CI, 10.5 to 26.7) at 20 years after HL diagnosis. The standard incidence ratio (SIR*) for any second malignancy was 22.9 (95% CI, 14.2 to 35) with an absolute excess risk of 93.7 cases per 10,000 person-years.

Standard Incidence ratio (
SIR): "The expected number is calculated by multiplying each age-specific cancer incidence rate of the reference population by each age-specific population of the community in question and then adding up the results. If the observed number of cancer cases equals the expected number, the SIR is 1. If more cases are observed than expected, the SIR is greater than 1. If fewer cases are observed than expected, the SIR is less than 1.  www.state.nj.us
 

Monday, February 10

*Lymphoma Hub 2014: for oncologists mainly
Prognostic tool outperforms standard IPI in DLBCL http://bit.ly/1oaEBjz

The authors recommend that patients in the low-risk group should be treated with conservative chemotherapy, while those in the high-risk group should be given intensive treatment with stem-cell transplant and/or novel targeted agents.

* Fox Chase 2014: frequently asked question
Can a Patient Be Too Old for Stem Cell Transplant? http://bit.ly/1bEKk92

Recent studies have clearly demonstrated that older patients reported similar benefits from transplant when compared with younger patients. There is no clear way to define “young” or “old” when it comes to patients. ....

*NY Times 2014:  communications
Lost in Clinical Translation http://nyti.ms/1fWALXH

A classic “Far Side” cartoon shows a man talking forcefully to his dog. The man says: “Okay, Ginger! I’ve had it! You stay out of the garbage!” But the dog hears only: “Blah blah Ginger blah blah blah blah blah blah blah blah Ginger …”

* Science Based Medicine 2014:
The return of the revenge of high dose vitamin C for cancer http://bit.ly/1oaFUPG

 

Sunday, February 9

Select "lymphomation" items posted by Anjou, Carol, and Karl for Patients Against Lymphoma - sometimes with comment:

* ASCO Post: “Major Cancer Advances in 2013 Highlight Importance of Federal Funding” http://bit.ly/1dzCa1p

The resulting databases are available to researchers worldwide and can facilitate the search for new targeted therapies. While developing targeted treatments is generally the province of drug and biotech companies, discovery of the target has often been in federal laboratories or with federal dollars, Dr. Schilsky noted.

The report also recommends more support for clinical trials in general and the NCI-sponsored cooperative groups, now consolidated into the National Clinical Trials Network, in particular. It notes that long-planned trials have not been able to open for patient enrollment and that as a result, the number of patients taking part in clinical trials has dropped from a high of more than 29,000 a year in 2009 to 20,000 in 2013.


* The ASCO Post Lenalidomide/Rituximab Doublet a Potential Front-Line Treatment in Some Lymphomas http://bit.ly/1dZk9cT

* The ASCO Post ‘R-Squared’ Lymphoma Treatment: Possible Markers of Response Identified http://bit.ly/1inMYow
*  PAL query: Lenalidomide (immune modulation) with Rituxan  Find trials
 

 

Saturday, February 8

Select "lymphomation" items posted by Anjou, Carol, and Karl for Patients Against Lymphoma - sometimes with comment:

*  Fred Hutchinson CRC 2014:
New drug shows promise in treating indolent non-Hodgkin lymphomas http://bit.ly/1dwtmcv
See also Idelalisib / GS-1101 (formerly CAL101)  Find trials
relapsed CLL, MCL, WM, and lymphoma, single agent or with Rituxan
* Brian Koffman's Blog 2014:
ASH 2013: Dr. Jennifer Brown Discusses the New Data on Obinutuzumab (GA-101 or Gazyva) http://bit.ly/1ip5KMf
See also GA-101 (Obinutuzumab), next generation cd20 antibody  Find trials
* Clinical Oncology News 2014:
CAR T-Cell Therapies: Positive Early Results http://bit.ly/1nhfJU7
See also Cd19 CAR T-cell therapy  Find trials 
chemotherapy-refractory CLL / Lymphoma

*In the Pipeline 2014:
The Evidence Piles Up: Antioxidant Supplements Are Bad For You http://bit.ly/1iDMWsf

*J Clin Onc 2014:
Role of Radiotherapy to Bulky Disease in Elderly Patients With Aggressive B-Cell Lymphoma. http://1.usa.gov/1iyFkaY

*Am J Hem 2014:
Role of routine imaging in detecting recurrent lymphoma; a review of 258 patients with relapsed aggressive non-Hodgkin and Hodgkin lymphoma. http://1.usa.gov/1f2C6bp

* Clinical Oncology News 2014:
ASH 2013: Study Suggests Wider Use of Half-Match Transplant-Immediate implications for transplantation referral http://bit.ly/NgLzpw

* NYT 2014
Living With Cancer: An Artist’s View http://nyti.ms/Mzjysp

* Int J Cancer 2014:
Cytokines in serum in relation to future non-Hodgkin lymphoma risk: Evidence for associations by histologic subtype. http://1.usa.gov/1jl5AIW

* J NCI 2014:
Crizotinib in advanced, chemo-resistant anaplastic lymphoma kinase-positive lymphoma patients. http://1.usa.gov/1ezA6g2

* Brian Koffman Blog 2014:
ASH 2013: Giora Sharf and Jan Geissler Discuss Mediation Adherence or “Drugs don’t work in patients who don’t take them.” – C. Everett Koop http://bit.ly/1iDK4LS

*Diagn Interv Radiol 2014:
Fluorine-18 fluorodeoxyglucose PET-CT for extranodal staging of non-Hodgkin and Hodgkin lymphoma. http://1.usa.gov/LY93io

* MNT 2014:
Caregiving and psychological stress http://bit.ly/1aYUg2s

* Lymphoma Hub 2014:
Obese patients with DLBCL have “improved OS” http://bit.ly/1lxQ2mF

* BBC 2014:
Cancer 'tidal wave' on horizon, warns WHO http://bbc.in/MWxnly
* Science Daily 2014:
Why cancer incidence increases with age http://bit.ly/LNWPZv
* Posted to PAL cost page:
News Article : More Assistance Programs to Accept Medicare Beneficiaries http://bit.ly/1cfCwL0 

Dated but relevant to current concerns about high out of pocket costs for on-patent cancer drugs:

BETHESDA, MD, 12 May 2006—A growing number of drug manufacturers are rethinking their decisions to bar Medicare beneficiaries from patient assistance programs (PAPs).

The AstraZeneca Foundation announced Wednesday that its assistance programs are now open to all Medicare beneficiaries who meet financial and eligibility criteria. The programs had previously been closed to Medicare beneficiaries who had enrolled in a Part D prescription drug plan.

Also this month, two companies—GlaxoSmithKline and ELi Lilly— announced that qualified Medicare beneficiaries who do not sign up for a Part D drug plan can enroll in the companies' assistance programs. Both companies had previously stated that all Medicare beneficiaries would be ineligible for the programs.

 

Friday, February 7

Select "lymphomation" items posted by Anjou, Carol, and Karl for Patients Against Lymphoma - sometimes with comment:

* Ther Adv Hematol v.4(3); Jun 2013
Clinical implications and prognostic role of minimal residual disease detection in follicular lymphoma http://1.usa.gov/1cc7vr2

* Study completed - will evaluate role of MRD in assessment:
Zevalin® First Line in Follicular Lymphoma - Full Text View - ClinicalTrials.gov http://1.usa.gov/1o2eg7x

ASCO Answers: |
Managing the Cost of Cancer Care  http://ow.ly/tjnGz

Includes Financial resources.

5 years ago today, we released the first edition of our booklet for patients and caregivers on managing the cost of care. And, it’s gone through several updates since then, including for 2014! Get our new update of “Managing the Cost of Cancer Care” (PDF).
* Test overuse: Why does it happen and what can we do about it? http://bit.ly/1eFVluY
* Study of interest:
Testing GDC-0199 (ABT-199) with CHOP-R for non-Hodgkin's lymphoma ClinicalTrials.gov http://1.usa.gov/1isYhvH

Not yet recruiting

There is considerable interest in ABT-199, an agent that targets the inhibitors of apoptosis -- based on significant single-agent activity in early studies. This study will evaluate different doses of the study drug with standard R-CHOP and also a new version of the Rituxan antibody called Obinutuzumab.

See also Targeting Apoptosis http://www.lymphomation.org/apoptosis.htm for background on ABT199
==
* BMT 2014: “Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how?” http://bit.ly/1eyiWiF 

Speaks to an urgent unmet need and novel approaches.  Encouraging that pd-1 antibody was noted as a possible advance - as I wasn't sure if I was overestimating the significance of the recent report by Leo Gordon's group on pd1 consolidation after transplant.  No mention of CART 19 ... which is another very promising approach for patients with lymphoma refractory to chemo. (Karl)
* Multi Media Presentations on Radiation Protection &
Radiation Safety Training   
Excellent explanation of dosing, effective dose, etc.,  with animations.  Added to radiotherapy and CT safety topics.
* PAL update to Minimal Residual Disease testing
* Am Soc Clin Oncol Educ Book 2014:
Targeting CD30 in Hodgkin Lymphoma: Antibody-Drug Conjugates Make a Difference. http://1.usa.gov/1mQ94mm

* NEJM:
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma  http://bit.ly/1jJAyrl

* KevinMD 2014:
After a medical mistake: Honesty is the best policy http://bit.ly/M1wV4U

* NYT 2014
Living With Cancer: Life of the Party http://nyti.ms/1hQlkQI
 

Tuesday, February 4

Select "lymphomation" items posted by Anjou, Carol, and Karl for Patients Against Lymphoma - sometimes with comment:

*MNT 2014:
Caregiving and psychological stress http://bit.ly/1aYUg2s

* Lymphoma Hub 2014:
Obese patients with DLBCL have “improved OS” http://bit.ly/1lxQ2mF

* Brian Koffman's Blog 2014:
ASH 2013: Dr. Jennifer Brown Discusses the New Data on Obinutuzumab (GA-101 or Gazyva) http://bit.ly/1ip5KMf

* BBC 2014:
Cancer 'tidal wave' on horizon, warns WHO http://bbc.in/MWxnly
 

Monday, February 3

Select "lymphomation" items posted by Anjou, Carol, and Karl for Patients Against Lymphoma - sometimes with comment:

* Walter and Eliza Hall Inst 2014:
Red alert: Body kills 'spontaneous' blood cancers on a daily basis http://bit.ly/1fmBkY9

* Leuk Lymph 2014:
Phase III Safety Study of Rituximab Administered as a 90-minute Infusion in Patients With Previously Untreated Diffuse Large B-Cell and Follicular Lymphoma. http://1.usa.gov/1afEcbW

* Thinking outloud a cancer blog 2014:
1 Year Post-Chemo: 10 More Things I've Learned From Cancer http://bit.ly/1i5Gnyh

* What Next 2014:
Be Prepared: 22 Things to Bring to Chemo http://bit.ly/1kvFd0B

* MSKCC 2014:
What You Need to Know about Non-Hodgkin Lymphoma http://bit.ly/1j0GleJ

* Cancer 2014:
Insurance status is related to diffuse large B-cell lymphoma survival. http://1.usa.gov/1fmx4b6

** Items of interest for those who are developing study concepts for lymphoma:
** Lymphoma hub 2014:
Use hematopoietic cell transplantation “early” in chemotherapy-sensitive mantle cell lymphoma http://bit.ly/1eIcPTH
** Blood 2014:
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. http://1.usa.gov/1fmwRol

** Proc Natl Acad Sci U S A. 2014:
High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. http://1.usa.gov/1eiyeIg

 

Friday, January 31

We feel that the opportunity for patients to benefit by participation in clinical trials has never been higher – however patients and treating physicians cannot consider trials unless informed about the new agents, the outcomes reported so far, and which study protocols are best matched with the patients clinical circumstances and needs.

See PAL resources to foster participation in trials PAL

Select "lymphomation" items posted by Anjou, Carol, and Karl for Patients Against Lymphoma - sometimes with comment:

* PAL topic: update and resource added
Off-label use of cancer drug PAL
 
* Huff Post 2014:  important to note!
Your Cancer Is Not My Cancer: The Danger of Comparison http://huff.to/1i9r6gF
* Science Daily 2014:
Concerned about the health risk of soda? http://bit.ly/1ecctd7
Well written review of study has been in the news recently

* Oncology Times 2014: Important debate!
Hodgkin Lymphoma: Brentuximab Active in Relapsed Disease, but Use as Maintenance Debated http://bit.ly/1ifxing

Younes said he does send some of his patients in this setting to allogeneic transplant, but he does not consider it the standard of care. His algorithm for patients with less than a complete remission or a relapse after autologous transplant is treatment with brentuximab. Those achieving a CR in his practice continue on observation, he said. “I don't rush them to transplant because if they relapse I can use brentuximab vedotin again, with allogeneic transplant always an option.”

* Oncology Times 2014:
For CLL and Myeloma Patients, MRD Remains Uncertain Goal http://bit.ly/1aLFPic

Kay, MD:  “Right now, we conventionally use clinical trial data for progression-free survival and overall survival estimates, but you'd have to be immortal to use those in routine trials. But if you could substitute MRD as a surrogate for progression-free or overall survival you could shorten clinical trials, test the promising new drugs more quickly, and then if they are effective, bring them to the patient in a reasonable time frame.”

Furman, MD:  The new tyrosine kinase inhibitors cause preferential lymphocytosis by interfering with adhesion molecules that hold the cells in the lymph nodes and in the different niches, ... “So I believe that MRD status will have lost its predictability and its importance when we deal with these tyrosine kinase inhibitors.”


* The Oncology Nurse Community 2014:
Cancer of the Hangnail http://bit.ly/1ehAXjD

* Nature 2014:
Antioxidants speed cancer in mice: Study suggests supplements such as vitamin E promote tumour growth. http://bit.ly/1bzHQIJ

* MNT 2014:
Vitamin D supplements: are they really good for our health? http://bit.ly/1a5l1S5

* The ASCO Post:
Science Magazine Names Cancer Immunotherapy as Scientific Breakthrough of the Year http://bit.ly/LstHXyc
* Related trial of interest:
Safety Study of Anti-Programmed Death-1 in Hematologic Malignancy http://1.usa.gov/Q9kY96

for non-Hodgkin's lymphoma or Hodgkin lymphoma must have at least one measureable lesion > 1.5 cm

Wednesday, January 29

* PAL topic: update and resource added
Off-label use of cancer drug PAL
 
bullet
NCI: Off-Label Drug Use in Cancer Treatment - About Off-Label Drugs   
* the Onc 2014:
What Not to Say http://bit.ly/1egxYIf

* Huff Post 2014;
Your Cancer Is Not My Cancer: The Danger of Comparison http://huff.to/1i9r6gF

* Lymphoma Hub 2014:
Idelalisib–rituximab combination superior to rituximab alone in relapsed CLL http://bit.ly/1dMFypt

* Oncology Times 2014:
ONLINE FIRST: Improved Access to Stem Cell Transplants for Elderly, Ethnic Patients http://bit.ly/1dMGWbD

* J Clin Onc 2014:
Treatment of Hodgkin Lymphoma: A 50-Year Perspective http://bit.ly/1cQCRD0  (link to full article)

* KevinMD 2014:
The truth about juicing http://bit.ly/1gnnoCp

* MNT 2014:
Many internists don't feel equipped to manage care of adults who had cancer as children http://bit.ly/19ZqVUP

 

Monday, January 27

Select "lymphomation" items posted by Anjou, Carol, and Karl for Patients Against Lymphoma - sometimes with comment:

* Weill Cornell 2014:
Two Modes of DLBCL Relapse http://bit.ly/19XkYrp
* MNT 2014:
Leukemia pill 'can melt away' cancer cells http://bit.ly/1jXbWvn

* Medscape 2014:
Subcutaneous Rituximab Recommended in the EU http://bit.ly/1aCCu4O

* NYTimes 2014:
How Long Have I Got Left? http://nyti.ms/M2oPsa  

* evertday Health 2014;
It’s Not a War. It’s Not a Football Game. It’s Cancer, and It’s Scary, Okay? http://bit.ly/1iBNqlM
(Ethan Zohn, hodgkin's survivor)

* Respectful Insolence 2014:
Cancer quack Robert O. Young is arrested and arraigned, but will he be convicted? http://bit.ly/19XkmSG
* Time out!
  Andy Griffith on football (1953) YouTube http://bit.ly/1cltYWv 
 

Sunday, January 26

Select "lymphomation" items posted by Anjou, Carol, and Karl for Patients Against Lymphoma - sometimes with comment:

* Positive developments last week for Idelalisib reported in the NEJM for CLL and for NHL

* PAL background on Idelalisib

* NEJM: Idelalisib in Patients with Relapsed Indolent Lymphoma  http://bit.ly/1jJAyrl
* NEJM: Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia — http://bit.ly/1aV2iXv

PAL Query: Idelalisib / GS-1101 (formerly CAL101)   Find trials
* The ASCO Post Mounting Success in Trials of Genetically Engineered T Cells to Treat Leukemias and Lymphomas http://bit.ly/KXVaPV 

SNIP: ‘Smart Bomb’ Approach: The promise of the “smart bomb” approach with this immunologic therapy has attracted industry to partner with some investigators and their institutions. For example, CAR-T cells developed at the National Cancer Institute have been licensed to Kite Pharmaceuticals, and CAR-T cells developed at the University of Pennsylvania have been licensed to Novartis. In fact, Novartis is building a manufacturing facility to produce these cells near the University of Pennsylvania campus. Most recently, Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center, and Seattle Children’s Research Institute have joined forces to launch Juno Therapeutics, a new biotechnology company that will develop CAR-T cells.

PAL query:  Cd19 CAR T-cell therapy:  Find trials 
chemotherapy-refractory CLL / Lymphoma


* KevinMD 2014:
When undergoing chemotherapy, savor the small victories http://bit.ly/1aTXC14

* Br J Hem. 2014:
Autologous stem cell transplantation for follicular lymphoma is of most benefit early in the disease course and can result
in durable remissions, irrespective of prior rituximab exposure.
http://1.usa.gov/1dXOC0N

* Chemotherapy 2014:
Bendamustine as Monotherapy and in Combination Regimens for the Treatment of Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma: A Retrospective Analysis. http://1.usa.gov/1laelXP
* PAL: update
Maintenance Rituxan after initial therapy - tradeoffs  PAL
* NEJM:
Idelalisib in Patients with Relapsed Indolent Lymphoma  http://bit.ly/1jJAyrl

PAL Query: Idelalisib / GS-1101 (formerly CAL101)   Find trials

Thursday, January 23

Select "lymphomation" items posted by Anjou, Carol, and Karl for Patients Against Lymphoma - sometimes with comment:

* PAL: perspective Pathways to Progress - 2014
* PAL update to Minimal Residual Disease testing
* NYTimes.com
 New Truths That Only One Can See -  http://nyti.ms/1g4qdZb  (Thanks, Paul)

It has been jarring to learn in recent years that a reproducible result may actually be the rarest of birds. Replication, the ability of another lab to reproduce a finding, is the gold standard of science, reassurance that you have discovered something true.

* BIG news! - Dr Sharman 2014:
Idelalisib prolongs survival in CLL http://bit.ly/1jEi6QV

* Weill Cornell 2014:
A pill 'melts away' common form of leukemia: Results on test of Idelalisib suggest CLL may be treated without toxic chemotherapy http://bit.ly/1eguuBT

* Medscape 2014:
Idelalisib Shows Efficacy in Relapsed CLL and Lymphoma http://bit.ly/1eTtHIy

* Brian Koffman's Blog 2014:
Dosing of Ibrutinib and Other Oral Agents http://bit.ly/1jBWN2z

* Cancer Research Inst 2014:
You Wanted to Know "What the Hell is Immunotherapy." We Answered. http://bit.ly/1jwOuVB

* KevinMD.com 2014;
Twitter and cancer patients: What to make of the outrage? http://bit.ly/KAm5Sh

* Medscape 2014:
FDA Drug Approvals: Quality of Evidence Varies Widely http://bit.ly/1aM72vA

* Deutsches Aerzteblatt International 2014:
Breast cancer in young women after treatment for Hodgkin's disease http://bit.ly/KI6cJD
 

Tuesday, January 21

Select "lymphomation" items posted by Anjou, Carol, and Karl for Patients Against Lymphoma - sometimes with comment:

* PAL: perspective Pathways to Progress - 2014
* Increasing number of trials for Pd1/L antibodies for lymphoma http://bit.ly/QlPona
See also background on immune checkpoint blockade with links to trials.
* J Clin Onc2014:
Treatment of Hodgkin Lymphoma: A 50-Year Perspective http://bit.ly/1cQCRD0

* Science Based Medicine 2014:
Stanislaw Burzynski: Using 1990s techniques to battle the FDA today http://bit.ly/1eMRcD4

* Brian Koffman's blog 2014:
iwCLL 2013: Dr. Byrd Discusses If and When to Stop and the Long Term Use of Ibrutinib http://bit.ly/1hDVXS9

Important questions raised here - that will be challenging to answer. (Karl)

* MSKCC 2014:
How do I know if a dietary supplement contains what the label says it contains? http://bit.ly/1mhYIsk

*KevinMD.com 2014:
Beyond Dr. Google: How new technologies will affect patient-provider relationship http://bit.ly/1bbFOhA

* Lymphoma Hub 2014:
Rituximab maintenance cost-effective in real-world patients with relapsed FL http://bit.ly/1mn09FZ

Comment: This report is specific to the relapsed setting.  In the PRIMA study testing the first line use of maintenance both arms of this large study had equivalent (excellent) overall survival at 6 years. (Karl)

* Bone Marrow Transplant 2014:
Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all!
http://1.usa.gov/1mAJpOu
 

 

Sunday, January 19

Select "lymphomation" items posted by Anjou, Carol, and Karl for Patients Against Lymphoma - sometimes with comment:

* PAL added 2 resources to DLBCL page on relapsed disease
* Lorig, RN: Speaking on behalf of patients is not the same as speaking as a patient http://bit.ly/1aBPpS5
* Hutchings, Medscape:  Expert review
PET Imaging in Lymphoma http://bit.ly/19F57NU
* Leuk Lymph 2014:
Symptom-oriented clinical detection versus routine imaging as a monitoring policy of relapse in patients with diffuse large B-cell lymphoma. http://1.usa.gov/19CxZ9K

* Leuk Lymph 2014:
Is there a role for therapy response assessment with FDG-PET/CT in Mantle cell Lymphoma? http://1.usa.gov/1kJKjtF

* Br J Hem 2014:
Incidence of marginal zone lymphoma in the United States, 2001-2009 with a focus on primary anatomic site http://1.usa.gov/1eIGrBI

* Br J Hem 2014:
Improved population level survival in younger Hodgkin lymphoma patients in Germany in the early 21st century. http://1.usa.gov/1dEHvKx

* Br J Cancer 2014:
Chronic fatigue in Hodgkin lymphoma survivors and associations with anxiety, depression and comorbidity. http://1.usa.gov/1h0B9U3

* Maclean's 2014:
When science isn’t science-based: In class with Dr. John Ioannidis http://bit.ly/1gY60Ra

* Ottowa Citizen 2014:
Reluctant panhandler Scott Murray ‘flabbergasted’ by strangers’ kindness http://bit.ly/1eSv64c

* Sunrise Rounds 2014:
Doctors often don’t have the time to address social slander http://bit.ly/1eStace

* Cancer Research Institute 2014:
Cancer Immunotherapy: The Next Decade? http://bit.ly/1dwr5RQ

Nice review of recent advances (Karl)

* LeuK Lymph 2014:
High dose chemotherapy with autologous stem cell transplantation for patients with transformed B-cell non-Hodgkin lymphoma in the rituximab era. http://1.usa.gov/KqjPwl


 

Friday, January 17

Select "lymphomation" items posted by Anjou and Karl for Patients Against Lymphoma - sometimes with comment:

* Dr Sharman 2014;
Talking to friends and loved ones http://bit.ly/1kH3iVy

* KevinMD.com 2014:
Thoughts after being diagnosed with cancer http://bit.ly/1dCrx1Y

*  kevinmd.com 2014:
Prevention, detection, and treatment of cancer has become more nuanced http://bit.ly/1avYVmL

* Cancer Network 2014:
What Did We Learn in 2013? http://bit.ly/1ePdlCQ (registration required)

* What Next 2014:
20 Things We Want Strangers to Know About Having Cancer http://bit.ly/19ydg6L

* News Medical 2014:
US underestimated its progress in war on cancer, say Dartmouth researchers http://bit.ly/1fBRP7E
*  Unsustainable prices of cancer drugs: from the perspective of a large group of CML experts - bloodjournal.hematologylibrary.org: Rising Costs and  Access to Quality Cancer Care  

The doctrine of justum pretium, or just price, refers to the “fair value” of commodities. In deciding the relationship between price and worth (or value), it advocates that, by moral necessity, price must reflect worth. This doctrine may be different from the doctrine of free market economies where prices reflect “what the market bears,” or what one is willing to pay for a product.

Which doctrine is better? One could argue that when a commodity affects the lives or health of individuals, just price should prevail because of the moral implications. Examples include the price of bread during famines, polio vaccine, ivermectin for river blindness (provided for free by Merck and estimated to have saved the vision of 30 million individuals), and treatments of chronic medical conditions (cardiovascular, hypertension, diabetes, tuberculosis, multiple sclerosis, etc). When commodities are not essential to life or suffering, what the market will bear is appropriate (competition will take care of price) because it is not restrained by ethical considerations. Examples include the price of a Picasso painting, a luxury cruise, a 2-week vacation in New York (or 4 weeks in Houston), a Bentley car, a Brioni suit, etc.

 

Thursday, January 16

Select "lymphomation" items posted by Anjou and Karl for Patients Against Lymphoma - sometimes with comment:

* Oncology Times 2014;
Burkitt Lymphoma: Low-Intensity Therapy Shown as Highly Effective http://bit.ly/1m64DRl

* Oncology Times 2014:
CLL: Can IMiDs & TKIs Replace Chemotherapy? http://bit.ly/1clEHM3
* Medscape 2014:
Rituximab, Abatacept May Interfere With Influenza Vaccine http://bit.ly/1m7TLT1

""If it is practically possible, patients planning to start rituximab should get immunized against influenza before treatment initiation. In patients who have been taking rituximab, the probability of initiating a protective immune response is best if H1N1 vaccination is performed a few weeks before the next rituximab course," Dr. Kapetanovic explained."
 
* Upworthy 2014:
Everything you Wanted to Know About Cancer But Your Doctor Was Too Busy To Tell You  
Good intro into the basics about cancer and how standard therapies work.

* Digital Journal 2014:
Narrow Networks and High Cost-Sharing Among Concerns Raised by New Report on Affordable Care Act from The Leukemia & Lymphoma Society http://bit.ly/1apFcov

Comment: It's important to choose wisely on the exchange - if feasible: to choose plans that have lower out of pocket cost sharing.

* Support Care Cancer 2014:
Role of oncologists and primary care physicians in providing follow-up care to non-Hodgkin lymphoma survivors within 5 years of diagnosis: a population-based study. http://1.usa.gov/1aHsRj6

* MNT 2014:
Growing artificial bone marrow http://bit.ly/KjQtjl

* NYtimes 2014:
After Cancer ‘Disruption,’ a Determined Comeback http://nyti.ms/1a81zEH


* Science Daily 2014:
Research Shows Early Promise of New Drug for Cancers Caused by Viruses http://bit.ly/1kB1BZX

After documenting the role of an enzyme called sphingosine kinase (SK), in the generation of biologically active sphingolipids in PEL tumors that keep the tumor cells alive, the researchers tested a novel clinical-grade small molecule that selectively targets SK.

Clinical trials: clinicaltrials.gov/ for sphingosine kinase (none yet for lymphoma)

* CBC New 2014:
Dr. C: We've all got stories to tell, about cancer and more: Dr. Nikhil Joshi has found sharing his story healing http://bit.ly/1j5nWNC

* You Tube 2014:
Risk Factors for Lymphoma http://bit.ly/1ktmsvI

* AACR journal: Catch-22 for Cancer Tests http://bit.ly/1aBUKZQ

It seems that a similar "catch" prevents researchers from moving forward with biomarkers:  it won't be used as an integral part of the study (to select patients) unless previously validated, and can't be validated unless previously tested in a prospective study. (Karl)
NEJM, 2014: Global Trends in Biomedical R&D Expenditures — http://bit.ly/1alcRmo 

For skeptics of government-funded research: In 2012, NIH funding accounted for $30.9 billion of the R&D investment in the United States. U.S. government funding contributed to the development of 48% of all drugs approved by the Food and Drug Administration (FDA) and 65% of drugs that have received priority review between 1988 and 2005.1
* PAL trial of interest:
T Cells Engineered to Contain Anti-CD19 ... in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas
PAL - Clinical Trials of Interest  

Updated background on CARs by PAL

 

Tuesday, January 14

Select "lymphomation" items posted by Anjou and Karl for Patients Against Lymphoma - sometimes with comments:

* AACR journal: Catch-22 for Cancer Tests http://bit.ly/1aBUKZQ

It seems that a similar "catch" prevents researchers from moving forward with biomarkers:  it won't be used as an integral part of the study (to select patients) unless previously validated, and can't be validated unless previously tested in a prospective study. (Karl)
NEJM, 2014: Global Trends in Biomedical R&D Expenditures — http://bit.ly/1alcRmo 

The National Institutes of Health (NIH) has been a key enabler of the global dominance of the United States in biomedical research and development (R&D). In 2012, NIH funding accounted for $30.9 billion of the R&D investment in the United States. U.S. government funding contributed to the development of 48% of all drugs approved by the Food and Drug Administration (FDA) and 65% of drugs that have received priority review between 1988 and 2005.1
* PAL trial of interest:
T Cells Engineered to Contain Anti-CD19 ... in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas
PAL - Clinical Trials of Interest  

Updated background by PAL

* infoEXCHANGE
Suicide Threats on Social Network Sites http://www.sprc.org/sites/sprc.org/files/library/Suicide_threats_on_social_network_sites.pdf

* Lifescience online 2o13:
Studies Evaluating REVLIMID® (Lenalidomide) in Lymphoma Presented at ASH
Posted to PAL- Lenalidomide mechanisms of action  

* Yottafire 2014:
NEJM study evaluates early stem cell transplants for non-Hodgkin’s lymphoma http://bit.ly/1a1oQrR

* Helio 2014:
Lymphoma expert elected ASCO president for 2015-2016 term http://bit.ly/1af5OIJ

* Brian Kauffman's Blog 2014:
The News about Ibrutinib from My Infusion Chair, The Resonate Trial, and Lancet Oncology http://bit.ly/1cXi00C

* Br J Haematol. 2014:
The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. http://1.usa.gov/1eMlqGK
* PAL update:
Guidance on how to report symptoms - and why it's important that we do so! PAL: reporting symptoms 
* NPR - off topic (sort of) history of science-based protection of public health:
The Poisoner's Handbook - American Experience - PBS (must see - but long)  

 

Saturday, January 11

Select "lymphomation" items compiled by Anjou and Karl for Patients Against Lymphoma - sometimes with comments:

* Dr Sharman's Blog 2014: highly recommended read
Relapsed Diffuse Large B Cell Lymphoma http://bit.ly/1ewMVUn
* Common Misconceptions in the Management of H-Pylori-associated Gastric MALT-lymphoma
     That ... Antibiotic Treatment Has No Role in the Management of H. pylori-negative MALT Lymphoma" http://bit.ly/1iqPvxS 
* Helio 2014:
Lymphoma expert elected ASCO president for 2015-2016 term http://bit.ly/1af5OIJ

* OncLive 2014:
Brentuximab Vedotin Should Not Be Combined With Bleomycin in First-Line Treatment of Hodgkin Lymphoma http://bit.ly/1a3m8iT

* Medscape 2014:
CLL Trial Stopped as Ibrutinib Shows Significant Benefits http://bit.ly/1evkDte
SNIP: All patients were at least 65 years of age, and most patients (74%) were at least 70 years old. They all received oral ibrutinib once daily at a dose of 420 mg (some initially received the higher dose of 840 mg, but this was discontinued after comparable activity of the 2 doses was shown).

After a median follow-up of 22.1 months, a complete response was reported in 4 patients (13%), a partial response in 17 (55%), and a nodular partial response in 1 (3%). The overall objective response rate was 71% (22 of 31 patients).

* MNT 2014
Potential new target for many cancers http://bit.ly/1iWyuyz

* USA Today 2014:
Texas charges controversial doctor with false ads http://usat.ly/1aIWLjp

* Respectful Insolence 2014:
It’s 2014, and Stanislaw Burzynski has begun his counteroffensive http://bit.ly/1eus2sN
 
* PAL - new and recently updated topics:
Minimal Residual Disease status  | Biomarkers  | Find Trials by Agents of Interest | Rising Costs and  Access to Quality Cancer Care | Agents that target disease pathways brochure  | Off-label use of treatments for lymphoma Agents that target apoptosis | Epigenetic agents | antibody-drug conjugates  | Lenalidomide mechanisms of action
How to Help  Please give what you can to support our mission. 

Giving Thanks! ... which are due for most recent and generous donations by Bill (today), Scott (recent) Jeffrey (recent), Iva (recent),  Rebecca (recent), Scott, Mark Phyllis, Teresa, Mina, Doug/Barb David,  Mary, Mark, Jama, Daniel , Judith, Bill, Phillip,  Elizabeth , Toby,  Patricia, Gail, Tina Paul, Erin, Steve, Betty, Leonard, Carol, Naomi , Marshall, Nancy, Dennis, David, Cheryl,  Susan, and Jane ...
 

Thursday, January 9

Select "lymphomation" items compiled by Anjou and Karl for Patients Against Lymphoma - sometimes with comments:

* Common Misconceptions in the Management of H-Pylori-associated Gastric MALT-lymphoma

    Management of H. Pylori-associated Gastric MALT-lymphoma: Antibiotic Treatment Has No Role in the Management of H.     pylori-negative MALT Lymphoma http://bit.ly/1iqPvxS 
* Herald Sun News 2014: Early but interesting
Melbourne scientists' discovery gives hope of new fight against cancer http://bit.ly/1iV6MC8

* American Psychological Association Monitor 2014:
Facing Cancer Together http://bit.ly/1czTvdf
* TedTalks 2014:
Roger Stein: A bold new way to fund drug research http://bit.ly/1lOdW8c
* News Medical 2014:
Cancer cells less likely to develop resistance when multiple drugs delivered simultaneously http://bit.ly/19PT54P
* Scientific American Blogs 2014:
Why drug discovery is hard – Part 2: Easter Island, Pit Vipers; Where do drugs come from? http://bit.ly/1dNM2bJ
* Medscape 2014:
US Cancer Death Rates Continue to Drop, Says ACS http://bit.ly/1idu6bz
* Innovations Report 2014:
Out-of-pocket costs play major role in treatment adherence for cancer patients http://bit.ly/1gBYhZv

"Your money or your life!"  Already, we have heard from investigators that patients have declined ibrutinib because of the “financial toxicity.”  Karl
* 2014 Physician's Desktop Reference (PDR) eBook |
available for download or use on the web (Carol) http://bit.ly/1a3TH4y
* PAL: Coming soon: 
Pathways to Progress - highlights of 2013: numerous pportunities and key challenges

Our notions about the most promising developments in the fight against lymphoma in year 2013 – and there were many! 
* PAL - new and recently updated topics:
Minimal Residual Disease status  | Biomarkers  | Find Trials by Agents of Interest | Rising Costs and  Access to Quality Cancer Care | Agents that target disease pathways brochure  | Off-label use of treatments for lymphoma Agents that target apoptosis | Epigenetic agents | antibody-drug conjugates  | Lenalidomide mechanisms of action
How to Help  Please give what you can to support our mission. 

Giving Thanks! ... which are due for most recent and generous donations by Bill (today), Scott (recent) Jeffrey (recent), Iva (recent),  Rebecca (recent), Scott, Mark Phyllis, Teresa, Mina, Doug/Barb David,  Mary, Mark, Jama, Daniel , Judith, Bill, Phillip,  Elizabeth , Toby,  Patricia, Gail, Tina Paul, Erin, Steve, Betty, Leonard, Carol, Naomi , Marshall, Nancy, Dennis, David, Cheryl,  Susan, and Jane ...
 

Tuesday, January 7

* Dana Farber 2013:
Excellent Web Conversation on lymphoma with Dr. Ann LaCasce
Posted to Talks by Experts on Lymphoma  
* OncLive 2014:
Researchers Aim to Improve Blood Cancer Outcomes With Engineered T-Cell Treatments - http://bit.ly/1iMg978

* Scientific Amer Blogs 2014:
Why drugs are expensive: It’s the science, stupid. http://bit.ly/1lKn4e0

* Respectful Insolence 2014:
Life is a fatal disease http://bit.ly/1da02hu

* NYTimes 2014:
Why Everyone Seems to Have Cancer http://nyti.ms/19W5QbJ

* Imedex 2013:
Long-term toxicity of CLL therapy http://bit.ly/1gA3fG2

* PAL - new and recently updated topics:

Minimal Residual Disease status  | Biomarkers  | Find Trials by Agents of Interest | Rising Costs and  Access to Quality Cancer Care | Agents that target disease pathways brochure  | Off-label use of treatments for lymphoma Agents that target apoptosis | Epigenetic agents | antibody-drug conjugates  | Lenalidomide mechanisms of action
How to Help  Please give what you can to support our mission. 

Giving Thanks! ... which are due for recent generous donations by Jeffrey (today), Iva (today),  Rebecca (today), Scott (today), Mark Phyllis, Teresa, Mina, Doug/Barb David,  Mary, Mark, Jama, Daniel , Judith, Bill, Phillip,  Elizabeth , Toby,  Patricia, Gail, Tina Paul, Erin, Steve, Betty, Leonard, Carol, Naomi , Marshall, Nancy, Dennis, David, Cheryl,  Susan, and Jane ...

Monday, January 6

How to Help  Please give what you can to support our mission. 

Giving Thanks! ... which are due for recent donations by Rebecca (today), Scott (today), Mark (today)  Phyllis, Teresa, Mina, Doug/Barb David,  Mary, Mark, Jama, Daniel , Judith, Bill, Phillip,  Elizabeth , Toby,  Patricia, Gail, Tina Paul, Erin, Steve, Betty, Leonard, Carol, Naomi , Marshall, Nancy, Dennis, David, Cheryl,  Susan, and Jane ...
* PAL: Draft of new topic page
Minimal Residual Disease (MRD) testing -  Minimal Residual Disease status

an investigational test using PCR amplification ... having the potential to predict the quality and duration of response to therapy.
* PAL: Quality of Life
Capturing and Evaluating Patient Reported Outcomes (PROs)  PAL
* PPM: Placebos in Pain Management http://bit.ly/1aysa80

A reason that studies recording patient reported outcomes (PPO) for new agents may need to have a placebo control

Sunday, January 5

* PPM: Placebos in Pain Management http://bit.ly/1aysa80

A reason that studies recording patient reported outcomes (PPO) for new agents may need to have a placebo control
* PAL Query:
Find Trials that apply MRD (minimal residual disease) testing with PCR

added to PAL's Biomarkers topic page
* PAL topic:  Epigenetic therapies  PAL

     background including videos ... and links to trials for this novel class of investigational therapy
*Huff Post 2014:
Love Is... (Holy S@#$$, I Have Cancer) http://huff.to/1bIAfqm
* The Economist 2014:
Getting close and personal http://econ.st/Kr8ugs
* Brian Kauffman's Blog 2014: iwCLL 2013:
Dr. Michael Hallek Discusses Clinical Trials in Germany versus the USA and BR versus FCR http://bit.ly/1gsbJPn
* NYT 2014:
Missing a Cancer Diagnosis http://nyti.ms/1a3OutL
* Consumer Repts 2013:
Don't mix your meds with these foods:
Some fruits, vegetables, and even some drinks can cause dangerous interactions http://bit.ly/19MDjFo
* Respectful Insolence 2014:
A fungus among us in oncology? (2014 edition) http://bit.ly/1evw2d1
* Cancer Treatment.met 2014:
Asparagus and Cancer Treatment http://bit.ly/JOCbHa
* edge 2014
Cancer’s Early Warning Signs http://bit.ly/JAwxbY
* KevinMD 2014:
Doctors cannot predict when the end of life truly comes http://bit.ly/1cRunzA

Saturday, January 4

* PAL - Find by agent: 
XmAb5574 / MOR00208 (optimized cd19 Mab) for CLL or Lymphoma
Posted to PAL - Find Trials by Agent Type  

MOR00208 is a novel humanized IgG1 CD19 monoclonal ab with an engineered Fc region to enhance ...
* PAL new study of interest: 
Urelumab and Rituximab for B-cell Non-Hodgkins Lymphoma or CLL - ClinicalTrials.gov
Posted to Find Trials by Agent Type
* PAL topic:  Targeting Apoptosis ...
     or more precisely:
Agents that inhibit the inhibitors of apoptosis  PAL

     background and links to trials for this class of investigational agents

     includes a VERY interesting and encouraging
video interview: Dr. John Seymour
      on the Efficacy of ABT-199 in High-Risk CLL 
* NEJM: Perspective 2013
Health Care Spending — A Giant Slain or Sleeping? — full text
Posted to PAL - Rising Costs and  Access to Quality Cancer Care  
NEJM
Engineered in India — Patent Law 2.0 — full text http://bit.ly/1iCyO5d

A patent law that treats incremental innovation and significant innovation in the same way encourages companies to prioritize less important research over more important research. Provisions like Section 3(d) can help reverse this effect and encourage companies to undertake the riskier and more expensive research that is required to generate breakthrough drugs.  Amen! (Karl)
* PAL updated content:
Find trials by agent - In the News with focus on agents with encouraging recent reports 
PAL find trials by type of AGENT

How to Help  Please give what you can to support our mission. 

Giving Thanks! ... which are due for recent donations by Rebecca (today), Scott (today), Mark (today)  Phyllis, Teresa, Mina, Doug/Barb David,  Mary, Mark, Jama, Daniel , Judith, Bill, Phillip,  Elizabeth , Toby,  Patricia, Gail, Tina Paul, Erin, Steve, Betty, Leonard, Carol, Naomi , Marshall, Nancy, Dennis, David, Cheryl,  Susan, and Jane ...

Thursday, January 2

* PAL topic:  Targeting Apoptosis ... or more precisely:
Agents that inhibit the inhibitors of apoptosis  PAL

background and links to trials for this class of investigational agents

Including
Video interview: Dr. John Seymour on the Efficacy of ABT-199 in High-Risk CLL 
* The Nocebo effect - this Video Will Hurt   http://bit.ly/1iwpCiR
Studies show how belief in harm can cause symptoms - can spread even from mind to mind.
A reason, perhaps, to avoid reading the list of possible side effects for that new drug you're about to take?
*The Atlantic 2014:
When Will Genomics Cure Cancer? A conversation with the biogeneticist Eric S. Lander about how genetic advances are transforming medical treatment http://bit.ly/19J7QUJ
*Imedex 2014:
Autoimmunity in CLL CLL & SLL in the News

*Leuk Lymph 2013:
Impact of 18F-FDG PET/CT Staging in Newly Diagnosed Classical Hodgkin Lymphoma:
Less Cases with Stage I Disease and More with Skeletal Involvement. http://1.usa.gov/1hTyWdP

*Blood 2013:
Whole-genome integrative analysis reveals expression signatures predicting transformation in follicular lymphoma. http://1.usa.gov/KiijNG

*MSKCC 2013:
Treatment Approaches for Localized and Systemic Lymphoma http://bit.ly/KhjInH

*Blood 2013:
Monoclonal B-cell lymphocytosis in healthy blood donors: an unexpectedly common finding http://bit.ly/Khjo8v

*Johns Hopkins:
Cancer Update Email -- It's a Hoax! http://bit.ly/JrIHnr
 

Tuesday, Dec 31

* PsychCentral 2013:
A New Type of New Year’s Resolution http://bit.ly/1cQaUkl
* Science-based Medicine 2013:
Doctors Are Not “Only Out to Make Money” http://bit.ly/JrFAfq
* NYTimes 2013:
Medical Billing Nears a New Era of Ultra-Specific Codes http://nyti.ms/1bwCHjK

* Flu shot recommended by expert:
Cancer Patients Vulnerable to Complications From Flu http://bit.ly/19x0nud
* Sunrise Rounds 2013:
Is giving false hope malpractice? http://bit.ly/1gdLgVH

* UMass 2013:  Early
Activating aging in tumor cells may be effective against lymphoma http://bit.ly/1fVRtVv

SNIP: The study, published in Nature Communications, details a novel, tumor-suppressive role for the Smurf2 protein—which typically plays an “enforcer” role in cellular aging, also called senescence —in a subset of DLBCL. Identification of this novel function for Smurf2 provides a new therapeutic target for treating this cancer.

* Youtube 2013:
Aggressive Non Hodgkin's Lymphoma: Michael Wang http://bit.ly/1cf4FE4

Focus on investigational protocols for Mantle Cell

* Targeted OncologyYoutube 2013
Updates from ASH 2013:
Dr. Amengual discusses dual targeting with an HDAC 6 Inhibitor and Bortezomib in lymphoma http://bit.ly/1jXyJup

Early:  New direction for epigenetic treatment - inhibiting HDAC 6 with ACY-215
* PAL updated today:
Biomarkers for lymphoma - about biomarkers, trials, perspectives, and resources  PAL
* PAL updated content:
Find trials by agent - In the News with focus on agents with encouraging recent reports  PAL find trials by type of AGENT

How to Help  Please give what you can to support our mission. 

Giving Thanks! ... which are due for recent donations by Phyllis, Teresa, Mina (today) , Doug/Barb David,  Mary, Mark, Jama, Daniel , Judith, Bill, Phillip,  Elizabeth , Toby,  Patricia, Gail, Tina Paul, Erin, Steve, Betty, Leonard, Carol, Naomi , Marshall, Nancy, Dennis, David, Cheryl,  Susan, and Jane ...

 

Sunday, Dec 29

* PAL updated today:
Biomarkers for lymphoma - about biomarkers, trials, perspectives, and resources  PAL
* PAL updated content:
Find trials by agent - In the News with focus on agents with encouraging recent reports  PAL find trials by type of AGENT

This NEW section helps to find trials for agents that have encouraging recent reports.
*Medscape 2013:
Top Clinical Cancer Advances: ASCO 2013 Report http://bit.ly/1hJJKLy

*ASCO 2013:
Talking With Someone Who Has Cancer, with Dr. Lidia Schapira http://bit.ly/1hGRMou

*MSKCC 2013:
Lymphoma Q&A http://bit.ly/K7B4U7

*Patient Power 2013:
Promising Advances in Treating Mantle Cell Lymphoma http://bit.ly/1ij2ZOG

*MNT 2013: discusses secondary targets as well
Study confirms target of potent chronic leukemia drug http://bit.ly/18OBcTf
How to Help  Please give what you can to support our mission. 

Giving Thanks! ... which are due for recent donations by Doug/Barb (today) David,  Mary, Mark, Jama, Daniel , Judith, Bill, Phillip,  Elizabeth , Toby,  Patricia, Gail, Tina Paul , Erin, Steve, Betty, Leonard, Carol, Naomi , Marshall, Nancy, Dennis, David, Cheryl,  Susan, and Jane ...

Just a few days remaining to make a tax-deductible contribution for 2013 to show your support for PAL's mission.

 

Friday, Dec 27

* PAL:   Message to supporters and advisors from the president: 
Thankful, encouraged, enthused, and determined PDF

How to Help 
Please give what you can to support our mission. 

Giving Thanks! ... which are due for recent donations by Mary (today), Mark (today), Jama (today),   Daniel , Judith, Bill, Phillip,  Elizabeth , Toby,  Patricia, Gail, Tina Paul , Erin, Steve, Betty, Leonard, Carol, Naomi , Marshall, Nancy, Dennis, David, Cheryl,  Susan, and Jane ...

Just a few days remaining to make a tax-deductible contribution for 2013 to show your support for PAL's mission.

*  NEJM: Perspective, full text:
First FDA Authorization for Next-Generation Sequencer Francis S. Collins, M.D., Ph.D., Margaret A. Hamburg, M.D. http://bit.ly/1dAzWQQ

*ASCO Post 2013:
“The Quest to Optimize Personalized Therapies for Cancer -- A Conversation With Brian J. Druker, MD” http://bit.ly/1a85k73
* ASCO post 2013:
“Sustained Complete Responses With Novel Immunotherapy in Lymphoma” http://bit.ly/1dCMEyI 
*ASCO post:
“Oncology Drug Dosing: Can an Optimal Dose Be Fine-Tuned for Each Patient?” http://bit.ly/1gWKkbb 

This is an important item to read for research advocates I feel. (Karl)
* MDA 2013:
Ibrutinib keeps CLL in check http://bit.ly/1cQvQlY
* The Atlantic 2013:
When Will Genomics Cure Cancer? A conversation with the biogeneticist Eric S. Lander about how genetic advances are transforming medical treatment http://bit.ly/19J7QUJ

*Cancer Research UK 2013:
Genetic profiling tracks progression from manageable blood cancer into deadly disease http://bit.ly/Joci0D

* Cancer Network 2013:
Regimen Shows Promise for Lymphoma Patients With Cardiac Conditions http://bit.ly/1cx1cDn
* J Nuc Med 2013:
Early Determination of Prognosis by Interim 3'-Deoxy-3'-18F-Fluorothymidine PET in Patients with Non-Hodgkin Lymphoma. http://1.usa.gov/1dD7HBb
* Medscape: Do Antihistamines Relieve Neupogen-Induced Bone Pain? http://bit.ly/1dbkCvX
* A trial to help find out:
Evaluation of Loratadine for Prevention of Pegfilgrastim-Induced Pain - Full Text View - ClinicalTrials.gov http://1.usa.gov/1c9nvc9
 

Monday, Dec 23

*  PAL update:  Cancer and treatment related fatigue
* “First FDA Authorization for Next-Generation Sequencer Francis S. Collins, M.D., Ph.D., Margaret A. Hamburg, M.D. http://bit.ly/1dAzWQQ
* PAL content:
Agents that target disease pathways brochure.pdf
* NYT 2013:
Life, Interrupted: By a Dog http://nyti.ms/1cNbwlr
* News Medical 2013:
Engineered immune cells show antitumor activity in two patients with advanced cancers http://bit.ly/1icV2KT
* Brian Koffman's blog 2013:
ASH 2013: Dr. Wiestner Discusses Why Therapy in CLL Needs to be Individualized   http://bit.ly/19leNxp
* MSKCC 2013:
Understanding Lymphoma http://bit.ly/1eyBOPb
* Video - imedex 2013: Dr. Myron Czuczman
ASH 2013: Lymphoma - Ibrutinib & Idelalisib - posted to  Experts on Lymphoma

 

Sunday, Dec 22

* Study of interest:
Lenalidomide + Vaccine for Early-Stage Asymptomatic CLL/SLL - ClinicalTrials.gov http://1.usa.gov/1bYB4ew

Lenalidomide modulates the immune system so this seems a rationale combination with relatively low risk. Look for similar studies combining immune-checkpoint antibodies with vaccine, such as anti-pd1/L in future.

See also for Len: http://www.lymphomation.org/lenalidomide-mechanism.htm 
Expert Interviews - Posted to PAL - Expert videos:
* Ann S. LaCasce, MD - excellent video presentation
Lymphoma at ASH 2013 BMT Grand Rounds   

Excellent summary of highlights for indolent lymphoma
* Imedex 2013:  Video
ASH 2013: CLL - Best of the day - video interview with Dr. Brown on outcomes in relapsed disease 

Impressive insights provided by Dr. Jennifer Brown.  Discussion and questions raised here on immune and targeted therapies.  A caution about use of fish oil with some targeted agents, such as ibrutinib. 
* MSKCC 2013: Video
Risk Factors for Lymphoma and how it's diagnosed Posted to Risk factors
* Leuk Lymph 2013:
Body mass index, height and risk of lymphoid neoplasms in a large United States cohort. Posted to PAL - Risk factors
* Br J Haematol 2013:
Safety and efficacy of Zevalin for untreated follicular lymphoma patients. An Italian cooperative study.
 Posted to PAL - Zevalin In the News

Single arm study:  50 patients with stage II "bulky", III or IV FL received a single treatment course with (90 Y)-Ibritumomab-Tiuxetan as initial therapy. The median age was 60 years. Bone marrow involvement (<25%) was observed in 24 patients (48%) and 7 (14%) had an elevated LDH level. The overall response (ORR) and CR rates were 94% and 86%, respectively with a median follow-up of 38·8 months. The median progression-free survival (PFS) was not reached, whereas the 3-year estimated PFS and overall survival (OS) rate was 63·4% and 90%, respectively.
* Br J Haematol 2013:
A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas. http://1.usa.gov/1dvY1sd 

Whereas efficacy of this combination was low in heavily pre-treated DLBCL, there was a signal of activity in relapsed/refractory PTCL utilizing the modified schedule.
* University of Iowa 2013:
Staph stoppers: New vaccine from University of Iowa protects against lethal pneumonia caused by staph bacteria http://bit.ly/JMPmsq

 

Saturday, Dec 21

Featuring today recent updates and new topic pages by PAL

* PAL:  Holiday card best wishes from Image file 
* PAL: New topic
Off-label use of treatments for lymphoma

A new topic page to keep track of possible changes in how the off-label use of treatments may evolve in the wake of the approval of expensive targeted oral drugs for narrow indications (such as ibrutinib for Mantle Cell lymphoma).
* PAL:   Message to supporters and advisors from the president: 
Thankful, encouraged, enthused, and determined PDF

How to Help 
Please give what you can to support our mission. 

Giving Thanks! ... which are due for recent donations by  Judith (today), Bill (today), Phillip (today),  Elizabeth , Toby,  Patricia, Gail, Tina Paul , Erin, Steve, Betty, Leonard, Carol, Naomi , Marshall, Nancy, Dennis, David, Cheryl,  Susan, and Jane ...
* PAL update:
Agents that target disease pathways
* PAL - Perspective on endpoints for first line treatment of indolent lymphoma
How might we better measure success ?   PAL
* PAL - Perspective on Rising Healthcare Costs ...
Threatening Access to Quality Cancer Care  PAL

Friday, Dec 20

* Holiday card best wishes from PAL 
* Blood 2013:
How I treat nodular lymphocyte predominant Hodgkin lymphoma http://bit.ly/1jq4Keu

* Ann Onc 2013:
Systematic review and meta-analysis on the diagnostic performance of FDG-PET/CT in detecting bone marrow involvement in newly diagnosed Hodgkin lymphoma: is bone marrow biopsy still necessary? http://1.usa.gov/1fLYOHL
* Clinical Oncology 2013:
Bruce Cheson, MD: How I Treat Follicular Lymphoma—Part II http://bit.ly/1kqnmJn
* Medscape 2013:
Is Obinutuzumab the Drug to Watch in CLL? video http://bit.ly/19Bi4qm
* Dana Farber 2013:
Live Webchat: Current and Future Treatments for Lymphoma http://bit.ly/1jlULXt
* Patient Power 2013:
Treating CLL: More Options Than Ever Before http://bit.ly/1cRraQg
* MSKCC 2013:
Will I become addicted to the pain medications I may need during my cancer treatment? http://bit.ly/1i22yIv
*Med Onc 2014;
Hodgkin lymphoma transformation of chronic lymphocytic leukemia: cases report and discussion http://1.usa.gov/1kkl26E
* Sunrise Rounds
The 46-Gallon Gift http://bit.ly/1eqUccZ

As lymphoma patients, we can't donate blood, but we are thankful for those who can and do.

* Medpage today 2013:
Tumors May Give Rise to Autoimmunity http://bit.ly/19BitZM
* Boing Boing 2013:
At 'The Houston Cancer Quack,' Skeptics call on Congress to investigate Stanislaw Burzynski http://bit.ly/1jpAvEo
See the web site and write your representatives here http://thehoustoncancerquack.com/

Wednesday, Dec 18

How to Help  Please give what you can to support our mission. 

Giving Thanks! ... which are due for recent donations by Elizabeth (today), Toby,  Patricia, Gail, Tina Paul , Erin, Steve, Betty, Leonard, Carol, Naomi , Marshall, Nancy, Dennis, David, Cheryl,  Susan, and Jane ...
* Oncology Times 2013:
View from the Other Side of the Stethoscope: Distressing Decisions
 Posted to PAL: Factors that Influence Treatment Decisions

"Faith. Gut feeling. Call it what you will. Science and reason could not produce one best option. Only because they couldn't, I trusted a feeling to make the final call."   Great advice here from a physician and patient on  the "distressing decisions" that are so common for lymphoma - because we have so many effective (standard) and promising (investigational) therapies to chose from. (Karl)

* Oncology Times 2013:
HIV-Associated NHL: Pooled Analysis Reinforces Several Standard Treatment Practices http://bit.ly/JFDJE1

* Weill Cornell 2013
EZH2 Represents a New Target for Treatment of B-cell Lymphomas http://bit.ly/1kfD9um
* Oncology Times 2013:
Novel Agents Rapidly Emerging for CLL http://bit.ly/19wQrPd
* Plain Dealer 2013:
Hodgkin's lymphoma patients who freeze sperm before treatment have better chance of becoming dads after, study shows http://bit.ly/1kVprdB
* MNT 2013:
Improving the prognosis of patients with chemo-resistant lymphoma http://bit.ly/1dOf3lP
* Medscape 2013:
Tailoring CLL Treatment to a TTT http://bit.ly/1gCvpTf

Karl:   Reposting this item with excellent vision here I feel – how to evaluate and make use of these new active agents. 
 

Tuesday, Dec 17

* PAL:

Helping to overcome barriers to participation in trials through education, outcome reporting, and trial location tools.

How to Help 
Please give what you can to help us ... 

Giving Thanks! ... which are due for recent donations by Toby (today),  Patricia, Gail, Tina Paul , Erin, Steve, Betty, Leonard, Carol, Naomi , Marshall, Nancy, Dennis, David, Cheryl,  Susan, and Jane ...
* Medscape 2013:
Idelalisib Raises Eyebrows in Lymphoma --  Posted to PAL PI-3-kinase inhibitors

* Patient Power 2013:
CLL Research: How Far Have We Come? Where Are We Headed? - http://bit.ly/IQpnQL

* Helio 2013L
Brentuximab vedotin induced long-term remissions in Hodgkin’s lymphoma http://bit.ly/1bLjSZG

* Oncology Times 2013:
ONLINE FIRST: Genetically Modified T Cells Now Shown to Produce Long-Term Responses in Leukemia Patients http://bit.ly/18Mx7cQ

* Baylor College of Medicine 2013:
Activated “killer” T-cells effective against resistant lymphoma http://bit.ly/1bLXOSa
* Patient Power 2013:
Optimism and Changes Ahead for Blood Cancer Patients http://bit.ly/1heU7Xp

* Medscape 2013:
Tailoring CLL Treatment to a TTT http://bit.ly/1gCvpTf

Karl:  Excellent vision here I feel – how to evaluate and make use of these new active agents. 

SNIP:  (Applies to lymphoma too)  “We are thinking about using a sequential TTT treatment (triple T), combining the best agents in a sequence that tailors the treatment according to the initial tumor load and the response to therapy (ie, complete response vs partial response), minimal residual disease [MRD]-positive vs MRD-negative). This treatment approach will utilize all currently available options in a nonaggressive, nontoxic way and will aim to eliminate or control the malignant clone.”


* Neurologica Blog 2013:
Strike Three for Multivitamin Use http://bit.ly/19PH75c

 

Monday, Dec 16

* Study of interest: not yet recruiting
   ABT-199 + Rituxan Versus Bendamustine + Rituxan for Relapsed or Resistant CLL http://1.usa.gov/J0zsdl

seems like everyone is taking aim at CLL as the path to take towards initial approval. Here we see ABT199 (a targeted agent) combined with Rituxan ... going up against Bendamustine + Rituxan.
* Reposting this VERY encouraging report for DLBCL - MNT 2013:
Patients with non-Hodgkin lymphomas resistant to treatment benefit from drug-antibody pair http://bit.ly/18IETHK

"To date, the trial has enrolled 62 patients with B-cell lymphomas, including 44 diagnosed with DLBCL. Most the patients were no longer responding to previous therapy, and 23 percent had never responded to any treatment.
* ASH Education Program 2013:
Novel therapy for Hodgkin lymphoma http://bit.ly/19LtK69
* MSKCC 2013:
New Diagnostic Test for Blood Cancers Will Help Doctors Tailor Treatments http://bit.ly/1b5oDxs
* MNT 2013
Improved cooling cap for chemotherapy hair loss 'more effective' http://bit.ly/18LORZ3
* Targeted Oncology:
Promising Ibrutinib Responses Demonstrated in Waldenström’s Macroglobulinemia http://bit.ly/1b6yeE2
* Br J Haematology 2013:
Hodgkin lymphoma patients in first remission: routine positron emission tomography/computerized tomography imaging is not superior to clinical follow-up for patients with no residual mass. http://1.usa.gov/1kMBsSJ
* KevinMD.com 2013:
Herbal supplements may be natural, but that doesn’t mean they’re safe http://bit.ly/IPHDJR
* NYtimes 2013:
Skip the Supplements http://nyti.ms/1bKFdpz

Sunday, Dec 15

* Onclive 2013:
Dr. Goy on CAR-Modified T Cells in Lymphoma http://bit.ly/1bNnG0V
* MNT 2013:
Patients with non-Hodgkin lymphomas resistant to treatment benefit from drug-antibody pair http://bit.ly/18IETHK

"To date, the trial has enrolled 62 patients with B-cell lymphomas, including 44 diagnosed with DLBCL. Most the patients were no longer responding to previous therapy, and 23 percent had never responded to any treatment.

Forty percent of the 43 evaluable DLBCL patients had an objective response to the drug with a median duration of 36 weeks, including some of more than eight months. Seven had complete remissions and 10 had partial remissions. In the other B-cell lymphoma patients, 22 had an objective response.
This and other reports on this story Posted to PAL - antibody-drug conjugates

* MSKCC 2013: When the Holiday Cheer Gets You Down:
Eight Tips for Coping with Difficult Emotions http://bit.ly/1dbH6ei
* New Statesman 2013:
Why it's time to ditch the word "cancer": A former president of the Association of Surgeons of Great Britain and Ireland argues that the word  “cancer” is unhelpful in efforts to lead patients away from quacks. http://bit.ly/1fq12wi
* PAL resources:
2 news items on activity of Immune Checkpoint Blocker Combo Posted to PAL - Immune Therapy  
* ASCO Connection 2013:
Parenthood and Cancer http://bit.ly/1kEriU3

* Cure 2013:
Why Observing Treatment Milestones is an Individual Decision http://bit.ly/1dv07ZE

* MSKCC 2013
Lymphoma Clinical Update http://bit.ly/1kEr3Iy

* Science-based Medicine 2013:
5 out of 4 Americans Do Not Understand Statistics http://bit.ly/1dblyON

 

Fri, Dec 13

* Lympho Bob:
Rituxan + Pidilizumab for Follicular Lymphoma http://bit.ly/1bCkJfk  
* PAL:

How to Help 
Please give what you can to help us ... to help accelerate progress against lymphoma!

Giving Thanks ... which are due for recent donations by Tina (today) Paul (today), Erin (today), Steve, Betty, Leonard, Carol, Naomi , Marshall, Nancy, Dennis, David, Cheryl,  Susan, and Jane!
* Study approach of interest:
Romidepsin + Oral 5-Azacitidine in Relapsed/Refractory Lymphoid (b and t-cell) Malignancies - ClinicalTrials.gov http://1.usa.gov/1frcpUP  Location: NY City
* PAL Update:
Capturing and Evaluating Patient Reported Outcomes in Clinical Trials

Thu, Dec 12

* BMNT 2013:
Growing umbilical cord blood stem cells in lab before transplant boosts leukemia, lymphoma survival http://bit.ly/18E8U8k
* News Medical 2013:
Combination therapy safe and active in follicular lymphoma http://bit.ly/1hOICbQ
* MNT 2013:
Discovery of CXCR4 mutations in Waldenstrom's Macroglobulinemia helps identify which patients are more likely to benefit from ibrutinib http://bit.ly/18CHVNR
* MNT 2013:
Scientists shed new light on the fight against cancer - They have discovered how the anti-tumor activity of immune cells can be restored http://bit.ly/Ja9ap9  (not lymphoma specific but interesting)
* NY Times 2013:
Limits of Vitamin D Supplements http://nyti.ms/1flbMMp
* Med xpress 2013
Targeted antibody, immune checkpoint blocker rein in follicular lymphoma (pidilizumab and Rituxan) http://bit.ly/JfFTKz

One drug attacks tumor cells directly, the other treats the immune system by taking the brakes off T cell response. Together, they put half of the patients with relapsed follicular lymphoma into complete remission in a phase II clinical trial at The University of Texas MD Anderson Cancer Center.
* News Medical 2013:
Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting http://bit.ly/1gZAsKM

* Brian Kauffman's Blog 2013:
ASH 2013: A Quick Perspective http://bit.ly/1jNsaZ0
* MNt 2013:
Discovery of CXCR4 mutations in Waldenstrom's Macroglobulinemia helps identify which patients are more likely to benefit from ibrutinib http://bit.ly/18CHVNR
* Medscape 2013:
Idelalisib With Rituximab Boosts Survival in Relapsed CLL http://bit.ly/1cBVK05
* Brian Kauffman's blog 2013:
iwCLL 2013: Dr. Tom Kipps Discusses the Changing Role of Chemo-immunotherapy in CLL and the New Role of BCL-2 Blockers http://bit.ly/1cqbfot
 

Wed, Dec 11

* Business Wire 2013:
Studies Evaluating REVLIMID® (Lenalidomide) in Lymphoma Presented at ASH Posted to PAL - Lenalidomide  
* ASCO 2013: Overview
Clinical Cancer Advances 2013: Blood and Lymphatic Cancers http://bit.ly/1bBNJIx
* FHCRC 2013:
Study finds link between allergies and increased risk of blood cancers in women: Gender may play a role in the association of chronic immune stimulation and development of hematologic cancers Posted to PAL - Risk factors
* Medical Xpress 2013:
Drug-antibody pair has promising activity in non-Hodgkin lymphoma Posted to PAL - antibody-drug conjugates  
* Helio 2013:
Reduced-intensity HSCT recipients spared from post-HSCT cognitive impairment http://bit.ly/1gnsWfj
* Onc Live 2013:
Dr. van den Brink on Adding Ibrutinib to R-CHOP in NHL http://bit.ly/18AjnF4
* Dr Sharman 2013:
Ibrutinib in front line elderly (CLL) http://bit.ly/1d7nZSr
* Onc Live 2013
Dr. Furman on Avoiding Chemotherapy With Idelalisib (CLL) http://bit.ly/1fhcVoe
* Onc Live 2013:
Dr. Flinn Discusses the Efficacy of IPI-145 in CLL http://bit.ly/1kwujG0
* Targeted Oncology 2013;
Novel PI3K Inhibitor IPI-145 Shows Promise in CLL http://bit.ly/IO2flc
* Medscape 2013:
Novel Targeted Therapies in CLL Might Expand Treatment Option http://bit.ly/1kwELgM
* Onc Live 2013:
Dr. Seymour on the Efficacy of ABT-199 in High-Risk CLL http://bit.ly/1d6ZOnf
 

Tues, Dec 10

*  PAL - Hodgkins in the News
* Dana Farber 2013:
Drug-antibody pair has promising activity in non-Hodgkin lymphoma http://bit.ly/18RLL8n
* Dr Sharman's Blog 2013:
IWCLL videos - thanks Brian http://bit.ly/INz41G
* MEdscape 2013:
Cognitive Impairment After HSCT Varies With Intensity of Regimen http://bit.ly/1cllF8X
* Medscape: 2013:
Excitement Over CAR-Engineered T-cells in Leukemia and Lymphoma http://bit.ly/1bQRLOL
* NYTimes 2013:
On Health Exchanges, Premiums May Be Low, but Other Costs Can Be High http://nyti.ms/18whwBe
* MNT 2013:
Penn study results for first 59 leukemia patients who received cell therapy http://bit.ly/18k9wVV
* OncLive 2013:
Dr. Brown on Idelalisib Plus Rituximab in CLL http://bit.ly/1bqXg0p
* News Medical 2013:
Bortezomib reduces GVHD, boosts survival for patients receiving stem-cell transplants http://bit.ly/18wy4WC
* Pharmagossip 2013:
FDA official: “clinical trial system is broken” - BMJ http://bit.ly/1iQVVdt

Monday, Dec 9 - late edition

* Publicly Funded Clinical Trials and Cancer Care -
by Richard L. Schilsky, MD - YouTube http://bit.ly/J7W8sZ

Long ... but very important information regarding the unique role of publicly-funded clinical research
-- that ask important questions that would not be asked in industry-funded trials.
* Broad Potential of IPI-145 in Blood Cancers http://bit.ly/18ua86e
NYT 2013:
Cancer Survivors Celebrate Their Cancerversary http://nyti.ms/1ckI7Pn
* Loyola 2013:
Breakthrough in treating leukemia, lymphoma with umbilical cord blood stem cells: Study finds that growing stem cells in lab before transplant  boosts survival http://bit.ly/1e0NY3k
* J Clin Onc 2013:
Fractionated 90Y-Ibritumomab Tiuxetan Radioimmunotherapy As an Initial Therapy of Follicular Lymphoma: An International Phase II Study in  Patients Requiring Treatment According to GELF/BNLI Criteria. http://1.usa.gov/1f05uRI
* Dana Farber 2013
Gene 'driver' of Waldenstrom's Macroglobulinemia in up to one-third of patients identified: Drug that targets the driver mutation proves effective in animal studies http://bit.ly/1hI8FRW
*  PAL - Compiled articles on CAR-Engineered T-cells

Chimeric antigen receptor t-cells - CART 19)  - brief overview:  where they harvest your killer t-cells ... then program the antigen receptor on these cells to bind to cd19 on the tumor cells - then give the cells back to you. The key is that the cells can persist and expand in the body - having the potential to eradicate all b-cells with cd19 - normal and malignant.  Karl
* Medscape 2013:
New Drug Combo Potentially 'Practice Changing' in CLL http://bit.ly/1hH4s0Y
* ASH 2013:
Innovative Compounds, Combination Therapies Improve Care of Patients with Wide Range of Blood Disorders http://bit.ly/1bpVOz5
* Leuk Lymphoma. 2013:
Use of Positron Emission Tomography-Computerized Tomography (PET-CT) in the Management of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL). http://1.usa.gov/1cuAauw

 

Monday, Dec 9, 2013

* Publicly Funded Clinical Trials and Cancer Care -
by Richard L. Schilsky, MD - YouTube http://bit.ly/J7W8sZ

Long ... but very important information regarding the unique role of Publicly funded clinical research
-- that ask important questions that would not be asked in industry-funded trials.
* Mantle Cell abstracts compiled by PAL - MCL In the News
* Brian Kauffman's Blog 2013:
iwCLL 2013: Dr. Byrd Discusses 17 p deletion with Ibutinib http://bit.ly/1bt9Occ
* Nature 2013:
Policy: Twenty tips for interpreting scientific claims http://bit.ly/197FZgT

* Lymphobob 2013:
ASH Day! Zevalin and Follicular Lymphoma http://bit.ly/J0bSOM
Some ASH press releases:

* Dana Farber 2013:
Novel drug regimen can improve stem cell transplantation outcomes: Bortezomib (Velcade) reduces GVHD, boosts survival http://bit.ly/1bpTyHZ
* Oncology Report 2013:
Treated T-cells induce remissions in chemo-refractory B-cell lymphomas http://bit.ly/1dYIqWU
* ASH :2013
High-tech gene-therapy advances offer hope for patients with hard-to-treat blood disorders http://bit.ly/1btaXjO
* For Traders 2013:
Sequenta's ClonoSIGHT MRD Test Can Detect Relapse of Diffuse Large B-Cell Lymphoma More Than Seven Months Before CT Scan Posted to PAL - Programmed T-cells - Licensed to Kill (CAR T-cells)  

See also compiled MRD abstracts by PAL

* CHOP 2013:
T cell immunotherapy: Promising results in children and adults with leukemia: Researchers from The Children's Hospital of Philadelphia and University of Pennsylvania harness engineered T cells to eliminate tumors in blood http://bit.ly/1bnIuYr

 

Saturday, Dec 7, 2013

* PAL - Draft Perspective on endpoints for first line treatment of indolent lymphoma
How might we better measure success ?   PAL
* PAL - Draft Perspective on Rising Healthcare Costs ...
Threatening Access to Quality Cancer Care  PAL
*Medpage today 2013
Major Studies, Novel Talks Highlight ASH http://bit.ly/IIuxgV
* Social Reader 2013:
Watch How These Cancer Patients Reacted To Getting Hilariously Awful Makeovers http://bit.ly/19nlCbM
* The Atlantic 2013:
How to Read About Science http://bit.ly/IIggRi
* Patient Power 2013:
Why MRD (Minimal Residual Disease) Matters for CLL http://bit.ly/18dPegI
 

Friday, Dec 6, 2013

* Draft Perspective on endpoints for first line treatment of indolent lymphoma
How might we better measure success ?   PAL
* MNT 2013
Doubts cast over benefits of vitamin D supplements http://bit.ly/18do9dG

"What this discrepancy suggests is that decreases in vitamin D levels are a marker of deteriorating health."
* Dr Sharman's Blog 2013;
Diffuse Large B Cell Lymphoma (knowing your ABC's and GCB's) http://bit.ly/1f1lALn

"This should be in their interest anyway because the FDA loves "companion diagnostics" for selecting individuals for therapy. I predict that in the future, DLBCL management will go like ..."
* Cancer Research Inst 2013:
Emily's Story: A Young Girl Beats Cancer with Immunotherapy http://bit.ly/18mlyfp
* Medpage Today 2013:
Should Bone Marrow Donors Be Paid? http://bit.ly/1kgyWnt
* Brian Kaufman's blog 2013:
iwCLL 2013: Dr. John Byrd Discusses the Role of Novel Therapies versus Standard Chemo-Immunotherapy http://bit.ly/1iEd1uV
News Medical 2013:
Cancer triggers scleroderma, shows evidence http://bit.ly/18pZWf1

Anjou: not directly related to NHL, but I find this interesting given the association btw NHL and autoimmune diseases.

* We morn the loss of fellow advocate: Lori Monroe
See tribute to Lori: Lung Cancer Foundation of America http://bit.ly/18dMaRT 
*  PAL - lymphomation.org  ... We can report many thousands of query clicks on our Locate Trials tools

See How to Help  Please give what you can to help us ... to help accelerate progress against lymphoma!

Giving Thanks ... which are due for recent donations by Steve (today), Betty, Leonard, Carol, Naomi , Marshall, Nancy, Dennis, David, Cheryl,  Susan, and Jane!
 

Thursday, Dec 5, 2013

* Stanford Social Innovation Review
The Elusive Craft of Evaluating Advocacy (politically charged reform)  http://bit.ly/ILfyD5 

Yet grantmakers have often hesitated to plunge in. Sometimes they worry about appearing too political or partisan. But more often they hesitate because effective advocacy is difficult, and evaluating whether various approaches are working is even harder.
* Hodgkins
3 ASH reports Post to PAL: Hodgkins Disease - In the News
* OncLive 2013:
ASH 2013 Preview: CAR Modified T Cells, Novel Assays, and Ibrutinib http://bit.ly/IPFLRN
* Medscape 2013:
ASH: 5 Hematology Procedures That Should Stop or Be Limited http://bit.ly/1iB8p8I

key points discussed page 2:
1) "limit the use of CT scans in asymptomatic patients following curative-intent treatment for aggressive lymphoma."
2) "diagnosis of lymphoma should be based on excisional biopsies, and clinicians should not initiate treatment of lymphoma based of tissue obtained exclusively from fine-needle aspirations."

* Stanford 2013:
An in-depth look at fertility and cancer survivorship http://stanford.io/1aBk1ic
* In the Pipeline 2013:
Cancer Cell Line Assays: You Won't Like Hearing This http://bit.ly/1bi7h4n
* Science Daily 2013:
New Insights Into Cancer Evolution Help Define Screening Window of Opportunity http://bit.ly/1cYRwxQ
* Medscape 2013:
'Tragedy' of Millions of Cancer Patients Not Getting Opioids http://bit.ly/1gFRrBN
* The ASCO Post:
Discussion of Protective Effect of Marriage' Found in 10 Most Clinically Significant Cancers http://bit.ly/IAvBUf

“Being married may contribute to improved outcomes because spouses may encourage their counterparts to seek medical attention for worrisome symptoms and to undergo definitive treatments. “There are many explanations for the vital question of why marriage is associated with improved cancer-specific survival after adjustment for demographics, stage, and treatment, but the most likely reason is that married patients have better adherence with prescribed treatments than unmarried patients,” the researchers reported.”

Comment: Research advocates might recommend that marriage status be included in the risk factors that will be accounted for in clinical trials. Patient-reported outcomes might do well to account for marriage status (and response to treatment) in the analysis.
 

Tuesday, Dec 3, 2013

* ASH Papers, 2013: MANY on Minimal Residual Disease (MRD) testing  - ASH papers compiled by PAL
* Brian Kauffman's Blog 2013:
iwCLL 2013: Dr. Jeff Sharman Discusses Richter's Transformation in CLL http://bit.ly/18eeXU1
* KevinMD 2013:
The importance of sex in the midst of a cancer diagnosis http://bit.ly/18z5I3J
* Lympho Bob 2013:
ASH: Follicular Lymphoma and Lifestyle Factors http://bit.ly/1cO8ZsU
* NYT 2013:
Palliative Care, the Treatment That Respects Pain http://nyti.ms/1aoEWoJ
* News Medical 2013:
Tips to protect yourself from getting sick during cold and flu season http://bit.ly/1eLfGNy
* Brian Kauffman's Blog 2013:
We are all Fragile http://bit.ly/1cIxJ5H
* Brian Kauffman's Blog 2013:
iwCLL 2013: Dr. Jeff Sharman Discusses Two Issues: 17p deletion and Residual Disease in CLL http://bit.ly/1cgFjGz
*MNT 2013:
New genetic links found to most common type of leukaemia (CLL) http://bit.ly/1beZgsN
* The ASCO Post:
Discussion of Protective Effect of Marriage' Found in 10 Most Clinically Significant Cancers http://bit.ly/IAvBUf
* CancerCare
Financial, Assistance, Help, Cancer, Patients | Posted to PAL - Financial Support and Resources   
   Call 800-813-HOPE (4673) and speak with a CancerCare® social worker
The ASCO Post 2013:
FDA Announces Strategic Plan to Prevent Drug Shortages Posted to PAL - Shortages of Vital Blood Cancer Drugs! 

snip:

The strategic plan, which was required by FDASIA and has been sent to Congress, describes actions the FDA will undertake to improve its current efforts to respond to early notifications of a potential shortage. These include improving the FDA’s communications about shortages, clarifying manufacturers’ roles and responsibilities by encouraging them to engage in certain practices that will reduce the likelihood of a shortage, updating the FDA’s internal procedures for responding to early notifications of potential shortages.

The plan also describes efforts the FDA is considering to address the manufacturing and quality issues that are most often the root cause of drug shortages. These include broader use of manufacturing metrics to assist in the evaluation of manufacturing quality, as well as incentives for high-quality manufacturing; internal organization improvements to focus on quality; and risk-based approaches to identify early warning signals for manufacturing and quality problems.

Saturday, Nov 30, 2013

* Financial, Assistance, Help, Cancer, Patients | CancerCare http://bit.ly/IoA5O9  
Call 800-813-HOPE (4673) and speak with a CancerCare® social worker
 
* Am J Hematology 2013:
Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management. Posted to PAL - Mantle Cell Lymphoma

For selected indolent, low MIPI MCL patients, initial observation may be appropriate therapy. For younger patients with intermediate or high risk MIPI MCL, aggressive therapy with a cytarabine containing regimen ± autologous stem cell transplantation should be considered. For older MCL patients with intermediate or high risk MIPI, combination chemotherapy with R-CHOP, R-Bendamustine, or a clinical trial should be considered. At the time of relapse ...
* Brian Koffman's Blog 2013
iwCLL 2013: Dr. Jeff Sharman Outlines Options if You Need Treatment NOW http://bit.ly/1cSspMS
* Sunrise Rounds 2013:
Playing doctor http://bit.ly/ItOEQb
* Brian Kauffman's Blog 2013:
More on to Tell or Not to Tell http://bit.ly/1eGgCUi
* Medscape 2013:
Advances in Follicular Lymphoma http://bit.ly/1iWXvId

"This activity is intended for hematologists and oncologists. The goal of this activity is to educate clinicians on key prognostic and clinical factors to be considered when selecting treatment for patients with follicular lymphoma, as well as the benefits and risks of current and emerging evidence-based treatment strategies in the first-line, consolidation/maintenance, and relapsed/refractory settings."
HODGKINS REPORTS
* Hematol Oncol Clin North Am. 2013
Relapsed/Refractory Hodgkin Lymphoma: What Is the Best Salvage Therapy and Do We Need RIC-Allo SCT?
Posted to PAL - Hodgkins Disease
* Hematol Oncol Clin North Am. 2013
Early Intensification Treatment Approach in Advanced-stage Hodgkin Lymphoma. http://1.usa.gov/1eJqoVz
* Hematol Oncol Clin North Am. 2013
Induction Therapy for Advanced-stage Hodgkin Lymphoma: Late Intensification (ABVD Chemotherapy Followed by High-dose Chemotherapy and Autologous Stem Cell Transplant Only for Those Who Relapse). http://1.usa.gov/Iu0aLd
TIPS for Using ACA Insurance Exchange:

There is no need to shop for insurance on the exchange if you have Medicare.

If you already have private insurance it’s wise to apply on the Exchange anyway so you can take advantage of providers competing with price when selling ACA compliant plans. If you received cancelation notices from your private insurance … there is no need to panic as you should shop on the exchange anyway.

Prudent - first step: SECURITY

Any online system (banking, etc) provides security risks - one such risk is when your local computer is infected with a program that can capture sensitive private information.

MalewareBytes is a free cleaning program that's highly rated.
You might run it prior to using ANY online system that involves private information:
http://www.malwarebytes.org/  (3 steps: download, install, run)

ACCOUNT (step 1):

Go to http://1.usa.gov/GzzB6L the Exchange and create an account

To create an online account requires a working email account and verification by email

After entering a username, desired password and email account, you will have to respond to the email sent to that account to create the Insurance Exchange online account.

APPLICATION (step 2):

I think there is only one application you can maker per account.
If you filed a joint tax return ... you probably want to apply for insurance as a family.

FINANCIAL INFO:

To create an application you will need last year's financial tax information. Have ready your 1040 and other income statements.

These are unofficial tips and tricks (not guarantees) ... that we hope will help you and others in the application process.
 

Friday, Nov 29, 2013

HOLIDAY ITEMS:
* NYT 2013:
Living With Cancer: Giving Thanks and Latkes http://nyti.ms/IhD0b8
* Dana Farber 2013:
Managing the Holidays When You Have Cancer http://bit.ly/1bXikNb
* News Medical 2013
Ten tips for safe Thanksgiving meals http://bit.ly/1ibWzlv
* NYT 2013:
Bad Thanksgiving http://nyti.ms/1bWNpAn

“So you think you have time for a cup of coffee?” Sybil asks finally. “If I make it instant?”... I am laughing. I am doubled over, laughing. Here is my big insight: You can have a Stage 3 cancer but when a friend cracks you up, you are as alive as anyone else. So here we are 18 years later.
PERSPECTIVES:
* Brian Kaufman's blog 2013:
iwCLL 2013: Dr. Jeff Sharman Discusses Why We Feels so Lousy with Cancer http://bit.ly/1b4wWsS
* Dr Sharman's Blog 2013:
Off label drug use http://bit.ly/187feFg
SURVIVORSHIP
* Study of interest:
Testing Ibrutinib for Relapsed/Refractory Marginal Zone Lymphoma - ClinicalTrials.gov http://1.usa.gov/1863kvn

Key eligibility: Previously received one or more lines of therapy including one CD20-directed chemoimmunotherapy regimen with documented failure to achieve at least PR or documented PD after, the most recent systemic treatment regimen
*  Science Daily 2013:
Cancer Patients at Increased Risk for Severe Flu Complications Posted to PAL - Immunization Guide
* Sunrise Rounds 2013:
Chemo in palliative perspective Posted to PAL - Palliative Care
* Science Daily 2013:
Supporting Others Brings Healing to Cancer Survivors http://bit.ly/1ep92wn

Wednesday, Nov 27, 2013

* ASH Paper:
Outcomes In Splenic Marginal Zone Lymphoma: Analysis Of 108 Patients Treated In British Columbia http://bit.ly/1h7ozoK
* Study of interest:
Testing Ibrutinib for Relapsed/Refractory Marginal Zone Lymphoma - ClinicalTrials.gov http://1.usa.gov/1863kvn

Key eligibility: Previously received one or more lines of therapy including one CD20-directed chemoimmunotherapy regimen with documented failure to achieve at least PR or documented PD after, the most recent systemic treatment regimen

If effective (given the eligibility requirement above) would show that Ibrutinib addresses an unmet need.
* NCI: Cancer Health Disparities: http://1.usa.gov/1jKkMe7
*  The ASCO Post:
IOM report on looming crisis in cancer care http://bit.ly/1hfYiEV  and proposed solutions.
* Medscape 2013:
Dr. Cheson on ASH 2013: Big Year for CLL, Lymphoma http://bit.ly/1b0SQNA
*  ASH Paper:
Rituximab Maintenance For a Max Of 5 Years In Follicular Lymphoma: Randomized Phase III Trial SAKK 35/03
Posted to PAL: Maintenance Rituxan - Comments on News 

 

Monday, Nov 25, 2013

* Medscape 2013:
ASH 2013: Big Year for CLL, Lymphoma http://bit.ly/1b0SQNA
* Nami.org:
Fact sheet on patient protections under Affordable Care Act (ACA) http://bit.ly/18wZor7
* American Journal of Gastroenterology:
Efficacy of an Encapsulated Probiotic Bifidobacterium infantis 35624 in Women with Irritable Bowel Syndrome http://bit.ly/18hIiQ5
* J Clin Oncol. 2013
False-Positive PET in allo but not auto SCT treatment for #lymphoma -  Posted to PAL: PET imaging
* NPR 2013:
Remember 'French Fries Cause Cancer'? Here's The Acrylamide Update http://n.pr/1izHg3J
* U Nebraska MC 2013:
UNMC researchers work to improve outcomes of lymphoma patients http://bit.ly/17S8Bqb

*  PAL - lymphomation.org

Day and night we provide evidence-based support for patients and caregivers. 
Today we need your support in order to continue our services. 

See How to Help  Please give what you can.

Giving Thanks ... which are due for recent donations by Michelle (today),
Naomi ,
 Marshall, Nancy, Dennis, David, Cheryl,  Susan, and Jane!
 

Friday, Nov 22, 2013

* Dr Harpham 2013:
The Dangers of Pseudoscience --II http://bit.ly/1c857CA

* Oncology Times 2013: ONLINE FIRST:
HIV-Associated NHL: Pooled Analysis Reinforces Value of Several Standard Treatment Practices http://bit.ly/1jqRwJ3

* Medscape 2013:
Burkitt's Yields to Longer-Duration, Lower-Dose Chemo Posted to PAL: Burkitt's lymphomas
Nature 2013: timely with ASH
Policy: Twenty tips for interpreting scientific claims http://bit.ly/1jqIsnH
* ASH Paper:
Outcomes In Splenic Marginal Zone Lymphoma: Analysis Of 108 Patients Treated In British Columbia  http://bit.ly/1h7ozoK 

The BC finding is that splenectomy remains a reasonable treatment option for patients with SMZL.
* ASH Paper:
Prognostic Impact Of Somatic NOTCH2 Mutation In Splenic Marginal Zone Lymphoma http://bit.ly/I8buNl

A technical item that could guide research (such as selecting patients with a need for novel or more aggressive therapies). We assume that the test needs to be validated and is not yet available to guide clinical practice. (Karl)
ASH Paper:
Effective Treatment Of Chemo-Refractory DLBC Lymphoma With Anti-CD19 CAR T-cells http://bit.ly/1h7HnUX
* ASH Paper:
The Role Of PET/CT For Staging /Response To Chemo In Marginal Zone #Lymphoma (retrospective) http://bit.ly/1caC4i3
* Ottawa Edu:
 Personal Decision Guide for helping to make tough health or social decisions http://bit.ly/I9pQ04
* NEJM:
Making Medical Decisions for Patients without Surrogates http://bit.ly/1bcxIdn
* NEJM: 
Association of Nut Consumption with Total and Cause-Specific Mortality http://bit.ly/1cIfc9q

Good news for us "squirrels."  (Karl)

 

Thursday, Nov 21, 2013

* ASH Paper:  
Myeloablative cd-45 Radioimmunotherapy then Auto transplant for High-Risk T/B-cell and Hodgkin lymphoma http://bit.ly/1jprN3H

Early but very encouraging and interesting approach with goal of addressing urgent unmet need - relapse in high risk lymphomas.
* Brian Kauffman's Blog 2013:
iwCLL 2013: Dr. Jeff Sharman Gets Down to Discussing How He Treats Patients with High Risk Disease http://bit.ly/1fm72sw

Excellent discussion on when to treat ... in light of new insights about cytogenetic risk factors, such as p17 deletion.  (KarlS)
* LymphoBob 2013:
ASH: Why Revlimid (Lenalidomide) + Rituxan Works (Maybe) http://bit.ly/18p5DgC

Nice discussion here on this important combination study and the clues or reactions in the body that are associated with best response.  We would add that there's a need to validate the importance of cereblon (a molecule that Lenalidomide binds to) as a potential predictive marker for response to this agent. (KarlS) 

See for example on Cereblon expression: Lenalidomide efficacy in activated B-cell-like... [Br J Haematol. 2013] - PubMed - NCBI http://1.usa.gov/1e3wb7x
* NYT 2013:
How Doctors Die http://nyti.ms/1bD59kd 

"Of the 765 doctors studied, 64 percent had advanced directives, compared with about 47 percent for American adults over 40."

See also
CARING CONNECTIONS - NHPCO
Download Your State's Advance Directives -  (scroll down to states) http://bit.ly/1a50vdr
* Today Health 2013:
Dishing up comfort: Program aims to boost cancer patients' appetites http://on.today.com/18mAlHk
See also Cancer Nutrition Consortium | Nutritional Guidance & Support Posted to PAL: Diet & Exercise

Tuesday, Nov 19, 2013

* PAL update:
Statistics versus Prognosis - a frequently asked question  PAL on Statistics
* Oncology Times 2013:
Large Study Shows: For Pregnant Women with Lymphoma, Standard Chemotherapy Causes Few Complications http://bit.ly/18iSCVS

*Medscape 2013:
Replacing Doxorubicin in DLBCL Patients With Cardiac Problems http://bit.ly/1dbpDqQ
* Medscape 2013:
Burkitt's Yields to Longer-Duration, Lower-Dose Chemo http://bit.ly/Id5xxU
* Lympho Bob 2013:
ASH: Rituxan vs. Watching and Waiting (in terms of cost) http://bit.ly/1jha6mN

I'm a fan of Lympho Bob and he does a very nice job here with the outline of the analysis. I wonder if Rituxan monotherapy was included in the simulation as a possible initial first therapy for the watch and wait group and if that would have changed the findings in respect to cost? KarlS

* Onclive 2013:
Dr. DeVita on Chemotherapy in Hodgkin's Lymphoma http://bit.ly/1az5OFF

* Lymphoma Hub 2013:
Study evaluates early stem cell transplants for non-Hodgkin’s lymphoma http://bit.ly/181teWH
* Selected papers from ASH:
Oral drug Idelalisib In Patients With Double Refractory Indolent B-Cell Lymphoma http://bit.ly/1bKKzSB

PET Compared With CT After Rituximab Induction Therapy In Follicular Lymphoma: National Lymphocare Study http://bit.ly/1f9TRuv

We've  heard expert comment that if you are PET negative after R-chemo following first treatment of FL that you probably don't need Rituxan maintenance - will do as well without it. We don't know if this is a consensus opinion though.

Follicular Lymphoma Grade 3 Treated With R-CHOP - long term outcomes (retrospective, single center) http://bit.ly/18jaQGI 

Follicular #lymphoma in young adults: clinical characteristics and early treatment outcomes http://bit.ly/I1MW96 

Selinexor (KPT-330) Phase I First-In-Class Oral Inhibitor Of SINE in Non Hodgkin’s #Lymphoma & CLL http://bit.ly/IdlxzY

No lymphoma trials listed on clinicaltrials.gov so far for this agent.  Always good to see a new class of drug showing activity this early in testing

CEOP Alternating With Pralatrexate Front Line for Peripheral T-Cell Lymphoma (PTCL): Preliminary results http://bit.ly/1bGrJMf 
*  PAL - lymphomation.org
Day and night we provide evidence-based support for patients and caregivers. 
Today we need your support in order to continue our services. 

See How to Help  Please give what you can.

Thanks are due for recent donations by Michelle (today), Naomi ,  Marshall, Nancy, Dennis, David, Cheryl,  Susan, and Jane!

Monday, Nov 18, 2013

* * * 6 Year Follow-Up Of The PRIMA Study of Rituximab Maintenance In previously untreated Follicular Lymphoma Pts following Frontline r-chemo http://bit.ly/1j082j2

UPDATE: One perspective I've heard from experts  .. on the six year follow up of the PRIMA study .. is that it has failed to demonstrate that delaying relapse with regularly scheduled Rituxan provides clinical benefit (improved survival).  Another perspective  is that that being free of disease improves one's quality of life because you have less stress and anxiety when there's no evidence of the disease.  So it seems that patient and physician preference will continue to determine the use of maintenance Rituxan.  ~ KarlS
* Brian Kauffman's blog 2013:
iwCLL 2013: Pharmacogenetics and Dr. Jeff Sharman Discusses New Prognostic Factors (CLL ) http://bit.ly/HTnJwU
* YouTube 2013:
Developing New Treatments for T Cell Lymphoma http://bit.ly/I9LQXR
* Blood 2013:
In the spotlight: a novel CD37 antibody-drug conjugate http://bit.ly/I9LBfi
* Newsweek 2013:
So Many Supplements, So Little Regulation http://bit.ly/1ilHI5r
* MNT 2013:
Personalized therapy using antitumor T cells from a patient's own cancer http://bit.ly/1cxvAcW
* *  ASH Paper, 2013:
Bcl-2 Inhibitor ABT-199 Shows Anti-Tumor Activity Including CRs In High-Risk Relapsed/Refractory CLL http://bit.ly/18BOCwa 

Find trials for ABT199 for CLL and Lymphoma http://1.usa.gov/SRZotl
* ASH Paper: ABT-199 in Relapsed/Refractory lymphoma: Responses Observed In All Mantle Cell Lymphoma (MCL) http://bit.ly/1b1rOM4
*  Donations to PAL have increased of late but we are still well behind our goal and need -- of meeting expenses.

See How to Help  Please give what you can.

Thanks are due for recent donations by Marshall (today) Nancy, Dennis, David, Cheryl,  Susan, and Jane!
* * ASH Paper:
Prolonged Survival Of Poor Risk Follicular Lymphoma after primary R-CHOP Or HDS Auto SCT http://bit.ly/1eeifIp

A randomized multicenter study of 134 Follicular Lymphoma (FL) patients, selected for age less than 60 yrs. and poor prognostic features according to age-adjusted IPI (2-3) and IIL-score (3 or greater). 

This study found an improved survival at 10 years for either approach (70%).  The study shows the importance of achieving a complete response (CR) and molecular remission (MR) with primary therapy.

Friday, Nov 15, 2013

*  PAL - carrying out our mission depends on public support - entirely:  See How to Help  Please give what you can.

Thanks are due for recent donations by Nancy (today), Dennis, David, Cheryl,  Susan, and Jane!

 such as by fostering the informed and routine consideration of clinical trials

* * * Ibrutinib in the News!
 approved by FDA under accelerated pathway for MCL (a Btk-inhibitor)  PAL 

Studies recruiting patients PAL query - Find trials
* Dr Sharman 2013:
ASH 2013 - my abstracts http://bit.ly/1bySDWe
* **  ASH Paper: Minimal Residual Disease (MRD) Predicts PFS In Mantle Cell #Lymphoma: CALGB 50403 (Alliance) http://bit.ly/18Bzj6q

Comment:  I'm very encouraged about this finding ... as the MRD test can substantially accelerate progress against lymphoma if it can be used reliably (instead of PFS) as a surrogate for clinical benefit. ~ Karl
* NYT 2013:
When the Doctor Disappears http://nyti.ms/HPHZiV
* Nat Rev Clin Oncol 2013:
Diffuse large B-cell lymphoma-treatment approaches in the molecular era. http://1.usa.gov/HWAUh0
* Dr Harpham 2013:
The Dangers of Pseudoscience http://bit.ly/1brUhpg
* Mayo Clinic Youtube 2013:
Celiac Disease and Risk of Lymphoma - Celiac Disease in the News http://bit.ly/17uAeFC
* USA Today:
Doctor accused of selling false hope to families http://usat.ly/18AzgYP 
* Science-Based Medicine
USA Today versus Stanislaw Burzynski http://bit.ly/1aIgmif

 

Thursday, Nov 14, 2013

*  PAL - carrying out our mission depends on public support - entirely:  See How to Help  Please give what you can.

Thanks are due for recent donations by Dennis, David, Cheryl,  Susan, and Jane!

 such as by fostering the informed and routine consideration of clinical trials

* * * Ibrutinib in the News!
 approved by FDA under accelerated pathway for MCL (a Btk-inhibitor)  PAL 

To locate trials for Ibrutinib see  PAL: Find Trials by Agent
* Blood 2013:
How I treat nodular lymphocyte predominant Hodgkin lymphoma. http://1.usa.gov/HRYBqQ
* Clinical Oncology 2013
Hodgkin Lymphoma Treatment Increases Stomach Cancer Risk http://bit.ly/HUb5OL
* ASH 2013:
 6 Year Follow-Up Of The PRIMA Study of Rituximab Maintenance  Posted to PAL with commentary
* Medical Xpress 2013:
Low-intensity therapy for Burkitt lymphoma is highly effective, study finds http://bit.ly/HUtsTE
* Br J Haemato
Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody Lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma. http://1.usa.gov/HSIQQ1
* Front Oncology 2012: Backgrounder
Therapy of newly diagnosed follicular lymphoma Posted to PAL: Follicular B-cell lymphoma
= SURVIVORSHIP
* KevinMD 2013:
The one little question that could save your life http://bit.ly/1hFFTmb
* CBS 2013:
Advocates push for straight talk about sex for cancer patients Posted to PAL: Sex & Fertility
= LEVELS of EVIDENCE - can we have confidence in scientific findings?
* Nature 2013
Weak statistical standards implicated in scientific irreproducibility http://bit.ly/HSZ8Jb

* E cancer news 2013"
World’s largest disease database will use artificial intelligence to find new cancer treatments http://bit.ly/1bCarOp
* Ars Technica
Is it time to up the statistical standard for scientific results?
A statistician says science's test for significance falls short http://bit.ly/HZ6UjH
= FINANCIAL SIDE EFFECTS OF TREATMENT
* Medscape 2013:
Frustration in Australia Over Slow Access to New Cancer Drugs http://bit.ly/1aEXvEQ

* ASH
American Society of Hematology as Part of “NDD United” Releases “Faces Of Austerity” Report http://bit.ly/1cpBpJi

= OTHER
* NY times 2013:
New Cholesterol Advice Startles Even Some Doctors http://nyti.ms/174CaYh
* Science Daily 2013:
Working Towards Personalized Cancer Treatment http://bit.ly/183IOyW
* NBCnews 2013
Vitamins don’t prevent heart disease or cancer, experts find http://nbcnews.to/17k5Spn

* Onclive 2013:
Another Immune Checkpoint Emerges as Anticancer Target http://bit.ly/1bp9smp
* Science Daily:
Finding Antitumor T Cells in a Patient's Own Cancer http://bit.ly/1bqCcI1
* John's Hopkins 2013:
Mystery explained: How a common chemo drug thwarts graft rejection in bone marrow transplants http://bit.ly/1apUc7U


 

Tuesday, Nov 12, 2013

*  PAL: While improving of late ...
we are still very much behind and cannot sustain operations at current levels of donations
Our services depends on public support - entirely: 
See How to Help

Please give what you can.  Thank you.
* Ibrutinib in the News - approved for MCL (a Btk-inhibitor)  PAL  | Find Trials for this type of agent
*  Blood 2013:
How I treat nodular lymphocyte predominant Hodgkin lymphoma. http://1.usa.gov/HRYBqQ
* NBCnews 2013
Vitamins don’t prevent heart disease or cancer, experts find http://nbcnews.to/17k5Spn
* Front Oncology 2012:
Therapy of newly diagnosed follicular lymphoma http://1.usa.gov/1dZEIJi
* Onclive 2013:
Another Immune Checkpoint Emerges as Anticancer Target http://bit.ly/1bp9smp
* Archives of Medical Research 2013:
Peri-Infusional Adverse Reactions to Rituximab in Patients with Non-Hodgkin's Lymphoma http://bit.ly/1i19VhI
*Brian Koffman's Blog 2013:
wCLL 2013: Part 2: Dr. George Calin Explains more about the Critical Role of micro-RNA in CLL http://bit.ly/19UfcEw
* Science-Based Medicine 2013:
Revealed by the FDA: The result http://bit.ly/1fwdUk7
* Forbes 2013
FDA Documents Paint Disturbing Picture Of Burzynski Cancer Clinic http://onforb.es/1bzIiYk
ASH
* * 6 Year Follow-Up Of The PRIMA Study of Rituximab Maintenance In previously untreated Follicular Lymphoma Pts following Frontline r-chemo http://bit.ly/1j082j2
* ASH 2013: Zevalin Vs. Maintenance With R In Patients With Newly Diagnosed Follicular Lymphoma after response to R-chemo http://bit.ly/17jNgpg

PAL and comments from others pending on these two important abstracts.

 

Sunday, Nov 10, 2013

*  PAL depends on and appreciates your support:  See How to Help
Thanks are due for recent donations by Jill,  B&B , and Molly!
*  Dartmouth 2006
Important study facts often missing in media reports about medical research http://bit.ly/17xcqVx
Anjou:  posting this again before big meetings like ASCO and ASH

* Leuk Lymphoma 2013:
Results of a prospective phase II trial evaluating interim positron emission tomography-guided high dose therapy for poor prognosis diffuse large B-cell lymphoma. http://1.usa.gov/1da8vOn 
*J Natl Cancer Inst 2013:
Independent validation of a model using cell line chemo-sensitivity to predict response to therapy.  http://1.usa.gov/1exkYiZ
* Blood 2013:
Eradication of non-Hodgkin lymphoma through the induction of tumor-specific T cell immunity by CD20-Flex BiFP. http://1.usa.gov/17UMin9

Early but interesting: "We found that the BiFP exhibited stabilities that were comparable to the parental antibody rituximab, and were able to bind to both targets with unaltered binding affinity. Notably, our data indicated that CD20-Flex BiFP could not only eliminate lymphoma temporarily, but also potentiate tumor-specific T cell immunity, which affords a long-lasting protection from tumor recurrence."

* Kevin MD 2013:
A not-to-do list for those with chronic pain or illness http://bit.ly/HiIKBb
* Youtube 2013:
What is lymphoma http://bit.ly/1aLitI3
* Youtube 2013:
Cutaneous Lymphomas: Diagnosis and Staging Posted to PAL: T-cell subtype - cutaneous  

Karl: Very nice, clear presentation
* Science-Based Medicine 2013
New concerns about the safety and quality of herbal supplements http://bit.ly/1eoYC39
* J Clin Onc 2013:
Rituximab, Methotrexate, Procarbazine, and Vincristine Followed by Consolidation Reduced-Dose Whole-Brain Radiotherapy and Cytarabine in Newly Diagnosed Primary CNS Lymphoma: Final Results and Long-Term Outcome http://bit.ly/1atL3aT
* Healthline 2013:
Hodgkin's Lymphoma and MS: A Genetic Connection http://bit.ly/1fkSAy7

 

Saturday, Nov 9, 2013

* Clinical Oncology News 2013:
Bruce D. Cheson, MD: How I Manage Follicular Lymphoma: Part I http://bit.ly/1iNRISj 
*Sunrise Rounds 2013:
Should I say “Goodbye?” http://bit.ly/1cKrZwH

Anjou:  Very interesting article on doctor-patient relationship
* Immunotherapy - not lymphoma-specifi:
Engineering hematopoietic stem cells to create melanoma specific CTL http://1.usa.gov/1bn64qu

ASH items:
* 3028 Long-Term Remissions Of Patients With Follicular Lymphoma Grade 3 Treated With Rituximab, Cyclophospamide, Doxorubicine, Vincristine and Prednisone (R-CHOP) https://ash.confex.com/ash/2013/webprogram/Paper64525.html 

Anjou Comment: interesting abstract on grade 3 altho I am guessing it has a typo and they meant 1993 instead of 1973 given that tx includes rituxan-- shows good LT responses for grade 3....

4401 Patterns Of Care and Outcomes Of Anthracyclines In Grade 3 Follicular Lymphoma (FL) https://ash.confex.com/ash/2013/webprogram/Paper62376.html

Anjou comment: suggests that w grade 3, CHOP-R best initial tx altho retrospective large sample

4321 Proliferative Activity Of Neoplastic B Cells - Impact On The Prognosis Of Follicular Lymphoma https://ash.confex.com/ash/2013/webprogram/Paper62455.html 
 

Wednesday, Nov 6, 2013

*  PAL needs your support:  See How to Help
Thanks are due for recent donations by Linda,  Joseph, Elizabeth, and Deborah!
*  Good Science and Good Medicine
Proposing the Patient-selected Control Trial (PCT)  PCT-Published-to-Lymphomation.pdf
* Brian Kaufman's CLL blog 2013:
iwCLL 2013: Dr. George Calin on Micro-RNA http://bit.ly/HGq8LY
* Oncolink 2013:
The Seasonal Flu Vaccine for People with Cancer Posted to PAL's Immunization Guide
* Oncolink 2013:
The Affordable Care Act: The Basics Cancer Patients Need to Know http://bit.ly/1b3I9xR
* Dr Sharman's Blog 2013:
11q deletion CLL http://bit.ly/1gq1jlw
* YouTube 2013:
Lymphoma Explained Clearly! 1 of 2 http://bit.ly/YpModN
* YouTube 2013:
Lymphoma Explained Clearly! 2 of 2 http://bit.ly/VbCmwj
* Science Daily 2013:
Do You Want the Good News or the Bad News First? http://bit.ly/177nGZU
* In the Pipeline 2013:
Compassionate Access: No Good Answer Posted to PAL Expanded Access - in the news

 

Tuesday, Nov 5, 2013

* YouTube 2013:
Dr. Goy on Lenalidomide for Mantle Cell Lymphoma http://bit.ly/HE5jRc
*Targeted Oncology 2013:
Brentuximab Vedotin as Frontline Therapy in Diffuse Large B-Cell Lymphoma http://bit.ly/1cJJMjB
*Oncology Times
Found: Inherited Cause of Predisposition to DLBCL http://bit.ly/1a3i9lc
*MNT 2013:
Liver tropism is key for B cell deletion immunotherapy http://bit.ly/HE75Sp
*MNT 2013
Study evaluates early stem cell transplants for non-Hodgkin's lymphoma http://bit.ly/1feNWl5
Lat Times: Science has lost its way, at a big cost to humanity - latimes.com#%21#%21 http://lat.ms/178gyMS

But concern about what is emerging as a crisis in science extends beyond the open-access movement. It's reached the National Institutes of Health, which last week launched a project to remake its researchers' approach to publication. Its new PubMed Commons system allows qualified scientists to post ongoing comments about published papers. The goal is to wean scientists from the idea that a cursory, one-time peer review is enough to validate a research study, and substitute a process of continuing scrutiny, so that poor research can be identified quickly and good research can be picked out of the crowd and find a wider audience.

NYT: Insurance Policies Not Worth Keeping - NYTimes.com http://nyti.ms/HEks58
* PAL: (subscription required)
Discussion and new articles on cd20 antibody approved for CLL http://lymphomation.forumchitchat.com/

 

Monday, Nov 4, 2013

* NYT 2013:
Doctor, First Tell Me What It Costs http://nyti.ms/1b799Jv
*NYT 2013:
Hopeful Glimmers in Long War on Cancer http://nyti.ms/17C378C
* NYTimes 2013:
Herbal Supplements Are Often Not What They Seem http://nyti.ms/1fdwHk9
* Targeted Oncology 2013:
Frontline Obinutuzumab (Gazyva) Approved for CLL http://bit.ly/1avCBxL

* Science Based Medicine 2013:
The sad saga of an Amish girl with a curable cancer whose parents are refusing chemotherapy in favor of “natural healing” http://bit.ly/1gn7GWI
* MNT 2013:
Study evaluates early stem cell transplants for non-Hodgkin's lymphoma http://bit.ly/1feNWl5
*  PAL:
We're getting close to the end of year and are not close to achieving what is needed to sustain our operations.
How to support this site and the fight against lymphoma
 

Saturday, Nov 2, 2013

*Dr. Sharman's CLL & Lymphoma Blog
Gazyva (obinutuzumab -new cd20 antibody) approved http://bit.ly/1aQznTN
*Onclive 2013:
FDA Approves Frontline Obinutuzumab for CLL http://bit.ly/1h6BqbE
* Philly.com 2013:
Early Stem Cell Transplant May Benefit Some Non-Hodgkin's Lymphoma Patients http://bit.ly/19mSxQQ

* Medscape 2013:
Your Patient's Brain on Drugs -- Cancer Drugs http://bit.ly/16SQyVC

* Haematologica 2013:
Autologous stem cell transplantation after conditioning with Zevalin plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial. http://1.usa.gov/1aigtkq

* Brit J Haematol 2013:
Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas. http://1.usa.gov/181hk9b
* Medscape 2013:
Mindfulness Helps Improve Sleep in Cancer Survivors http://bit.ly/1iAxprE
* You tube 2013:
Diffuse large b-cell lymphoma http://bit.ly/1aZyEMS
* You Tube 2013:
Mr T T Cell Lymphoma Survivor http://bit.ly/HjoH59
You Tube 2013:
Medicines in Development - Leukemia & Lymphoma http://bit.ly/1ahTbvd
* Science Daily 2013:
Study Offers New Theory of Cancer Development http://bit.ly/HtgtI8
 

Friday, Nov 1, 2013

* * FDA Approves Gazyva™ (Obinutuzumab) for People With Previously Untreated Chronic Lymphocytic Leukemia (CLL) | http://bit.ly/1h6sza7

Gazyva AKA obinutuzumab (GA101)  was approved for use in combination with chlorambucil for untreated CLL and is the first drug that the FDA has approved under its "Breakthrough Therapy" designation.

Comment: Another drug name I will have trouble pronouncing.   You have to hand it to Roche - they know how to pick a protocol to go up against.  That Chlorambucil + Gazyva beat Chlorambucil alone does not seem surprising.  Why was the comparator not Chlorambucil + Rituxan ... or Chlorambucil + ofatumumab?    Having new effective options is good for patients!  Hopefully the off-label use of this drug will not inhibit testing of how it actually compares to other cd20 antibodies.  ~ KarlS
*You Tube 2013:
Hodgkin's Lymphoma http://bit.ly/1aZvokv
*Columbia University 2013:
Celiac and Lymphoma: What Have We Learned? http://bit.ly/1hzAMRU
* U Mich 2013:
Newly identified proteins make promising targets for blocking graft-vs.-host disease
Finding could help improve outcomes from bone marrow transplants http://bit.ly/1dVVXxA
*NY Times 2013:
The Pills of Last Resort: How Dying Patients Get Access to Experimental Drugs http://nyti.ms/1afTJBB
* NEJM
Autologous Transplantation as Consolidation for Aggressive Non-Hodgkin's Lymphoma —  http://bit.ly/1aiasUM
*Medpage Today 2013:
Stem-Cell Therapy Misses Mark in Lymphoma Trial http://bit.ly/17yjj8G
*Annals of Oncology 2013:
Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study http://bit.ly/1aHJKHR
*JCO 2013
Patient-Physician Communication About Health-Related Quality-of-Life Problems:
 Are Non-Hodgkin Lymphoma Survivors Willing to Talk?  http://bit.ly/17uTBnA
*Medscape 2013:
Early Transplant Improves Survival in High-Risk Lymphoma http://bit.ly/16ne4rp
* NIH VideoCasting and Podcasting --
Interesting Upcoming Events: http://1.usa.gov/16Tg2gk

Thursday, October 31, 2013

*Your support is what makes this resource - lymphomation.org possible!
How to support Patients Against Lymphoma -
with the easy-to-use vehicle donation program http://bit.ly/11tqxX8

A shout-out Thanks to John for his generous contribution on Oct 24th via PayPAL!
*Medscape 2013:
PD-1 Blockade Agent Promising for Hematologic Malignancies http://bit.ly/16NeQLl
* PAL query of ClinicalTrials.gov: Lymphoma Trials using PD-1 blockade: http://1.usa.gov/QlPona 
*Psych Central 2013:
How Healthy Couples Handle Tough Times http://bit.ly/HuLzhQ
*Medscape 2013:
'Dead Man Walking': A Too Common Cancer Patient in the US http://bit.ly/16Nfb0C
*Science Daily 2013:
Unpublished Trial Data 'Violates an Ethical Obligation' to Study Participants, Say Researchers http://bit.ly/1dNT8yw
* Science Daily 2013:
Quality of Care Improves for Cancer Patients Who Get Palliative Care Consultation http://bit.ly/17xKwZ6
* JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma http://bit.ly/1aIdggu 

The finding that SEC31A-JAK2 responds to JAK inhibitors indicates that patients with cHL and JAK2 rearrangements may benefit from targeted therapies.
* Related study: Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and PMLBL -http://1.usa.gov/19YXLEf 

 

Wednesday, October 30, 2013

* PAL online survey
Would you enroll in this follicular lymphoma trial - and which arm do you prefer?

For patients, caregivers, or oncologists!

* News Medical 2013:
High levels of omega-3 fatty acid consumption may lead to unintended health consequences http://bit.ly/1amAvjT

* New Yorker 2013:
The Cost of Living: New drugs could extend cancer patients’ lives—by days. At a cost of thousands and thousands of dollars.
Prompting some doctors to refuse to use them. http://nym.ag/1dIyEqP

* Respectful Insolence 2013:
So chemotherapy does work, after all (revisited) http://bit.ly/1aoAqMk

 

Tuesday, October 29, 2013

* PAL - Update to transformation page: 
   Posted to About Transformation
* Medpage Today 2013:
Statin May Cut GVHD in Stem-Cell Recipients http://bit.ly/1dFEysO
* Blood 2013:
Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study http://bit.ly/1aap74v
* KevinMD 2013:
When a patient teaches you to tango http://bit.ly/17TM4Jo

* Digital Journal 2013:
The Non-Hodgkin's Lymphoma Drug Market Will Nearly Double to More Than $10 Billion by 2022 http://bit.ly/HoT62H
* Rheumatology News 2013:
Anti-TNFs Have Not Raised Lymphoma Risk http://bit.ly/1dE61uO
* Psych Congress 2013:
No Link Between Depression and Cancer Risk: Study http://bit.ly/1aBbKyu
* Science-based Medicine 2013:
Chemotherapy doesn’t work? Not so fast… (A lesson from history) http://bit.ly/1aOS0nD
* MSKCC 2013: At Work:
Anas Younes, Chief of the Lymphoma Service http://bit.ly/1ar0VgE

* Oncology Tube 2013:
Subtyping of Non-Hodgkin Lymphoma in Adults, with John Sweetenham, MD http://bit.ly/17pjcMx
* Targeted Oncology 2013:
Addressing Challenges in Indolent Non-Hodgkin Lymphoma and Mantle Cell Lymphoma - http://bit.ly/16eDqI4
* Sunrise Rounds 2013:
What is End-of-Life Quality? http://bit.ly/17VKYg9
* Drugs from the Crucible of Nature |
Guest Blog, Scientific American Blog Network by David Kroll http://bit.ly/16HtsRW

Monday, October 28, 2013

* PAL Update to transformation page: 
   Clinical trial search tool  ... and
   Lossos and Gascoyne, 2011:
   Transformation of Follicular Lymphoma Posted to About Transformation
* Helio 2013:
Regimen produced durable response in indolent B-cell, mantle cell lymphomas http://bit.ly/Hipxjc
* Therapy for CLL:
Where Are We Today? Where Will We Be Tomorrow? - http://bit.ly/1gQoYNb

* Targeted Oncology 2013:
Emerging Therapies for the Treatment of Mantle Cell Lymphoma http://bit.ly/1anio9z
* KevinMD 2013: A not-to-do list for those with chronic pain or illness http://bit.ly/HiIKBb
* Ann Hematol 2013:
GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma. http://1.usa.gov/HlRTsN
* Science Daily 2013:
Nano-Dwarves Turn Tumor Assassins http://bit.ly/1asg6bg
* Science Daily 2013:
Debunking Myths About How Cancer Spreads http://bit.ly/1chEr72
* Live Science 2013: 11
Surprising Facts About the Immune System http://bit.ly/1hh39nH
* Leuk Lymph 2013:
High-dose therapy and autologous hematopoietic stem cell transplantation in T-cell lymphoma: a single center experience. http://1.usa.gov/H9ek3W

Friday, October 25, 2013

* CDC:
Vaccines: Recs/Vac-Admin/Contraindications to Vaccines Chart for Adults PAL: Immunization Guide
* CDC: Vaccine Information Statement:
Diphtheria, Tetanus, and Pertussis - Vaccines - CDC PAL: Immunization Guide 
* Targeted Oncology 2013:
Dr. Zelenetz Discusses Diagnosis and Treatment Issues in Indolent NHL http://bit.ly/17O4Emf

Comment: This could be a tough read for patients in that it discusses survival expectations and the uncertainty about how an indolent lymphoma will behave.  Other experts say that even advance indolent lymphoma is cured but at a modest rate - about 20%. KarlS
* Sunrise Rounds 2013:
…so sayeth the proxy http://bit.ly/Hgsu3w
NYtimes 2013:
Living With Cancer: Brains on Chemo http://nyti.ms/1ihhLkz

Comment: It's important to appreciate that the chemo agents and doses used to treat lymphoma are not expected to cause major cognitive problems and that when it happens it is generally reversible with time.  KarlS
* Medscape 2013:
Dazed and Confused About Molecular Data? http://bit.ly/H5xg3t
* Study ties bone marrow transplant to negative sexual side effects: Radiation, graft-versus-host disease cited as particularly damaging http://bit.ly/18hv27i
* Live Science 2013:
Suzanne Somers' Health Advice May Be Dangerously Wrong http://bKit.ly/17hWCrl
* CARING CONNECTIONS - NHPCO
Download Your State's Advance Directives -  (scroll down to states) Posted to PAL: Palliative Care

 

Thursday, October 24, 2013

* CARING CONNECTIONS - NHPCO
Download Your State's Advance Directives -  (scroll down to states) http://bit.ly/1a50vdr
* Targeted Oncology 2013:
Clinical Advances in Mantle Cell Lymphoma http://bit.ly/1fXycWr
* OncLive 2013:
Novel B-Cell Receptor Signaling Inhibitors Show Promise http://bit.ly/1aHLHSU
* U Penn 2013:
Penn docs find successful strategy to expand patient participation in hard-to-enroll clinical trials http://bit.ly/Hi5KzE
* Helio 2013:
Rituximab prevented corticosteroid-requiring chronic GVHD http://bit.ly/19wD8wx
* Science Daily 2013:
 Cancer Wasting Due in Part to Tumor Factors That Block Muscle Repair, Study Shows http://bit.ly/1cfGoRt
* PAL notice:  2 new trials of interest for indolent b-cell lymphoma:
Testing Idelalisib combinations - ClinicalTrials.gov Clinical Trials of Interest  

Comment:  Idelalisib is an oral drug that targets a kinase in the b-cell receptor pathway, which is overactive in b-cell lymphomas.
 

Wednesday, October 23, 2013

* Science Daily 2013:
Genome of Aggressive Lymphoma Sequenced (mantle cell) http://bit.ly/1adZvrE
* Helio 2013:
Combination therapy plus WBRT effective in CNS lymphoma http://bit.ly/Hgxfth
* Immunol Lett 2013:
Standard Therapies versus Novel Therapies in Hodgkin Lymphoma. http://1.usa.gov/1aEWVYj
* Oncology Tube 2013:
Owen O'Connor, MD, PhD lymphoma, targeting b-cell receptors, CD 30, Rituxan http://bit.ly/18I1hk9

EJNMMI 2013:
Explorative analyses on the value of interim PET for prediction of response in pediatric and adolescent non-Hodgkin lymphoma patients. http://1.usa.gov/1gDesc6
* New Statesman 2013: article by Jerome Groopman
Inside the quackish cult of alternative medicine http://bit.ly/1bSHZbx 

KevinMD 2013:
Admit when you fall short: The power of “I don’t know” http://bit.ly/1adZNyy
* Cancer Research UK 2013:
Genetic risk factor links Hodgkin lymphoma and multiple sclerosis http://bit.ly/1bcRLEo
 

Tuesday, October 22, 2013

* The Promising Path for CAR Immunotherapy - OncologyTube
Posted to: Programmed T-cells - Licensed to Kill (CAR T-cells)  
* Kaiser Health News
Thousands Of Consumers Get Insurance Cancellation Notices Due To Health Law Changes -  http://bit.ly/H6nQoM

The main reason insurers offer is that the policies fall short of what the Affordable Care Act requires starting Jan. 1.
* Health News Review 2013:
Canadian journalist: every cancer cure claim needs scrutiny http://bit.ly/1h0mzx8  (on DCA)

Comment on conspiracies:  The US drug evaluation process truly deserves our respect and admiration.  If you have a drug product that you believe can cure, you write up the protocol that pre-specifies what it will achieve, run it and then submit the results. ... It will  get approved in a timely fashion if it meets the primary endpoint -- worked out between the sponsor and the regulatory agency.  We can also be thankful and reassured that the review of such evidence is done independent of financial conflict of interest.  KarlS.
* Onclive 2013:
Evidence-Based Medicine: Examining the Gap Between Rhetoric and Reality - http://bit.ly/1fRABlF
* New York Mag 2013
The Cost of Living: New drugs could extend cancer patients’ lives—by days. At a cost of thousands and thousands of dollars. Prompting some doctors to refuse to use them. http://nym.ag/1fSGtuP 

 

Monday, October 21, 2013

* Respectful Insolence 2013:
No, redefining cancer doesn’t mean death panels http://bit.ly/1azzbou

Esquire 2013:
The End of Cancer In the near future, our immune systems will be genetically supercharged to kill cancer. We will all be like Logan  Parker. http://bit.ly/GX90AA
* SafeShare TV 2013:
The Operating Room of the Future http://bit.ly/1a2hVx7

 Not lymphoma related but interesting research from Israel.
* Today Health 2013:
After diagnosis, some keep their cancer a secret http://on.today.com/1d8U540
* ASH Paper: A Phase I Study of DCDT2980S, an Antibody-Drug Conjugate (ADC) Targeting CD22, in
Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL)
Posted to related study in Clinical Trials of Interest - mixed types
* ASH 2012, Paper: A Phase I Study of the Anti-CD79b Antibody-Drug Conjugate (ADC) DCDS4501A
Targeting CD79b in Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL)
Posted to related study in Clinical Trials of Interest - mixed types
* Testing Ibrutinib in Patients With Refractory Follicular Lymphoma - ClinicalTrials.gov Clinical Trials of Interest  
* Testing Ibrutinib With Bendamustine and Rituxan for Newly Diagnosed Mantle Cell #Lymphoma -
ClinicalTrials.gov Clinical Trials of Interest  

Saturday, October 18, 2013

*  PAL: Updated Trials of Interest:
status of trials and click counts updated for all types Clinical Trials of Interest

Satisfying to see that a good number of trials in our list achieved enrollment goals ... and that perhaps we played a part.
* Cleveland Clinic 2013:
6 Scary Myths About Cancer http://bit.ly/16XRAhj
* Clin Lymphoma Myeloma leuk 2013:
 Limited Utility of Surveillance Imaging for Detecting Disease Relapse in Patients With Non-Hodgkin Lymphoma in First Complete Remission. http://1.usa.gov/19KMktM
* Dr Len's Cancer Blog 2013:
Personalized Medicine Revolution Will Require Revolutionary Changes In How We Care For Cancer Patients
http://bit.ly/19gaf7u
* NYT 2013:
In Sickness and in Health: A Wedding in the Shadow of Cancer http://nyti.ms/H2wlBb
* Slate 2013:
What’s the Point of Finding Cancer Mutations? http://slate.me/1avYtUD
* Study of interest: Untreated Follicular Lymphoma - ALLIANCE study:
Rituximab, Lenalidomide, and Ibrutinib http://1.usa.gov/1cBniFe

Exploring non-chemo, targeted combination approach
* Br J Haematol. 2013 Transformed non-hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database. PubMed - NCBI http://1.usa.gov/1avIWEi

See also PAL:  About Transformation
* Medscape:
Old Drugs That Are Still Good Drugs http://bit.ly/H7orXx
(Requires free login)
 

Friday, October 18, 2013

* Healthleadersmedia.com:
Med Schools Failing on Conflict of Interest Policies http://bit.ly/1cDfZtp

* PAL: Updated Trials of Interest: Lymphoma - mixed type section
status of trials and click counts Clinical Trials of Interest
*  PAL: New topic  Background on support group policies
PAL support groups options: PAL forum, Lymphomation yahoo group, Facebook, Twitter:  Support Groups

Snip from Background:  On the Yahoo groups lists we sometimes get emails from subscribers who want information only and resent getting their inbox filled with patient-to-patient correspondence. That said, others appear to like having a feeling of community - where they can talk about anything anytime ... encourage one another, and get reassured (the community approach). So these are two equally valid and understandable desires and expectations ... Background on support group policies

* The ASCO Post
Comparative Effectiveness Research: Its Time Has Arrived
A Conversation With Gary Lyman, MD http://bit.ly/16iAxTm
* Helio 2013:
Alisertib active in relapsed, refractory B-cell, T-cell non-Hodgkin’s lymphomas http://bit.ly/18sChgG
* Telemanagement 2013:
Infection (Chlamydia) linked to eye lymphoma http://bit.ly/1atNpao
* Sunrise Rounds 2013:
Thoughts on suicide http://bit.ly/1gR66el
* Onc Times 2013:
Leukemia & Lymphoma Society Survey Finds 'Alarming' Gap in Public Knowledge about Hematologic Cancers http://bit.ly/1asFdqY
* Medscape 2013:
Discuss Costs of Tests and Therapies With Patients http://bit.ly/16jrly8
* NEJM 2013: Full Disclosure —
Out-of-Pocket Costs as Side Effects http://bit.ly/19VzdtW
* MedPage Today 2013:
Doctors Urged to Talk About Costs of Treatment http://bit.ly/17PoYTj
* Onc Times 2013: MUSINGS OF A CANCER DOCTOR:
How Much Life? http://bit.ly/175I5Pu
 

Wednesday, October 16, 2013

* Weill Cornell 2013:
Two Newly Opened Clinical Trials Evaluate Idelalisib (targeting a kinase in the B-cell receptor pathway)
in Indolent non-Hodgkin Lymphoma http://bit.ly/1aom8pW
* Cancer Research UK 2013;
A new age of cancer classification and treatment http://bit.ly/1epDA1f

Provides an excellent overview of the complex picture of cancer - "the inadequacy of simple anatomical explanations of the disease."
* Helio 2013:
Rituximab plus epratuzumab effective in follicular lymphoma http://bit.ly/1apxlq5

“The combination therapy was continued as extended induction in weeks 12, 20, 28 and 36.”

“Our study confirms that immunotherapy without cytotoxic therapy can achieve durable remissions in untreated follicular lymphoma,” Cheson and colleagues wrote. “The high response rate and prolonged time to progression observed with this antibody combination ... further support the development of biologic, nonchemotherapeutic approaches for these patients.”
* Respectful Insolence 2013:  An article about Gerson Therapy
Sharyn dies tragically because she followed the example of her daughter, The Wellness Warrior  http://bit.ly/16dfjvm 

BBC 2013:
The problem with taking too many vitamins http://bbc.in/19TxYvg
* From ajcp.ascpjournals.org:
Fine-Needle Aspiration Cytology in the Diagnosis of Lymphoma The Next Step
Linda M. Sandhaus, MD Post to PAL - Diagnostic
* eMedicineHealth:
Candidiasis (Yeast Infection) Symptoms, Causes, Treatment - Posted to PAL - Side Effect - Fungal Infection 

Tuesday, October 15, 2013

* Goda - 2010 - Cancer (full text)
Long-term outcome in localized extranodal MALT lymphomas treated with Radiotherapy  http://bit.ly/19LlMbW
* Neurologica 2013:
What’s In Your Herbal Supplement? http://bit.ly/19L4Y94
* MNT 2013:
Nearly 60 per cent of herbal products studied omitted ingredients, contained fillers http://bit.ly/1coCAdd

Comment: This is what can happen when you don't regulate an industry - some of the companies will take shortcuts to gain a competitive advantage - putting the public at risk.

* ANN Oncol 2013:
An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma. http://1.usa.gov/19EcXCO
* Leuk Lymphoma 2013: Treatment with cyclophosphamide, vindesine, cytarabine, dexamethasone, and bleomycin in patients with relapsed/refractory diffuse large B cell lymphoma. http://1.usa.gov/1gfMWkG
* Blood 2013:
The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). http://1.usa.gov/17q1GE8
* J Clin Onc 2013:
Rituximab, Methotrexate, Procarbazine, and Vincristine Followed by Consolidation Reduced-Dose Whole-Brain Radiotherapy and Cytarabine in Newly Diagnosed Primary CNS Lymphoma: Final Results and Long-Term Outcome. http://1.usa.gov/17DZd8i
* NYT 2013:
Breaking Through Cancer’s Shield http://nyti.ms/1alNyNc
* NewsMedical 2013:
Study provides novel link between cellular aging and diffuse large B-cell lymphoma http://bit.ly/19EdVPB
* Science Based Medicine 2013:
Yes, Chris beat cancer, but it wasn’t quackery that cured him http://bit.ly/19L6eJ9

 

Monday, October 14, 2013

* Eurekalert.org:
protein experiment in mice links exercise to brain health ... http://bit.ly/1brokPU
* Study: Herbal products omit ingredients, contain fillers http://bit.ly/1bRFYAC
* Dr. Sharman's CLL & Lymphoma Blog:
Engineered T Cells for Lymphoma at NIH http://bit.ly/164yAiu

* ClinicalTrials.gov:
Show studies recruiting for CART-19 (Engineered Lymphocyte Therapy)   http://1.usa.gov/1cDypNe

* PAL:  Advocates needed
Introducing The North American Consortium for
Familial (common to families) Hematologic (blood cell) Malignancies PAL
* * Brian Koffman interviews - iwCLL 2013:
Dr. Jan Burger tells us how the kinase-targeted agents,
specific to the B-cell receptor pathway, are thought to work in CLL  PAL: Experts on Lymphoma and CLL

First and Second interview embedded from
the source: http://bkoffman.blogspot.com/
 

Friday, October 11, 2013

* HELP needed!
How to support Patients Against #Lymphoma - with the easy-to-use vehicle donation program http://bit.ly/11tqxX8
* Vitamin D supplements ineffective in preventing osteoporosis, Lancet published study finds http://bit.ly/16B6YzW
Taking vitamin D supplements does not improve bone mineral density at the total hip, spine, forearm, or in the body as a whole, a large meta-analysis involving more than 4000 healthy adults published in The Lancet has found.

* MNT, 2013:
Persistent anti-tumor immune response enabled by novel gene therapy for lymphoma and CLL http://bit.ly/GP4Uuu
* Dr. Sharman's CLL & Lymphoma Blog:
The race [for marketing approval of CLL agents] tightens http://bit.ly/15YLnmK

Thursday, October 10, 2013

* HELP needed!
How to support Patients Against #Lymphoma - with the easy-to-use vehicle donation program http://bit.ly/11tqxX8

* Press release
Gilead to Stop Phase 3 Study 116 of Idelalisib in Chronic Lymphocytic Leukemia Early Because of Positive Risk-Benefit http://bit.ly/16Thk0k

Study 116 was a randomized, double-blind, placebo-controlled, Phase 3 study evaluating the efficacy and safety of idelalisib in combination with rituximab. The study enrolled 220 adult patients with previously treated recurrent CLL who had measureable lymphadenopathy with disease progression less than 24 months following completion of prior therapy, and who required treatment but were not fit to receive cytotoxic therapy. Eligible patients were randomized to receive eight infusions of rituximab over 24 weeks plus either idelalisib (150 mg) or placebo taken orally twice daily continuously until disease progression or unacceptable toxicity. Patients who progressed on Study 116 were eligible to receive active idelalisib therapy in a double-blind extension study (Study 117).

* From well.blogs.nytimes.com:
exercise-as-preventive-medicine http://nyti.ms/1grxHme
* Kevin, M.D. - Medical Web
How do we empower patients with information while not scaring them? http://bit.ly/1e9GrLT
* Study of interest: Relapsed or Refractory Hodgkin Lymphoma
Ipilimumab and Brentuximab Vedotin in Treating Patients With http://1.usa.gov/16ECdpo

Exploring inhibiting immune checkpoint blockade with a proven targeted therapy.
* Immunol Lett. 2013
Reprogramming cell death: bcl2 family inhibition - PubMed - NCBI http://1.usa.gov/16Sfm0j
* Managing Infections in Patients With Hematologic Malignancies
Medscape 2003 (free login req.) http://bit.ly/axtWSg 

Initial Evaluation, Initial Management, Bacterial Infections,
Intravascular Devices, Community Respiratory Viruses, Fungal Infections
* HemOnc Today ‏
Single-agent lenalidomide safe, effective in mantle-cell lymphoma: http://ow.ly/pG7D4

 

Wednesday, October 9, 2013

* Kevin, M.D. - Medical Weblog
Clinicians do not have the luxury to not care about costs http://bit.ly/1a8Maxg
* Non-Hodgkin Lymphoma Risk and Variants in Genes Controlling Lymphocyte Development.
From ncbi.nlm.nih.gov: http://1.usa.gov/GMoI12
* The ASCO Post, 2013:
Ibrutinib in Mantle Cell Lymphoma Yields 'Unprecedented' Response Rates http://bit.ly/Yu9Ru3

The investigational agent ibrutinib demonstrated “unprecedented” single-agent activity in relapsed or refractory mantle cell lymphoma, according to the lead author of an international phase II study reported at the Annual Meeting of the American
* Ther Adv Hematol. 2013
Clinical implications and prognostic role of minimal residual disease detection in follicular lymphoma
From ncbi.nlm.nih.gov: http://1.usa.gov/12H6NDw 

Minimal residual disease (MRD) is defined as any approach aimed at detecting and possibly quantifying residual tumor cells beyond the sensitivity level of routine imaging and laboratory techniques.

 

Tuesday, October 7, 2013

* Brian Koffman interviews:
iwCLL 2013: Dr. Jan Burger Discusses the Role of the Micro-environment in #CLL: Part 1 http://bit.ly/17e2lsk
*  PAL update:
7 Patient-centered reasons to consider Clinical Trials
* PAL trial of interest: Look mom, no R!
Lenalidomide and Ibrutinib for Relapsed B-Cell Non-Hodgkin #Lymphoma - ClinicalTrials.gov http://1.usa.gov/19aHfwU
* The ASCO Post
The Direction of Immunotherapy Over the Next Decade
A Conversation With David L. Porter, MD http://bit.ly/19wbz2W
* Science Blog:
Cancer Treatment Centers of America:
Revisiting the epitome of “integrative” cancer care « Science-Based Medicine http://bit.ly/1e6cBHT 

* PAL:
Donate to support our mission and receive a set of 4 postcards
with original line drawings as a thank you.

 

Monday, October 7, 2013

* The ASCO, 2013:
Under-treatment of Cancer Pain Remains a Persistent Problem in Oncology
A Conversation With Russell K. Portenoy, MD Post Lymphomation - Pain: In the News
* The ASCO Post:
New Research on Combination Chemotherapy, Prognostic Biomarkers, and PET-guided Radiation Therapy in B-cell Malignancies http://bit.ly/1bCF4Yq
* Medical News Today:
Depression affects memory by 'impairing ability to differentiate similarities' http://bit.ly/15RyiM1

* Choosing a Medigap Policy: 
A Guide to Health Insurance for People with Medicare (PDF) medicare.gov
 
* PAL - Advocate perspective on  PAL
Phase I studies - when to participate?   Should participants receive increasing doses?

TIP:  Searching for phase I trials is a good way to keep current with the direction of research as this is where you will find what novel agents are in development.    FIND: Phase I studies for Lymphoma OR CLL: ClinicalTrials.gov

Saturday, October 5, 2013

* The Medical News:
Tips to avoid food-borne illness PAL Treatment Support page

 

* Brian Koffman's Awesome Transplant and CLL Adventure:
Learning from and about Cancer: iwCLL 2013: The Patient's Perspective http://bit.ly/GBzPKi

* NPR:
Some Online Journals Will Publish Fake Science, For A Fee http://n.pr/19pefoO

The importance of being selective about the journals you read and take seriously.  A short list for me: Lancet, NEJM, JCO, Blood, ...

TED talks -
Can technology solve our big problems? http://bit.ly/192fHJP

Karl:  Maybe a bit off topic as I'm optimistic we can and will solve the lymphoma problem

* NeuroLogica Blog:
CAM Research – Be Careful What You Wish For http://bit.ly/15c2cYI

Edzard Ernst is the first professor of complementary and alternative medicine (CAM). He began 20 years ago as a CAM enthusiast, and a trained homeopath, and genuinely wanted to point the critical eye of science onto CAM. Many CAM proponents claim this, but Ernst was different in a key respect – he wanted to use rigorous scientific research to find out if

Thursday, October 3, 2013

* Healthcare.gov: The ACA insurance exchange is open  http://1.usa.gov/GzzB6L

Wait for a login screen to create a secure account  - which could take a while today because of VERY high volume
* NEW Please take our VERY short 2-question Survey on a Trial for untreated Follicular Lymphoma

For patients, caregivers, or oncologists!

* MD Anderson Cancer Center
Tips for organizing your medical records - Cancerwise  http://bit.ly/GAVRNM 
* The ASCO Post, 2013: FDA Approves Mechlorethamine Gel for Cutaneous T-Cell Lymphoma  http://bit.ly/18Ultxa

This gel is the first and only FDA-approved topical formulation of mechlorethamine, which is commonly known as nitrogen mustard. The gel is applied topically once a day and dries on the skin.

RISK FACTORS
* Research, 2013:
Children with inherited anti-inflammatory defect may have predisposition to lymphoma http://bit.ly/1f2t2YO 

Fits with a known risk factor for lymphoma - chronic inflammation and infection.
* PubMed - NCBI Asian Pac J Cancer Prev. 2013:
Breastfeeding and the Risk of Childhood Hodgkin Lymphoma: A Systematic Review and Meta-analysis. - http://1.usa.gov/GBb4O1
TRIALS
* Constellation Pharmaceuticals
Initiates Clinical Development of CPI-0610, a Novel BET
Protein Bromodomain Inhibitor, in Patients with Lymphoma http://bit.ly/18R2V0T

* Study to consider?
  A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma - Full Text View
- ClinicalTrials.gov http://1.usa.gov/15MC83D

This is a safety study ... perhaps reasonable to consider when you are out of other options ... reasonable given
its unique mechanism of action.
TECHNICAL ITEMS:
* Haematologica. 2012:  Technical
MicroRNA profiling of follicular lymphoma identifies microRNAs related to cell proliferation and tumor response From ncbi.nlm.nih.gov: http://1.usa.gov/172EDxW

The potential value of prognostic markers being it helps to identify patients who may  benefit from novel experimental approaches to treatment.
* PubMed - NCBI, 2013:
Lactate Dehydrogenase 5 Expression in NHL predicts higher risk lymphoma http://1.usa.gov/GAWfvF 

* PubMed 2013: Technical
CLL Cells Respond to B-Cell Receptor Stimulation with a MicroRNA/mRNA Signature Associated with MYC Activation and Cell Cycle Progression http://1.usa.gov/1a2u0hT (full text)
 
BELIEF SYSTEMS
* Medscape Today video:
Do You Believe in Magic? Topol, Offit on Alternative Medicine  http://bit.ly/1g767L2 

Dr. Offit takes a look at the billion-dollar, unregulated supplement, vitamin, and alternative medicine industries.

* NeuroLogica Blog:
Science Rejection, and Conspiracy Thinking http://bit.ly/GATNFj

This item nicely explains how our view of the world influences what we tend to believe.

Wednesday, October 2, 2013

* Exchange and Government shutdown dominates the news:
* NEJM: Only the Beginning — What's Next at the Health Insurance Exchanges? http://bit.ly/172LOat
Perspective by Henry J. Aaron, Ph.D., and Kevin W. Lucia, J.D., M.H.P.

Excellent overview of the Exchange - challenges and advantages.
* CNN 2013:
Government shutdown forces clinical trial patients to wait http://bit.ly/1c5sSi6
* ASCO 2013: ASCO Update:
Government Shutdown Impact on Cancer Care http://bit.ly/1hlfoNo
* MNT 2013:
Government shutdown delays NIH trials and impairs CDC http://bit.ly/1bvZdfo
* MDA 2013:
Depression in cancer patients: What you should know http://bit.ly/1c5masH
* Scientific American 2013:
Hallmarks of Cancer 3: Evading Apoptosis http://bit.ly/1fJo9oI
* KevinMD.com 2013: Social support matters in cancer survival http://bit.ly/15J0DDZ
* List of Health Apps for Phones http://bit.ly/GzJjX0  (pharma sponsored)
* INSERM 2013:
Depression does not expose someone to a greater risk of cancer http://bit.ly/18r9Tuw
* Sunrise Rounds 2013:
Sex versus Cancer http://bit.ly/152g9bL
* Fierce Drug Delivery 2013:
John Theurer Cancer Center touts two oral lymphoma drug studies http://bit.ly/19m0i57
* Video feature - Dr. James Grime:   PAL: expert videos
A simple controlled study showing how our political beliefs affect how we interpret the same numbers - applied to different questions (neutral vs. controversial).

If you don't like what the numbers show - you look deeper. If you like it, you stop.
Dr. Grimes then explains how the peer review system protects against this in science.
* Gottlieb, BMJ. 2000:
Part of the rationale for ACA - to prevent personal bankruptcy from medical bills http://1.usa.gov/19hocVe

The findings illustrate how fragile middle class status is for many American families, Professor Warren said. These families are “just one serious illness away from financial collapse,” she said. “What a scary way to think about America.”

 

Tuesday, October 1, 2013

* A phase III randomized study comparing CHOP plus rituximab with CHOP plus RIT for front-line treatment of follicular lymphoma: Results of subset analyses and a comparison of prognostic models. http://bit.ly/16ejO7g  

Elevated B2M AND LDH (blood test markers) were equivalent to the FLIPI (an large index of risk factors) in predicting high risk follicular lymphoma.  Limitation: a retrospective analysis.
* News medical 2013:
Biology of tumour more important than primary site, say researchers http://bit.ly/19c6nqD
* Cancer Research 2013:
Poetically Inspired by the Emperor of all Maladies http://bit.ly/18mrsMb
* ECCO 2013:
The State of Oncology 2013: New report draws attention to urgent need to tackle disparities in cancer care worldwide
http://bit.ly/16a19cG
* Science Daily 2013:
New Approaches to Testing Cancer Drugs Needed http://bit.ly/16bzTKW
* Univ of Michigan 2013:
Liquid biopsy could improve cancer diagnosis and treatment http://bit.ly/16DOn8z 

Early research- not lymphoma specific
* Annals of Oncology 2013:
Lymphoma occurring in patients over 90 years of age: characteristics, outcomes, and prognostic factors.
A retrospective analysis of 234 cases from the LYSA PAL - In the News: Lymphoma in elderly patients

Monday, September 30, 2013

*  Leuk Lymphoma 2013:
Treatment of splenic marginal zone lymphoma: should splenectomy be abandoned? PAL: Splenic MZL - In the News
* KevinMD 2013:
How to meet your doctor and receive your diagnosis in a better way http://bit.ly/1fQJ5b3
* CNN 2013:
In cancer drug battle, both sides appeal to ethics http://bit.ly/18yrS2I  
* PAL - About Expanded Access (compassionate use) 
* Bone Marrow Transplant 2013:
Multiple infusions of CD20-targeted T cells and low-dose IL-2 after SCT for high-risk non-Hodgkin's lymphoma:
A pilot study. http://1.usa.gov/1bk7Tc0 
* J Clin Onc 2013:
Patient-Physician Communication About Health-Related Quality-of-Life Problems:
Are Non-Hodgkin Lymphoma Survivors Willing to Talk? http://1.usa.gov/16VJTob

Saturday, September 28, 2013

*  NYTimes 2013:
A Guide to the New Exchanges for Health Insurance http://nyti.ms/1haLSK7
* Mitt Romney explains ACA - better than Obama: YouTube http://bit.ly/1fQWTCo
* Helio 2013:
Rituximab maintenance did not significantly extend PFS in follicular lymphoma http://bit.ly/18vB73O
* Columbia Univ- Youtube 2013:
Celiac and Lymphoma: What Have We Learned? http://bit.ly/1awbgYU
* Mindbodygreen 2013:
5 Things You Should NEVER Say To People With Cancer http://bit.ly/198rxjA
* Irish Medical Times 2013:
Tracking the trends in Hodgkin’s lymphoma http://bit.ly/1avopS4
 

 

Friday, September 27, 2013

*  Medscape 2013:
Making Cancer Survivorship Last: How Docs Can Help http://bit.ly/17jcdQK
* Medscape 2013:
8 ways to keep cancer survivors healthy http://bit.ly/187fINy
* J Clin Onc 2013:
Patient-Physician Communication About Health-Related Quality-of-Life Problems:
re Non-Hodgkin Lymphoma Survivors Willing to  Talk? http://1.usa.gov/1bgss9a
* NYTimes:
Living With Cancer: Feeling Older Than My Age http://nyti.ms/196j54d
* Weill Cornell 2013:
Ibrutinib Promotes a High Frequency of Durable Response in Relapsed/Refractory
and Older Treatment Naive CLL Patients http://bit.ly/15Xf1H4
* Medscape 2013: C difficile:
Symptomatic Patients No Longer the Main Source http://bit.ly/15W1VK8
* KevinMD 2013:
Defining the 3 goals of palliative care http://bit.ly/19KQToy
* Science-Based Medicine 2013:
A closer look at Dr. Oz’s 15 Superfoods http://bit.ly/1749tKI
 

Thursday, September 26, 2013

* LLS 2013:
The Affordable Care Act: What Blood Cancer Patients Need to Know http://bit.ly/1fDRgaz
* Sequester Still Impacting Scientific Research.

The Washington Post (9/25, Cha, 4.28M) reports on George Mason University researcher Yuntao Wu, “one of thousands of scientists who lost his grant in the wake of sequester cuts,” which “took effect March 1 have sent shock waves through the nation’s research labs, delaying research and forcing layoffs.” The National Institutes of Health budget was reduced 5.5 percent, and its impact on the scientific and medical community has been described as “deeply demoralized,” by NIH Director Francis Collins. According to Collins, “the NIH issued 640 fewer grants in the last fiscal year and that if the cuts continue at the same level next year, several hundred more projects will not be funded.” The odds of receiving funding now stand at one in six, compared to the previous one in three chance.

A segment on Kansas Public Radio (9/26) reports on the sequester’s impact on medical research funding. The piece notes that ASCO’s “Chief medical officer Dr. Richard Schilsky says 75 percent of cancer researchers surveyed say the struggle for federal funding is having a direct impact on their work.”
* Statistician Susan Murphy
2013 MacArthur Fellow | MacArthur Foundation - YouTube http://bit.ly/1arV7ni
* Weill Cornell:
An Open-Label Treatment Use Protocol for Ibrutinib (PCI-32765) in Subjects with Relapsed or Refractory Mantle Cell Lymphoma http://bit.ly/16KcxIP
* Medscape 2013:
Boxed Warning on HBV Reactivation for Blood Cancer Drugs http://bit.ly/191AtqW

Product labeling updates for 2 drugs used in the treatment of hematological malignancies, rituximab (Rituxan) and ofatumumab (Arzerra)
* Medpage Today 2013:
Novel Antiviral Blocks CMV After Stem Cell Tx http://bit.ly/1h2L4Xu
* Patient Power 2013:
Why an Expert is Excited About New Pills vs. Chemo for CLL http://bit.ly/172iPqy

Comment:  Ibrutinib appears to be a cytostatic agent, thus a key to the successful management of CLL (and other b-cell cancers) will be its safety profile with long term use.  Anecdotally the CLL comes back soon after the drug is discontinued.
* We are greenbay.com 2013: HealthWatch: video on Ibrutinib for CLL
Experimental Drug Turns Off Leukemia Cells http://bit.ly/191zHKz
* Sunrise Rounds 2013:
When the mirror cracks http://bit.ly/1fDdSYG
* Scientific American
The Hallmarks of Cancer: 2 – Insensitivity to Antigrowth Signals http://bit.ly/1aotCeo
* Dr Sharman 2013:
Video update from IWCLL http://bit.ly/182um8J

Excellent overview of current treatments-- some are also used for other indolent b cell lymphomas
* PAL update:  In the News
Medical xpress 2013: Cancer: Lymphoma-linked risk factor identified Risk factors
 

Wednesday, September 25, 2013

* Psych Central 2013:
Tips for Coping with Chronic Illness http://bit.ly/14FxBm4
* KevinMD 2013:
The side effects of cancer treatment can become permanent glitches http://bit.ly/18ozMdf
* Dr Sharman 2013:
Summer off http://bit.ly/1bCvG68
* Ny Times 2013:  more on:
Married Cancer Patients Live Longer http://nyti.ms/1dHVYlP
* PAL update:
About Lenalidomide - immune modulation Lenalidomide - putative mechanisms of action
 

Monday, September 23, 2013

* PAL Update:
Help with CO-PAY  PAL - Insurance: Key Resources
* NYTimes 2013:
After Cancer, Fertility Is Often Within Reach http://nyti.ms/16CrgFG
* Science Daily 2013:
Public Says Childhood Cancer Should Be Top Children's Health Research Priority http://bit.ly/1fvmGQg
* Opposing Views 2013:
BP Oil Spill Cleanup Workers Have Elevated Risk of Leukemia, Lymphoma and Liver Damage http://bit.ly/18SEHkB

Reminds that there's a need to speak up regarding the risks to public safety of fracking in public areas  
* Dana Farber 2013:
Marriage associated with better cancer outcomes, study finds http://bit.ly/1eCBSw8

Authors state: "We don't just see our study as an affirmation of marriage, but rather it should send a message to anyone who has a friend or a loved one with cancer: by being there for that person and helping them navigate their appointments and make it through all their treatments, you  can make a real difference to that person's outcome,"

* Science-Based Medicine 2013:
Obesity, cancer, and chemotherapy http://bit.ly/16m3kvW
* Respectful Insolence 2013:
Cancer quackery promoted on Fox News http://bit.ly/18lmcXS
* MNT 22013:
Tackling drug-resistant cancers using a genome-forward approach http://bit.ly/15mfzTb
* PAL update:  final tweaks
The Patient-selected Controlled Trial PAL
 

Saturday, September 21, 2013

* Patient Advocacy: http://bit.ly/1bzyAsy

a non-partisan tool to help you to write your elected officials regarding your views on the defunding of the Affordable Care Act
* Haematologica 2013:
Actual prognosis during follow-up for B-cell non-Hodgkin lymphoma survivors in the Netherlands. http://1.usa.gov/16gTrzF

Five-year conditional relative survival was computed for every additional year of survival up to 16 years after diagnosis, according to entity, grade, gender, age, and Ann Arbor stage. The prognosis for indolent B-cell non-Hodgkin lymphoma survivors improved slightly with each additional year survived up to 91%. For patients with aggressive non-Hodgkin lymphoma conditional relative survival improved strongly during the first year after diagnosis (from 48% to 68%) and gradually thereafter to 93% after 16 years.
* Psychological Interventions for people with Cancer:
Therapy and Self-Help http://bit.ly/1gLNx8G

Helio 2013:
BEACOPP escalated may be new standard of care for advanced-stage Hodgkin’s lymphoma http://bit.ly/14tvvpi
* Weill Cornell 2013:
Interview with the Dean: Unlocking Cancer’s Code http://bit.ly/1b0hkgv
* Medscape 2013:
Federal Funding Cuts Have Huge Impact on Cancer Research http://bit.ly/16vKw7w
* Br J haemoatol 2013:
A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma.
http://1.usa.gov/14ttF83

J Clin OncL 2013:
Lymphoma Occurring During Pregnancy: Antenatal Therapy, Complications, and Maternal Survival in a Multicenter Analysis
http://1.usa.gov/1bxQyvx
* PAL update: Interesting that there have been more clicks for untreated than relapsed.
Find trials by type of lymphoma and treatment status  (2,027 clicks versus 1,295 respectively)

Friday, September 20, 2013

* Haematologica 2013:  technical
Origin and migration of follicular lymphoma cells http://bit.ly/15NpIOv

Takeaway:  "the bone marrow may harbor a small pool of less-cycling “founder” cells, either fully malignant (FL) or “premalignant” (FLLC), which may be relatively resistant to chemotherapy, explaining the frequent but sometimes very late relapses observed in FL. It would, therefore, be very informative to have a more thorough characterization of the bone marrow resident cells in FL (and possible also other B-cell lymphomas) at the molecular level,"
* USA TODAY 2013:
Obese cancer patients often shorted on chemo doses http://usat.ly/1etycg8
* Forbes 2013:
A Day In The Life Of A Patient: Why Can't We Do Better http://onforb.es/16K7JGo

Thursday, September 19, 2013

* Cure 2013:
Fear Factor Ruminating on possible cancer recurrence can adversely affect quality of life. http://bit.ly/155g897
* Onc Times 2013:
View from the Other Side of the Stethoscope: The First Recurrence http://bit.ly/16op4l3

* Cure 2013:
Worse Off Alone-Emotional isolation during cancer can negatively impact healing. http://bit.ly/15Ekcvx

* KevinMD 2013:
When a physician resorts to jargon, educating patients can fail http://bit.ly/1557iYN

* Onc Times 2013:
How I Talk to Patients about Difficult Issues http://bit.ly/18Atj2w

* Respectful Insolence 2013:
The Institute of Medicine report on cancer care: Is the system “in crisis”? http://bit.ly/18Ca2hc

* Pharmaceutical Processing 2013:
FDA Approves Teva’s TREANDA® Injection, a New Liquid Formulation http://bit.ly/16GsQcL

* Cancer Network 2013:
NDA Filed for Idelalisib for Treating Non-Hodgkin Lymphoma http://bit.ly/1558RGq
* PAL update:
T-cell prolymphocytic leukemia added to Find Studies by Subtype and Treatment Status
* PAL update - Onc Times 2013:
Lymphoma Specialists Lament the Discontinuation of Under-prescribed Bexxar Bexxar information
 

Wednesday, September 18, 2013

* CancerNetwork 2013:
Peripheral T-Cell Lymphoma: New Therapeutic Strategies http://bit.ly/16jvstM
* Time 2013:
Reality Check on Cancer: Fast Progress But Too Many Preventable Deaths http://ti.me/154IuuU
* Weill Cornell 2013:
Ofatumumab Granted Breakthrough Therapy Designation for Untreated CLL http://bit.ly/18vpWtP
* Reuters 2013:
Looking for lessons in cancer's 'miracle' responders http://reut.rs/19cljQu
* Live Science 2013:
Some Antioxidants Linked with Shorter Life http://bit.ly/1a2p7Gd
* ASCO Post: 
Clinical Trials, Crossover, and Clinical Equipoise: patients, company, and FDA perspectives
* A Patient's Perspective By Bob Levis http://bit.ly/1a3WfND 

I am writing with regard to two articles on the ethical imperative of clinical equipoise written by Susan O’Brien, MD, and Stephen J. Schuster, MD, and published recently in The ASCO Post.1,2 I was a victim of Pharmacyclics’ policies during one of their randomized ibrutinib trials (PCI-32765) conducted in 2012. I was diagnosed with chronic lymphocytic leukemia (CLL) in 2002. …

* An Advocate's Perspective By Karl Schwartz The ASCO Post http://bit.ly/14iNf6T

* Pharmacyclics' Reply http://bit.ly/15CLpOV

* FDA perspective http://bit.ly/1f6DL2R
Thanks is due to the ASCO post for publishing all sides of this story.

Tuesday, September 17, 2013

* MNT 2013:
Patients warn other patients about the danger of untested cures on the web http://bit.ly/16784W2
* Science Daily 2013:
Immune System Marker Tied to Improved Bone Marrow Transplant Outcomes http://bit.ly/1677qIj

* Ann Onc 2013: Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study. http://1.usa.gov/199XAAn
* Sunrise Rounds 2013:
Medical Secret: 1 + 1 = 1 http://bit.ly/18t5SSX

 Article explore how an onc looks at the wife's body language to try to determine if the husband is telling the truth when he says he is "fine" etc....
* Ped Blood Cancer 2013:
Ten-year follow-up of pediatric patients with non-hodgkin lymphoma treated with allogeneic or autologous stem cell
transplantation. http://1.usa.gov/1boW0k9
* MNT 2013:
New approach subtypes cancers by shared genetic effects; a step toward personalized medicine http://bit.ly/16bBcoi
* Onclive 2013:
Ofatumumab Receives Breakthrough Therapy Designation for Earlier Use in CLL http://bit.ly/1aOxCZX
* Haematologica 2013:
Actual prognosis during follow-up for B-cell non-Hodgkin lymphoma survivors in the Netherlands. http://1.usa.gov/15AbZIL
* Scripps Research Inst 2013:
 Scientists create extremely potent and improved derivatives of successful anticancer drug http://bit.ly/15y6Lgr

Way to make vincristine more potent
* MSNBC 2013:
Looking for lessons in cancer's 'miracle' responders http://nbcnews.to/1aNMXdk

* Medscape 2013:
Trial Participation May Affect Care of Non-enrolled Patients http://bit.ly/187SlSK
 

Monday, September 16, 2013

* Brian Koffman's Blog 2013:
Interview with Dr. Castro on the Biology of CLL http://bit.ly/18rkwjy
* Science-Based Medicine 2013:
Is U.S. cancer care “in crisis,” as the Institute of Medicine proclaims? http://bit.ly/180lrFp
* Blood 2013:
Staging DLBCL: bone marrow biopsy or PET-CT? http://1.usa.gov/183M6zf
* Blood 2013:
PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement.  http://1.usa.gov/166J0IV
* MNT 2013:
First randomized trial of targeted cancer medicine in all tumor types http://bit.ly/1aNBZEx
* News Medical 2013:
New approach subtypes cancers by shared genetic effects; a step toward personalized medicine http://bit.ly/150aVtV

Sunday, September 15, 2013

September 15th is World Lymphoma Awareness Day! 
What is Lymphoma? PDF
Please print the tri-fold brochure  prepared by PAL and distribute to friends and local businesses 
* NEJM Perspective -
e-Referral — A New Model for Integrated Care http://bit.ly/1dg7sg2

"Overall, we believe that the eReferral model has the potential to transform the primary–specialty care interface by enabling a move away from a narrow reliance on visit-based care. It reinforces the patient-centered medical home by supporting PCPs in providing longitudinal care for a broader range of conditions and reducing fragmentation of care without placing PCPs in the difficult position of “gatekeeper.” It has also enhanced teamwork and collegiality between PCPs and specialist reviewers"

KarlS: Makes sense, increasingly.  This idea resonates with me ... after having to wait 2 months for a specialist to look at a suspicious lesion.  There should be a way to make this system more efficient.
* Radiother Oncol 2013:
Reduction of the treated volume to involved node radiation therapy as part of combined modality treatment for early stage aggressive non-Hodgkin's lymphoma. http://1.usa.gov/191s3QQ
* KevinMD:
Researching your health is about balance http://bit.ly/140WxEo
* Health Canal 2013:
Study explores breakthrough drug for mantle cell lymphoma (Ibrutinib) http://bit.ly/18ZoACw
* Hum Path 2013:
B cells in classical Hodgkin lymphoma are important actors rather than bystanders in the local immune reaction.
http://1.usa.gov/190tmRk
* Medscape 2013:
US Cancer Care in Crisis, Says IOM Report http://bit.ly/1behfoN
* Cancer Research UK 2013 :
Miracle cancer cures? Ask for evidence http://bit.ly/16q3nnz
* Sense about Science 2013:
Ask for evidence http://bit.ly/17w0Ckj

 Sound to good to be true?  You can ask for evidence here.

Friday, September 13, 2013

* Institute of Medicine:
High-Quality Cancer Care - System In Crisis (Complete Video):  http://bit.ly/14RQrDr
* Gilead Submits New Drug Application to U.S. FDA for Idelalisib for the Treatment of Indolent lymphoma http://bit.ly/13Wb8AZ
* NYtimes 2013: Living With Cancer:
A Rainbow Coalition http://nyti.ms/15ojdiI
* Anticancer Res 2013:
Brentuximab Vedotin: First-line Agent for Advanced Hodgkin Lymphoma. http://1.usa.gov/15U2AxL
* Telegram.com 2013:
Six things parents of children with cancer should know http://bit.ly/13QAoIC
* Cell.com:
The Hallmarks of Cancer Poste to Lymphoma, a simplified description

Wednesday, September 11, 2013

* CNN 2013:
More than 1,100 have cancer after 9/11 http://bit.ly/15S48Cx
* PAL update:
SEER-based Lymphoma Subtype Statistics Lymphomation.org
* PAL update:
Describing Waldenstrom's Lymphomation.org 

* NEJM: Chris Feudtner, M.D., Ph.D. et al
Perspective Risks (and Benefits) in Comparative Effectiveness Research Trials nejm.org 

* Blood 2013:
Exposure to ultraviolet radiation and risk of Hodgkin lymphoma: a pooled analysis. http://1.usa.gov/14Fhwil
* Medscape 2013:
Not-so-negative to Super-negative Trials http://bit.ly/14FgAut
* MSNBC 2013:
US cancer care in crisis, experts say http://nbcnews.to/14DE3wd
* NEJM: Perspective:  Henry J. Aaron, Ph.D., and Kevin W. Lucia, J.D., M.H.P.
Only the Beginning — What's Next at the Health Insurance Exchanges? http://www.nejm.org/doi/full/10.1056/NEJMp1308032

* NEJM, 2013:
Probability of Cancer in Pulmonary Nodules Detected on First Screening CT http://bit.ly/14FeuuB

the rates of cancer in the two data sets were 5.5% and 3.7%, respectively. Predictors of cancer in the model included older age, female sex, family history of lung cancer, emphysema, larger nodule size, location of the nodule in the upper lobe, part-solid nodule type, lower nodule count, and spiculation (needle-like structure).
* Science-based medicine 2013:
Everything Causes Cancer http://bit.ly/17qcjZM
* News Medical 2013:
New Report Lays Out Guidelines To Improve Cancer Care http://bit.ly/17OWqgc
* KevinMD 2013:
Survivorship care after cancer is a shared effort http://bit.ly/19El3Mb
* KevinMD 2013:
People who participate in clinical trials are trailblazers http://bit.ly/17OUapm
* NYT 2013:
Futile Care at Life’s End http://nyti.ms/16kukcj

Tuesday, September 10, 2013

* IOM, 2013:
Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis  http://bit.ly/1anG12E
* J Clin Onc 2013:
Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly
increased use, older recipient age, and use of unrelated donors. http://1.usa.gov/1d0WGdx
* J Clin Onc 2013:
Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to
Bortezomib: Phase II MCL-001 (EMERGE) Study. http://1.usa.gov/15LBDGF
* Haematologica 2013: (TECHNICAL)
Origin and migration of follicular lymphoma cells http://bit.ly/15NpIOv
* Haematologica 2013;
Transplantation in follicular lymphoma: not "yes or no" but "whom and when". http://bit.ly/14ABWch

As lymphoma-treating physicians, we should stress the point that future randomized trials applying new agents in FL should also address the aspect of sequence in that we ask for overall rather than event-free survival. The study groups and working parties should stimulate experimental treatment arms that are randomized against either autologous or allogeneic stem cell transplantation following the current standard of care as defined by the best available evidence, even if this is “only” a consensus of experts. Otherwise, the possible economic impact of new and potentially effective pharmacological agents will direct the attention away from defining a more definite role for ASCT and allo-HSCT in the therapeutic sequence for patients with follicular lymphoma.
* Leuk Lymph 2013:
7-Year Follow-up of Allogeneic Transplantation using BEAM chemotherapy in Hodgkin Lymphoma Patients after Autograft Failure: Importance of Minimal Residual Disease. http://1.usa.gov/19CzYq9
* Cancer 2013:
Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: Results of the National  LymphoCare Study. http://1.usa.gov/19CynAE
* Leuk Lymph 2013:
NODAL MARGINAL ZONE LYMPHOMA. http://1.usa.gov/1d0WScA
* Medpage Today 2013:
'Nose Knows' Devices Not Ready for Clinic http://bit.ly/1d0PwpN
* Health News Review 2013:
The NY Times Well blog isn’t always so well http://bit.ly/1ayfhQB

Excellent discussion about some of the problems in scientific journalism in stories with headlines like "Some fruits are better than others" (at  reducing risk of type 2 diabetes" Worth a read. --anjou
* Health News Review 2013:
A patient’s perspective on an NIH/NCI news release – a punch in the gut http://bit.ly/14Hb9WC

Excellent commentary and perspective on recent news story about Hodge patients being at risk of developing stomach cancer down the road-- anjou   "The following thoughts were sent to me by Carol Countryman, who had chemotherapy and radiation therapy for Hodgkin’s disease in the early ’70s.  She’s had two mastectomies and last year was diagnosed with delayed-onset myopathy from the radiation – a new disease and very rare. She says her quality of life “is already a bit grim and now I read about stomach cancer.” Here’s what she wrote:  Dear Gary: Today I read a news release headlined “NIH Study Links Hodgkin Lymphoma Treatment to Possible Risk of Stomach Cancer.” After reading the article, I felt like someone punched me in the gut. This sentence was most troubling: “Of 17,477 Hodgkin lymphoma cases examined, the researchers identified 89 survivors who later developed stomach cancer.” Isn’t that an infinitesimal number? That’s only one-half of one percent. But that wasn’t made clear in the article."
* KevinMD 2013:
Don’t confuse death with dignity with suicide http://bit.ly/15RRi6i
 

Monday, September 9, 2013

* J Natl Cancer Inst. 2013
Ginseng for cancer-related fatigue - randomized trial http://1.usa.gov/1fRx2HP 

KarlS:  Positive studies for natural products in their native forms are rare.  This seems to be an exception. 

* Patient Power 2013:
Exercise-and-complementary-medicine#sthash.66rznJzt.dpuf http://bit.ly/19AU18v

* Helio 2013:
Cutaneous T-cell lymphoma incidence stabilized in US http://bit.ly/15QxlwT

* Philly.com 2013:
Cancer pills convenient but costly, confusing http://bit.ly/16f1oTb

* Dr Sharman's blog:
GA-101 (Obinituzumab) Strikes Again http://bit.ly/1eu7eDu

* JCI 2013:
Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells http://bit.ly/1dU3219

 

Saturday, September 7, 2013

* MNT 2013:
Cancer may get help from immune cell http://bit.ly/15Dw9gY
The Guardian 2013:
Six stubborn myths about cancer: The internet is awash with misinformation about cancer, with potentially tragic consequences for patients http://bit.ly/15EL8gH
* Blood 2013:
Defining characteristics of classical Hodgkin lymphoma microenvironment T helper cells. http://1.usa.gov/19pArf9
* Medscape 2013: Free registration and login required
Cancer Drug Costs: Oncologists Must Be 'Part of the Solution' http://bit.ly/165hUFk

* Sunrise Rounds, 2013:
The Bridge http://bit.ly/18zWmzf

Thoughts from an onc on what it means to be a good doctor "While a good doctor must have a solid foundation of knowledge and the proper skills to perform his or her specialized task, I believe that the “great” doctor is one who recognizes, at least intuitively, the gap between the emotional, irrational state in which we live our lives and the rational- objective structure of the healthcare system. The skilled physician understands that he must bridge the chasm."
* Eur Heart J. 2012:  (technical - describes a research method to decrease bias in non-randomized trials.)
Do observational studies using propensity score methods agree with randomized trials?
A systematic comparison of studies on acute coronary syndromes http://1.usa.gov/18Kt7Zo 

For this indication, "observational studies using PS methods produce treatment effect estimates that are of more extreme magnitude compared with those from RCTs, although the differences are rarely statistically significant."
* Proposing the Patient-selected Controlled Trial (PCT) - PAL

We are seeking input from statisticians on the PCT (Patient-selected Controlled Trial) - as an additional tool to consider when comparing treatments for cancer - such as (but not limited to) when the compared interventions have very different risks, or when both treatments can be used off-study … study questions that are unlikely to be answered with a RCT design because of low patient acceptance.

Briefly, the PCT lets the patient either (1) choose to be randomized or (2) pick the study arm they want to be in. The arm they select may be based on their own expectations, preference, or their unique clinical risk factors. Such decisions will most often be guided by the patient's physician.

Mary, for example, might prefer the study arm that would not put her fertility at risk. John might prefer the treatment arm that appears to have the greater chance to achieve a cure. Tom, having no opinion or expectation about which is better, might well choose to let a computer decide.

Our thought is that for the PCT to provide reliable answers would require pre-specified rules for adapting the study size and perhaps Propensity Score Methods described above. Not having background in this area we don’t know if it’s feasible to get unbiased answers with the PCT … or put differently, if this method would be better than doing a large single arm study using historical controls?
 

Friday, September 6, 2013

* Clinical Oncology News 2013:
Minimizing Hodgkin Lymphoma Treatment With PET http://bit.ly/1abgDx1

Requires registration to enter the site
* Bionews 2013:
MD Anderson Researcher Testing New Therapies For Refractory Mantle Cell Lymphoma http://bit.ly/17cdoV8
* Science Daily 2013:
New Research Suggests Cutting Calories May Improve Response to Cancer Treatment http://bit.ly/1dWGopU

based on an animal model - lymphoma cells in mice.
* Patient Power 2013:
Promising Advances in Treating Mantle Cell Lymphoma (talk by Dr Sharman) http://bit.ly/14n6PRr
* Rational Wiki 2013:
Alternative Medicine 2013: http://bit.ly/17S04b2
* KevinMD 2013:
Treating cancer patients puts everything else into perspective http://bit.ly/151KKGG
* Medscape 2013:
New PET/MRI Hybrid May Enhance Cancer Diagnoses http://bit.ly/18FDbD0
 

Thursday, September 5, 2013

* Psychology Today: Rant: Shared Decision Making in Medicine http://bit.ly/19ioEiN
Several excerpts:

"when a physician resorts to jargon, the effort to educate patients can fail. Imagine yourself sitting half naked on an exam table with the word cancer rattling around your brain. Do you think you'd be able to comprehend such a conversation? Jargon is ubiquitous in physician-patient encounters; doctors frequently use undefined technical terms and patients rarely have the confidence or assertiveness to ask for clarification.

All too often, the result is precious time wasted on ineffective communication despite the many important decisions doctors and patients need to make together"

"To make matters worse, physicians often fail to account for a patient's negative emotional state during medical consultations. In one study of senior oncologists, researchers discovered that when patients expressed negative emotions ("I'm scared" or "I can't sleep because of pain"), the oncologists acknowledged and responded to the emotions only one in five times"
* NYT 2012: Is the Cure for Cancer Inside you? http://nyti.ms/100LMAo
 

Wednesday, September 4, 2013

* Science Daily 2013:
New Therapeutic Approach to Fight Cancer: Inhibiting Cancer Cells' Energy Metabolism http://bit.ly/17qXYsA
* NYTimes 2013:
Values Conflict at the End of Life http://nyti.ms/175uhAJbbb

* J Clin Onc 2013:
Hematopoietic Cell Transplantation for Systemic Mature T-Cell Non-Hodgkin Lymphoma http://bit.ly/17ocMIB

Outcomes of 241 patients (112 anaplastic large-cell lymphoma, 102 peripheral T-cell lymphoma not otherwise specified, 27 angioimmunoblastic T-cell lymphoma) undergoing autologous HCT (autoHCT; n = 115; median age, 43 years)

or allogeneic HCT (alloHCT; n = 126; median age, 38 years) were analyzed.
* Sunrise Rounds 2013:
Cancer Chaos http://bit.ly/1cE3Hkj

* Lymphoma coalition 2013:
Know your nodes http://knowyournodes.org/
* PAL, 2013 - update:
Patient Recommended Oncologists - OH Cleveland Clinic  PAL

Monday, September 2, 2013

* PAL, 2013
   6 New Lymphoma and CLL studies of interest  PAL
* Salon 2013:
Cancer research in crisis: Are the drugs we count on based on bad science? http://bit.ly/1dFQTxN 

A paper finding that important preclinical experiments can't always be reproduced suggests that some new drugs could be based on bad science.  KarlS:  Not publishing (or being able to publish) failed experiments could contribute to this problem.
* Brian Koffman's CLL Blog 2013:
   Large Granular Lymphocytic Leukemia:
   What We CLL Patients Can Learn from a Novel Therapy for a T Cell Cancer http://bit.ly/19WnVof
* Exchange shopping for health insurance begins soon
This information is provided in the state of PA ... which should be about the same elsewhere.
The Marketplace (overview of the rules) http://bit.ly/15Pymtd  

The Federal Marketplace (shop Oct 2013- effective Jan 2014)  http://bit.ly/15PyGrK
* PAL, 2013 ... What is Lymphoma? PDF
September 15th is World Lymphoma Awareness Day 

Please print the tri-fold brochure about lymphoma prepared by PAL  and distribute to local businesses 

Friday, August 30, 2013

* Medscape 2013:
Reprogramming Aggressive Lymphoma Into More Benign Disease http://bit.ly/14ImY25

More on low dose azacitidine as a pretreatment for DLBCL ... a promising new approach.  Requires login in and one-time registration.
* Patient Power 2013:
Gauging the Success of Relapsed-Refractory Hodgkin Lymphoma Treatment - http://bit.ly/15qsxOB

Use of PET scan to monitor for relapse following transplant.
* Medical Daily 2013:
Court Rules That Sarah Hershberger, Amish Girl Battling Cancer, Should Be Appointed Legal Guardian After Parents Stop Her Chemotherapy http://bit.ly/1cofCCC

When values clash ... is particularly difficult issue to resolve when the decision to forgo lifesaving therapy involves a child
* Science Daily 2013:
New Imaging Technology Promising for Several Types of Cancer (PET/MRI) http://bit.ly/1fn4p51
* NYTimes 2013: Living With Cancer: Is It Back? http://nyti.ms/15krDtR
* The Economist 2013:
Lucrative lifesavers: The hopes and perils of betting on cancer treatments http://econ.st/159rFyD

 

Thursday, August 29, 2013

* KevinMD 2013:
How long do you continue to fight when death is certain? http://bit.ly/1chxQFS
* Medscape 2013:
Can We Identify Risk for Drug Toxicity? http://bit.ly/1dmKWVk
* KevinMD 2013:
Choosing a doctor is like choosing a spouse http://bit.ly/1dqeAKo
* Science-Based Medicine 2013:
The Science of Clinical Trials http://bit.ly/17gKGVB
* Respectful Insolence 2013:
A cancer quackfest http://bit.ly/1dtZiEl
* PAL, 2013 - Revision 3 - ready for stakeholder input
Proposing the Patient-selected Controlled Trial design   PAL
* Independent of industry funding, Patients Against Lymphoma depends on your support!
 

Wednesday, August 27, 2013

* American Psychological Association 2013:
Coping with a diagnosis of chronic illness http://bit.ly/1dnbJBU
* xconomy 2013:
Why Good Drugs Sometimes Fail: The Bexxar Story
And In the Pipeline 2013: Promise that didn't pan out. 

Posted to PAL's Bexxar page with commentary
* KevinMD 2013:
After cancer treatment, primary care becomes even more important http://bit.ly/15v9whP
* Violent Metaphors 2013:
How to read and understand a scientific paper: a guide for non-scientists http://bit.ly/12JbHgI
* U S Florida 2013:
New treatments better than standard ones just over half the time: That's evidence the randomized clinical trial system works, University of South Florida researcher reports in Nature http://bit.ly/181NdiB

Article citation: "Medical research: Trial unpredictability yields predictable therapy gains;"
* Sunrise Rounds 2013:
An unneeded apology? http://bit.ly/16JVZzd
* Fox Business 2013:
I've Had Lymphoma. Can I Get Life Insurance? http://fxn.ws/16NOP0r
* Forbes 2013:
Alternative Medicine Providers Show Their Greedy Side http://onforb.es/12HHCON
* MNT 2013:
Discovery of novel way gene controls stem cell self-renewal http://bit.ly/1aLHZg7
* News Medical 2013:
Tips from experts can help cancer survivors continue pre-diagnosis daily routines http://bit.ly/1ccVeUU

Tuesday, August 26, 2013

* NIH 2013:
NIH study links Hodgkin lymphoma treatment to possible risk of stomach cancer http://1.usa.gov/13UGZnN
* KevinMD 2013:
6 tips to prevent being intimidated at the doctor's office http://bit.ly/1c9GhDc
* Slate 2013:
Why Aren’t There More Cancer Vaccines? Blame America’s lousy patent system. http://slate.me/13T3pWn
* MNT 2013:
How our own bodies help turn cancer against us http://bit.ly/17gURpp
Not lymphoma specific but interesting. Talks about how the immune system can be a "double edged sword" when it comes to cancer...
* Forbes 2013:
Death With Dignity Should Not Be Equated With Physician Assisted Suicide http://onforb.es/143aO04
* Cancer Network 2013:
Maintenance Rituximab in Advanced Follicular Lymphoma: Therapy does not significantly improve PFS after chemoimmunotherapy induction and consolidation http://bit.ly/174IBMj

 

Sunday, August 25, 2013

* Sunrise Rounds, 2013: Once more into the fray http://bit.ly/1ddvlHC
* Fox: Hospital Fights to Treat 10-Year-Old Amish Girl’s Cancer http://bit.ly/1dDuiiNancer/
* Karmanos
App Helping Patients & Caregivers Find Cancer Clinical Trials http://bit.ly/16qD4JO
Iphone app to find clinical trials
* NYT 2013:
Life, Interrupted:  A Test of Faith http://nyti.ms/17OMgKw
* News Medical 2013:
Novel Approach Developed On Antitumor Immunotherapy http://bit.ly/1bYNwOg
Preclinical but interesting...
* J Clin Onc 2013:
Rituximab Maintenance Compared With Observation After Brief First-Line R-FND Chemoimmunotherapy With Rituximab Consolidation in  Patients Age Older Than 60 Years With Advanced Follicular Lymphoma: A Phase III Randomized Study by the Fondazione Italiana Linfomi.  Posted with comment to PAL Maintenance page

Thursday, August 22, 2013

* Medscape 2013: BEACOPP Beats ADVD for Survival in Hodgkin's Lymphoma http://bit.ly/1bTMZwY
This is an important report -- likely to stimulate very active debate among experts -- as it finds in favor of an approach that has lost favor in the US. See also comment on this news item  PAL
* ASH 2013:
New research suggests cutting calories may improve response to cancer treatment http://bit.ly/1d5zkGd

A mouse study ... so very preliminary evidence here - an influence that could vary from cancer to cancer and by drug.  Off-hand, due to the common influence of treatments on appetite, restricting calories during treatment could already be common practice.
* The New Yorker 2013:
How Should Doctors Share Impossible Decisions with Their Patients? http://nyr.kr/13G3YCJ
* PsychCentral 2013: How to Read a Journal Article http://bit.ly/17KmwyK
* Pesticides: after Parkinson's the Non-Hodgkin's Malignant Lymphoma http://bit.ly/1f2l0L3
Article appears to be about a legal judgment linking a farmer's non-hodgkin's a herbicide
(although the title says pesticides)

 

Wednesday, August 21, 2013

* U Penn 2013:
Penn Medicine study shows survivorship care plans empower cancer patients: Online tool for planning life after cancer fills knowledge gaps, arms patients with information to take charge of their care http://bit.ly/14UApYm

"Despite the close watch from health care providers cancer patients receive during their treatment, it's often not clear who – an oncologist, a primary care physician, or another type of specialty physician – is responsible for mechanizing the disparate aspects of a survivor's health, from monitoring for and managing late effects of therapy to ordering routine preventive health exams such as bone density tests and colonoscopies. Consequently, important health needs among cancer survivors needs may go unmet, the authors say."
bullet
Survivorship Care Plan - an Online Tool Powered by Penn Medicine's OncoLink Posted to PAL Support Topics

IOM recommended - this online tool can help to make a "survivorship care plan" that is individualized based on the answers you provide in a brief questionnaire.
* KevinMD.com 2013:
How fear affects cancer survivorship http://bit.ly/157z58v
* Sunrise Rounds 2013:
Goodby in the Mist http://bit.ly/16sJbRb
 An oncologist talks about his feelings when a long-term patient is dying.
* KevinMD.Com 2013:
The complicated existential dilemma of living with cancer http://bit.ly/16uj8cm
 

Tuesday, August 20, 2013

* Respectful Insolence 2013:
The key difference between alternative medicine and evidence-based medicine http://bit.ly/155yg05
*  Scientific American 2013:
Sex Makes You Rich? Why We Keep Saying “Correlation Is Not Causation” Even Though It’s Annoying http://bit.ly/14gc03G
* Oncology Times 2013:
Survey: Most Oncologists Avoid Using the Word 'Cure' in Discussions with Patients http://bit.ly/19u8L9I
* Oncology Times 2013:
View from the Other Side of the Stethoscope: Patient Handout-Facing Cancer Together http://bit.ly/1d0VSHW
Helpful tips for couples
* Weill Cornell 2013:
Pre-treating DLBCL with Targeted Therapy Improves Patient Outcomes and Chemotherapy Effectiveness http://bit.ly/17ECoCY

SNIP: The implications for this study are far ranging. Dr. Cerchietti explained, ”Oncologists have long believed that using high doses of an anti-cancer drug is the best strategy. Our study shows that is not the case in this kind of lymphoma, and suggests this new approach can potentially be translated to other tumor types.”

Researchers plan on expanding the study to additional DLBCL patients in a multi-center clinical trial, while studying pre-treatment strategy options in other tumor types and lymphomas.
* Also on this:  Science Daily 2013:  http://bit.ly/18AhdmF

Monday, August 19, 2013

*  KevinMD 2013:
Why you should consider a second opinion from a pathologist http://bit.ly/16kUieX

Comment: An important piece - a way for patients to help to optimize their care.

"Expert second opinions are also particularly valuable if the patient’s initial diagnosis is inconclusive or supposedly diagnostic of a rare or unusual tumor. In addition to identifying incorrect diagnoses, in many other cases an expert second opinion can fine-tune a diagnosis in a way that may be significant, such as reclassifying the subtype of a lesion or changing the grade or stage of a tumor. Even when the expert consultation results in no change in the diagnosis, it provides the patient with peace of mind that their diagnosis is correct."
* Fox News 2013:
Indian cancer patients forced to camp in the street http://fxn.ws/14NGbLk
* Blood 2013:
Egress of CD19+CD5+ cells into peripheral blood following treatment with the BTK inhibitor ibrutinib in mantle cell lymphoma patients.  http://1.usa.gov/14Vv0nS
* Am J Hem 2013:
The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy. http://1.usa.gov/13tlB8Z
* Haematolgica 2013:
Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: a large multicenter study involving
1191 patients, in the pre and post rituximab era. http://1.usa.gov/15Ta6Su  Full Text

The 5 years OS was 60% and 72% for LMR ≤2.1 and >2.1, respectively (Figure 1c).
 

Saturday, August 17, 2013

*  Onclive 2013:
  Ibrutinib Combo Achieves 100% Response Rate in Patients With NHL - http://bit.ly/16UWta3
 
"Adding ibrutinib to standard (R)-CHOP chemotherapy for non-Hodgkin lymphoma (NHL) resulted in an objective response rate of 100% In the study, first-line treatment with ibrutinib and chemotherapy led to complete responses in 10 of 15 patients, and the remaining five patients had partial responses."

Comment:   It's a small study with no control group. Focus should be on the Complete Response rate for this indication, which is treated with curative intent.  Complete response rates are also very good with standard therapy so more study is needed to validate these encouraging results.
* Oncology Report 2013:
Epigenetic approach tames aggressive B-cell lymphoma http://bit.ly/14kVKuH

"Complete responses were achieved in 11 of 12 newly diagnosed patients treated with the novel strategy, with 10 remaining in remission after a median follow-up of 13 months (range 5-28 months).

    * Also Science Daily 2013: http://bit.ly/18AhdmF
    * Also Medical Xpress 2013:  http://bit.ly/18zXnIn

    Comment:  This is a report on encouraging outcomes but in a very small study - for 12 patients. The novel approach was not compared to regular therapy in a controlled study.  Complete response rates are also very good with standard therapy so more study is needed.
* Huff Post 2013:
Surviving Cancer Won't Be My Biggest Accomplishment http://huff.to/17SlZK8
* Cancernetwork 2013:
 “I’m the Decider! (Is That OK with You?)” http://bit.ly/14Q59Ao
* xkcd 2013:
Increased risk cartoon http://imgs.xkcd.com/comics/increased_risk.png
* Brian Koffman's CLL blog 2013:
More Comments on to Tell or Not to Tell About Our CLL http://bit.ly/15OmzGU
* KevinMD 2013: How should doctors and patients look critically at medical decisions? http://bit.ly/19n3xfP
* Forbes 2013:
Beware Of Cancer Metastasizing To Your Wallet http://onforb.es/16hebnc
* J Natl Compr Canc Netw 2013:
Targeted therapy in relapsed classical Hodgkin lymphoma. Posted to Hodgkin page - In the News

Comment: This technical article highlights some of the agents either approved or in development for relapsed/refractory Hodgkin lymphoma, such as cd30 antibodies and much more.

Friday, August 16, 2013

*  PAL Comments on the discontinuation of Bexxar
* Oncology Times: ONLINE FIRST:
    Underprescribed Bexxar Discontinued by GlaxoSmithKline http://bit.ly/18yBbyc
* The Jewish Voice 2013:
    Lymphoma Risk Varies for Celiac Disease Patients http://bit.ly/1a9Mn8s
* Cancer Research Inst 2013:
    Cancer and the Immune System http://bit.ly/16RVGXo
* Cur Opin Oncol 2013:
    Refractory hodgkin lymphoma. http://1.usa.gov/17PJZ0j
* WSJ 2013:
    Epratuzumab and Rituximab Produce High Rate and Durable Progression-Free Survival in Previously Untreated Follicular Lymphoma  http://on.wsj.com/1cPXep7  (company press release)
* Lymphobob 2013:
    Follicular Lymphoma: Epratuzumab http://bit.ly/18xqyLU
* Science Based Medicine 2013:
    facts of the alternative medicine industry http://bit.ly/14fWAJ2
* The ASCO Post, 2013:
    B-cell Receptor Signaling Inhibitors Moving Forward in Lymphoma http://bit.ly/1eNkArP
 

Thursday, August 15, 2013

* Medscape 2013:
New Scoring System Evaluates Prognosis in Burkitt Lymphoma http://bit.ly/140xHVo
* Cancer Research UK 2013:
Huge genetic analysis points to cancer-causing culprits http://bit.ly/1cDCTnL
* BBC 2013:
Milestone study probes cancer origin http://bbc.in/1bwX2YE
* My Angry Cancer 2013:
Speak No Evil: Or, "What Not To Say To a Cancer Patient." http://bit.ly/1cBFZbM
* Eurpean J Cancer 2013:
A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide
(Revlimid®) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: The EXPECT trial http://bit.ly/1cNvl0F
* Leukemia Research:
Hepatitis B infection increases the risk of non-Hodgkin lymphoma: A meta-analysis of observational studies
http://bit.ly/16kdQ5J
* In the Pipeline:
Another T-Cell Advance Against Cancer http://bit.ly/1eJx4AV
early, pre-clinical work with engineered t-cells
* Huff Post 2013:
How a Car Accident and Cancer Taught Me Different Things About Mortality http://huff.to/15C5FeM

Wednesday, August 14, 2013

* Weil Cornell 2013:
    New Clinical Trials: Innovative Approaches for Follicular Lymphoma http://bit.ly/16862RU
"The Weill Cornell Lymphoma Program has recently opened two clinical trials sponsored by The Alliance for Clinical Trials in Oncology. These trials are notable for their innovative approach. As Lymphoma Program Director and current chair of the committee, Dr. John Leonard explained, “Under the leadership of Bruce Cheson, MD, the lymphoma committee has been focused on ‘biologic doublets’ with targeted agents, a treatment approach that has been quite innovative. Following up on his work we are now moving toward ‘targeted triplet therapy’ which is a first in lymphoma therapeutics.”
See for details study details, eligibility, trial location:

* Rituximab, Lenalidomide, and Ibrutinib in Untreated Follicular Lymphoma -
ClinicalTrials.gov http://1.usa.gov/1cBniFe

The primary objective is to determine the recommended phase II doses of ibrutinib and lenalidomide for combination with rituximab. 
* KevinMD 2013:
   After a medical mistake, an apology is both simple and difficult http://bit.ly/123uGSS
* J Clin Onc2013:
    Follicular Lymphoma Cells Induce Changes in T-Cell Gene Expression and Function:
    Potential Impact on Survival and Risk of Transformation http://bit.ly/17If33X

Tuesday, August 13, 2013

* Channel5 2013:
Super Strength Immune Cells Fighting Cancer http://bit.ly/1bq66hZ 
Interesting interview about a treatment used for multiple myeloma, another blood cancer
* Brian Koffman CLL blog 2013: ASCO 2013:
Dr. Sharman on The Biology of CLL being Cracked with a Therapeutic Renaissance Underway http://bit.ly/162FykB
* OncLive 2013:
The Antibody Arsenal: More Complex Targeted Agents Primed for Increased Potency http://bit.ly/19cF396
*  Onclive 2013: Novel PI3K Inhibitor Active in Non-Hodgkin Lymphoma http://bit.ly/15uTj7Y
*  blog 2013
The OTHER Burzynski Patient Group http://bit.ly/14HaSIN
* Science Based Medicine 2013:
When doctors betray their patients and science-based medicine for money http://bit.ly/1eEj3o8
* Consumer Reports
Compare over-the-counter drugs for common ailments  http://bit.ly/1cvl7Ca
Nice to have an independent group helping to sort through the gazillion options and ads.
Lancet:
Probiotics for C-diff in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, trial http://bit.ly/17huIq9
 

Sunday, August 11, 2013

* Dr Harpham 2013:
Naked Statistics http://bit.ly/1630ryF
Recommends a good basic book on statistics
* Health Canal 2013:
Burkitt lymphoma survival improves for some http://bit.ly/17eVlvL
* Brian Koffman's CLL Blog 2013:
CLL: More on to Tell or Not to Tell http://bit.ly/161p8M3
* Cancer: 2013:
Population-based prognostic factors for survival in patients with Burkitt lymphoma: An analysis from the Surveillance, Epidemiology, and End Results database. http://1.usa.gov/11U96jM
* KevinMD 2013;
More health information is not necessarily better http://bit.ly/13rhsNq
* Cancer 2013:
Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab:
A comprehensive analysis from the NCCN lymphoma outcomes project. http://1.usa.gov/1cn5iyn

Patients who underwent autoSCT (N=136) were older compared with patients who underwent alloSCT (N=48) (54 versus 51 years, respectively, P=.01) and more frequently had grade 3 FL (35% versus 8%, respectively, P = .006).

Patients who underwent alloSCT received more prior therapies (4 versus 3, respectively, P < .0001) and more often had resistant disease at SCT (19% versus 6%, respectively, P = .008).

Comment: ... highlighting the challenge of comparing outcomes from different approaches across different studies.  KarlS
* * Leuk Lymph 2013:
Loss of utility of bone marrow biopsy as a staging evaluation for Hodgkin lymphoma in the PET imaging era: a West of Scotland study.  Posted to Hodgkins - In the News

Sat, August 10, 2013

* Cancer 2013:
Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab:
A comprehensive analysis from the NCCN lymphoma outcomes project. http://1.usa.gov/1cn5iyn
* Cancer 2013:
A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701. http://1.usa.gov/14h2atR
* Research to Practice 2013:
Go "Beyond the Guidelines" with the video proceedings from RTP's lymphoma & myeloma symposium
held at ASCO 2013.   http://bit.ly/14CVMnH
* Onc Times 2013:
Orphan Drug Status for E7777 for CTCL http://bit.ly/1cQQ6av
* Dr Len's Cancer Blog 2013:
Palliative Care Is About Quality Of Life Throughout The Cancer Journey http://bit.ly/14Ckwwg
* Scripps Research Inst 2013:
Scripps Research Institute study shows microRNAs can trigger lymphomas http://bit.ly/11Q5aR6
* Brown Univ 2013:
Study shows who survives Burkitt lymphoma: Proposed score delineates risk, prognosis http://bit.ly/13RZ9Rg
* Int J Pharm 2013:
Pharmaceutical follow-up for patients on rituximab therapy for NHL: what is the evidence?   http://1.usa.gov/1cxnPXD

J Nucl Med 2013:
Interim 18F-FDG PET in Hodgkin Lymphoma: Would PET-Adapted Clinical Trials Lead to a Paradigm Shift? http://1.usa.gov/17zw6n0

====

* MNT 2013:
Biomarker identified to predict immune response risk after stem cell transplants PAL - comments on the news

Thu, August 8, 2013

* Medpage Today 2013:
    Marker Warns of GVHD After Stem Cell Transplant http://bit.ly/15NnjSL
* KevinMD 2013:
    Do you worry about the diseases you learn in medical school? http://bit.ly/14yKxfV
* LymphoBob 2013:
    Cancer Cup Song http://bit.ly/1ccvRpP

Wed, August 7, 2013

* New Medical 2013
    Study finds cancer survivors do not always have best access to primary care http://bit.ly/14juDmS
* Dana-Farber 2013
    Vaccine stirs immune activity against advanced, hard-to-treat leukemia CLL http://bit.ly/16t2E2T

“scientists at Dana-Farber Cancer Institute report in the Journal of Clinical Investigation that they observed a strong and selective immune response in some patients who received, shortly after the transplant, several doses of a "personalized" tumor vaccine composed of their own inactivated leukemia cells combined with an immune stimulant, GM-CSF.”

KarlS: This setting for vaccine seems more promising … as a way to build on the graft versus lymphoma effect. Perhaps with a donated immune system there is less ability for the lymphoma / CLL cells that survived high dose therapy to turn off the immune response. So activating that response with a vaccine could actually work more reliably.

Consider that for abnormal cells to develop into a lymphoma and grow that they must evolved ways to shut down the immune system – to give the bad cells a free pass. With a new immune system any previous "deals" could well be null and void – (as evidenced by the graft vs. disease effect).
* Cambridge University 2013
    Cancer patients want more shared-decision making about their treatment:  http://bit.ly/17wf9d1
* Oncology Report 2013
    Immune microenvironment linked to prognosis of follicular lymphoma http://bit.ly/1baBNf7
* Reuters 2013
    Unhealed intestines in celiac disease tied to lymphoma http://reut.rs/13iFpq0 
 

Tues, August 6, 2013

* Sunrise Rounds, 2013:
What we blame on chemo http://bit.ly/15KwDUZ
* Forbes, 2013:
Can We Build A Kickstarter For Cancer? http://onforb.es/1c5mEiX
* Onc Times, 2013:
Debating the Role of Interim PET Scans in Lymphoma http://bit.ly/11IPfnn 
* Columbia Univ, 2013:
Celiac disease patients with ongoing intestine damage at lymphoma risk http://bit.ly/15Iw51S 
* MNT, 2013:
Tumor cell vaccination trial to promote anti-leukemia responses http://bit.ly/1c3IYcI 
* HEMOnc Today, 2013:
Obinutuzumab active in three types of lymphoma http://bit.ly/13Apg2I

"Obinutuzumab demonstrated encouraging single-agent activity with acceptable toxicity in the treatment of indolent non-Hodgkin’s lymphoma, diffuse large B-cell lymphoma and mantle cell lymphoma, according to results of the phase 2 GAUGUIN study."

KarlS: Activity is good -- but is not necessarily a way to measure benefit.
* Medical News Today, 2013:
Novel drug shuts down master protein key to lymphoma http://bit.ly/1cDiwEy
* UT San Diego, 2013:
Cancer drug resistance mechanism unraveled http://bit.ly/17sOYDZ
* MedLexicon, 2013: Diffuse Lymphoma: PET/CT bests gold standard bone marrow biopsy for diagnosis and prognosis of lymphoma patients http://bit.ly/15HB6rw

 

Thursday, July 25, 2013

From various news sources:  PAL; In the Pipeline,  New Yorker
* New Treatments for indolent lymphomas: How do you measure success?

   An advocate's perspective on endpoints - old, misleading, new, and investigational
* More Details on T-Cell Therapy for B-cell Leukemia / lymphoma 

SNIP: "This all should be seen in a larger context of immunotherapy, too. People have been trying to recruit the immune system for years in the fight against tumor cells, with mixed success. But we may be just on the verge of knowing enough about what we're doing to get more of these to work. At this point, it would not surprise me if immune system approaches become the dominant form of treatment for several types of cancer over the next 25 years. The next few years will tell us." 
* When Doctors Tell Patients What They Don’t Want to Hear
 

Wednesday, July 24, 2013

From various news sources:  OncLive, News Medical, Semin Cancer Biology, Med Lexicon, Sunrise Rounds
* Novel therapies for peripheral T-cell lymphomas (full text)

   KarlS: Posted to In the News on the PTCL page
* Conclusion: Final Thoughts on Managing Hodgkin Lymphoma 
* Female cancer patients unhappy with the way doctors discussed about fertility preservation options
* The microenvironment in classical Hodgkin lymphoma: an actively shaped and essential tumor component
* Time between cancer diagnosis and treatment provides 'window of opportunity' to optimize health
* Wasting a precious gift

   Anjou: Deals with end of life issues. An oncologist talks about the sometimes futile, brutal care for terminal patients
 

Tuesday, July 23, 2013

From various news sources:  Detroit News, NYTimes, Kevin MD, Leuk Lymph, Haematologica, Cancer Research, Br J Cancer, Science Daily,  Lymphobob, Science Based Medicine, The Health Care Blog
* Big pharma mobilizing patients in battle over drugs trials data 

Leaked memo from industry bodies reveals strategy to combat calls by regulators to force companies to publish results

KarlS:  This story has angered patient advocates.  It reminds that developing new drugs is a business - thankfully a regulated business ... to some degree.
* Omega-3s May Raise Prostate Cancer Risk  
* A Guide to giving patients bad news

snip:  It is a mistake to simply walk up to a patient and say, “sorry but the cancer has come back, I’ll get back to you.”
* Dissecting the grey zone between follicular lymphoma and marginal zone lymphoma (technical)
* Increased risk of second malignancies in CLL compared with follicular lymphoma: a Canadian population-based study 
* Too Many Antioxidants? Resveratrol Blocks Many Cardiovascular Benefits of Exercise 
* Stanislaw Burzynski: The Early Years, part 1
* How Doctors Die

SNIP:  It’s not a frequent topic of discussion, but doctors die, too. And they don’t die like the rest of us. What’s unusual about them is not how much treatment they get compared to most Americans, but how little. For all the time they spend fending off the deaths of others, they tend to be fairly serene when faced with death themselves. They know exactly what is going to happen, they know the choices, and they generally have access to any sort of medical care they could want. But they go gently.
 

Sunday, July 21, 2013

From various news sources:  KevinMD, The Atlantic, OncLive, OncLive
* News on cancer breakthroughs: Curb your enthusiasm

KarlS:  Timely information - resonates in light of recent findings for Lenalidomide in elderly patients with CLL
* The Vitamin Myth: Why We Think We Need Supplements
* On the Frontier of Cancer Care Holland Helped Pioneer Psychosocial Treatment 

Anjou: Excellent interview with one of the leaders in the field of psychology and social needs of cancer patients
*** Experts on Novel Treatment Approaches in Hodgkin Lymphoma - with video

KarlS:  Direct link to excellent and important interviews video

Friday, July 19, 2013

From various news sources:  The ASCO Post, NYT, Counsel and Heal News,  Nature,  Dr Kauffman, GEN, Bloomberg, KevinMD,  DigTriad.com, Med News Today, Cancer Research Inst, Cancer Network
* Idelalisib, Obinutuzumab Show Encouraging Results in CLL Studies
* Walking 800 Miles Away From Cancer 
* Nemo, the First Hampshire Pig to be Treated for Lymphoma
* Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737  
* Cancer Immunotherapy Goes Viral
*** Celgene Halts a Phase III B-Cell CLL Trial Because of imbalance of Deaths in Lenalidomide arm of study
Lenalidomide (Revlimid) Associated with Excess Deaths in the Elderly
* Deaths Force End to Celgene Trial to Expand Top Cancer Drug

    KarlS:  Did the eligibility criteria influence the risk for this drug - 65 years or older?

 The finding speaks to the importance of doing randomized trials - not only to compare efficacy but to understand risks.

In this case it’s a sobering reminder that the setting can count – that safety for one indication does not assure safety in another.  Lenalidomide has been studied (in randomized trials) for other indications – such as myeloma and MDS. It may be that something in this setting (CLL, older patients) that increases the risk. So the risks may also depend on the class of drug in respect to how unexpected the side effects can be when used in a new setting.  How Lenalidomide works (it’s mechanisms of action) is a bit of a mystery.

* What is the biggest mistake patients make?

"No, the biggest mistake patients make is thinking anecdotally rather than statistically"
* Houston Woman Gets Chemo, Later Learns She Doesn't Have Cancer   

   Anjou: Good discussion about importance of getting second opinions on pathology
* Link Discovered Between Intestinal Bacteria And White Blood Cell Cancer
* Death With Dignity Program Well Accepted at Seattle Cancer Center  
 

Thursday, July 18, 2013

From various news sources:  Oncology Times, Blood, Medscape, Medscape, Dr Len's Cancer Blog, NPR, News Medical, The North American Menopause Society (NAMS), The Onc, Science Based Medicine, Respectful Insolence, Koffman blog,  News Medical
* FDA Grants Obinutuzumab Priority Review for CLL

The FDA's priority review designation shortens the time to complete a drug's review and aims to deliver a decision on marketing approval
* Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase II trial

We hypothesized that post-transplantation B cell depletion could prevent the occurrence of chronic GVHD.
* Universal HBV Screening Is Cost-Effective in Lymphoma (hepatitis b screening)  

There has been some debate about whether all patients with cancer should be screened for HBV before treatment with chemotherapy and immunosuppressive drugs.
* Want To Help Make This Cancer's Last Century? Then Sign Up For Cancer Prevention Study 3
* Mining Cell Data To Answer Cancer's Tough Questions

The group has decided to make all of their data publicly available on the NIH sponsored website Cell Miner, so that it can be widely used for hypothesis-driven pharmaceutical research, and hopefully speed up our understanding and improvement of cancer treatments.
* Cancer patients who receive chest radiation should screen for heart disease every 5-10 years 

He added: "Survivors of Hodgkin's lymphoma and breast cancer received high doses of radiation on their chest under the old treatment regimes.
* Cancer survivors have more frequent and severe menopausal hot flashes: But they fare better than other women psychologically and socially
* Sexuality and the Cancer Patient  
* Researching SBM Online (science Based Medicine)
* Orac does Stanislaw Burzynski propagandist Eric Merola a favor…  
* ASCO 2013: Dr. Wierda on Prognostic Factors in CLL

* Mechanisms of chemotherapy-induced neurological side effects  
 

Wednesday, July 17, 2013

From various news sources:  News Medical, News Medical, MNT, Newswise, Cancer Research, Pharmagellan, Oncology Times, Science Daily
* White blood cells and the spread of cancer   (not lymphoma specific)
* Study explores mechanisms of chemotherapy-induced #neurological side effects
* Having Type 2 Diabetes Increases Risk For Some Cancers  
* Researchers Find Link Between Intestinal Bacteria and #White Blood Cell Cancer
* Intestinal Bacteria Modify #Lymphoma Incidence and Latency by Affecting Systemic Inflammatory State, Oxidative Stress, and Leukocyte Genotoxicity
* How to cure cancer? A review of “The Truth in Small Doses” by Clifton Leaf  
* Debating the Role of #Interim PET Scans in Lymphoma
* Strong #Pregnancy Outcomes for Survivors of Childhood Cancer

Tuesday, July 16, 2013

From various news sources:  Pharmagellan, Oncology Times, Science Daily
* How to cure cancer? A review of “The Truth in Small Doses” by Clifton Leaf
* FIRST: Debating the Role of Interim PET Scans in Lymphoma
* Strong Pregnancy Outcomes for Survivors of Childhood Cancer
 

Monday, July 15, 2013

From various news sources:  Science Daily, NewsFix, The Onion, NYTimes, NCCAM, Science Daily
* DNA Flaws May Contribute to Cancer Risk in People With Type 2 Diabetes
* Infection may be linked to eye lymphoma
* Deleted - found to be offensive.
* Do Clinical Trials Work?

Snip: Disappointing though its outcome was, the study represented a victory for science over guesswork, of hard data over hunches. As far as clinical trials went, Dr. Gilbert’s study was the gold standard. The earlier studies had each been “single-arm,” in the lingo of clinical trials, meaning there had been no comparison group.  

KarlS:  So important to realize -- for the benefit of patients.
* How Safe Is This Product or Practice?
* New Theory Uncovers Cancer's Deep Evolutionary Roots

 Anjou: Interesting hypothesis
 

Sunday, July 14, 2013

From various news sources:  Psych Central,  Boston Globe,  Leuk Lymph, J Clin Onc,  Br J Hem, Blood, Am J Hematololgy
* What to Do with Worry Thoughts
* Hope for women dealing with infertility after childhood cancer
* Comparison of outcomes among patients aged 80 and over and younger patients with diffuse large B cell lymphoma: a population based study
* Obinutuzumab (GA101) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: Results From the Phase II GAUGUIN Study
* Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Mantle-Cell Lymphoma: Results From the Phase II GAUGUIN Study
* Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-hodgkin lymphoma who received prior stem cell transplantation
* Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients
* Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study 

* Fludarabine-mitoxantrone-rituximab regimen in untreated intermediate/high-risk follicular non-hodgkin's lymphoma: Experience on 142 patients
 

Saturday, July 13, 2013

From various news sources: Sunrise Rounds, Weill-Cornell, NYTimes
* Referring to hospice - to save the doctor too - Posted to PAL topic page

In some circumstances it does not take an advanced degree to list the reasons why “hospice,” [can be] the best answer:
* Ibrutinib is Effective Therapy for Relapsed CLL Patients 
* Anxiety Lingers Long After Cancer 

Discusses anxiety in both the patient and caregivers

 

Friday, July 12, 2013

From various news sources: OncLive, NY Times, KevinMD, Science-based Medicine
* A Cancer Doctor of One’s Own
* Ask the (Science-Based) Pharmacist: What are the benefits of coffee enemas?

Anjou:  Over the years, some lymphoma patients on lymphoma support boards have brought up alternative cancer treatments that involve coffee enemas
* Genomics and personalized medicine: Is it really different this time
* 3 secrets my doctor doesn’t know
* Video: Emerging treatments for CLL Dr. Sharman's CLL & Lymphoma Blog
* First Washington Leukemia Patient to New Therapy ... is Cancer Free
* OT:  Link Between High Blood Levels of Omega-3 Fatty Acids and Increased Risk of Aggressive Prostate Cancer Confirmed

Thursday, July 11, 2013

From various news sources: OncLive, AIDs Meds, Medscape, Huffington Post, Cancer Research Institute,  Brian Koffman's Blog
* NDA (New Drug Application) Filed for Ibrutinib in CLL and MCL
* Abolishing High Co-pays for Oral Chemotherapy: Is the Third Time the Charm for the Cancer Drug Coverage Parity Act?
* Cancer: Things I wish I were told when diagnosed… Wicked Local Danvers

* Cancer Is Not All I Have

* Cancer and the Immune System 

* Single-agent LENALIDOMIDE is active in patients with relapsed or refractory aggressive NHL who received prior stem cell transplantation

a retrospective analysis of two phase II trials (NHL-002 and NHL-003) that studied single-agent lenalidomide in patients with relapsed/refractory aggressive NHL with prior (n = 87) compared with no prior ASCT (n = 179).

* Radioimmunotherapy deemed safe and effective for lymphoma patients: New study evaluates maximum tolerated dose and clinical response (177Lu-DOTA-rituximab)

The prospective study included 31 patients with histologically confirmed relapsed or refractory CD20-positive B-cell lymphoma.

* ASCO 2013: Dr. Wierda Discusses Immune Therapies in CLL
 
 

Wednesday, July 10, 2013

From various news sources: Cancer Research UK, AIDs Meds
* HIV Viral Load Associated with Risk of Death After Lymphoma Diagnosis

The risk of death from HIV-related lymphoma is associated with a higher cumulative viral load during the first six months after diagnosis with the cancer, supporting the argument for early antiretroviral (ARV) intervention, aidsmap reports. Publishing their findings in the online edition of the journal AIDS, investigators culled the records of more than 25,000 people receiving care for HIV between 1996 and 2011 and identified 224 who were diagnosed with lymphoma. All members of the group were still living six months after their lymphoma diagnosis and had received at least two viral load screens during that period.


* ‘Chocolate detects cancer’ headlines are misleading

Anjou- very well written article about an MRI imaging technique, in early development, that uses glucose that does not have to be radioactive. Also addresses the oversimplified notion that "sugar feeds cancer," message one finds all over the internet.
Anaplastic large cell lymphoma, ALK-neg Review - includes promising investigational agents  

Tuesday, July 9, 2013

From various news sources: Lymphoma Weill Cornell, Oncology Practice , Medscape, Medpage Today, KevinMD, Medical News Today, Blood, Asian Scientist
* Preliminary Results From a Phase I Trial of Palbociclib (PD 0332991) plus Bortezomib in Patients with Previously Treated Mantle Cell

Palbociclib is an oral drug that specifically inhibits CDK4, enzyme that is central to the proliferation of mantle cell lymphoma cells
* Ibrutinib shows promise for CLL del 17p 

KarlS: Interesting how many trials evaluating agents with targeted mechanisms of action are selecting patients with a marker of high risk CLL - in this case a marker that predicts resistance to standard chemotherapy.  A form of personalized medicine.  This can also be an accelerated path to marketing approval - to address an unmet need.

* Personalized Medicine in Oncology: Where Have We Come From and WHERE Are We Going? 

* Researchers Develop MRI Scan To Detect Cancer Using SUGAR 

* AFRICAN Americans With Blood Cancer Do Not Live As Long As Caucasians, Despite Equal Care

* Statin On-Board MAY Cut Cancer Risk in HIV Infection

* Genetic Variant That Increases Lymphoma Risk In Chinese Discovered

* PET-CT staging of DLBCL provides new insight into the clinical significance of bone marrow involvement 

* It's hard to grasp the experience of being a patient

Monday, July 8, 2013

Also see late Sunday post below

From various news sources: KevinMD, Haematologica, Am J Hematology, Leuk Lymphoma,Br J Cancer, Brit J Cancer,
* When the weight of illness suddenly descends on an individual
* Recognizing nodal marginal zone lymphoma: recent advances and pitfalls. A systematic review  

Anjou: The expert pathologist who read my path in 99 had trouble determining if mine was follicular or marginal zone-- wonder if the distinction would have been clearer 14 years later? Sounds like there still is some difficulty with certain presentations.
* Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party
* Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era
* Respect diagnostic radiation, but don’t have an irrational fear of it 
* FDG-PET/CT for assessment of response to Brentuximab Vedotin treatment in relapsed and refractory Hodgkins

* Risk and outcome of non-Hodgkin lymphoma among classical Hodgkins
* Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy 

* Why docs don’t do death?

PAL's new web-based support message board:

 Forum

Sunday, July 7, 2013

From various news sources: Live Science, NPR, News Medical, Respectful Insolence, Medical News Todaygov 
* Blinatumomab (bITE) induces autologous T cell killing of CLL cells

* Dr. Sharman's CLL & Lymphoma Blog Monoclonal B Cell Lymphocytosis 

"Monoclonal" means that there is a single population of cells (a clone) that look identical. In the normal healthy situation B cells should look different from one another. When they all look alike, we get worried that it could be a sign of cancerous growth. "B-Cell lymphocytosis" means that the ratio of lymphocytes are off and there are too many of them.

* Ice Pops May Lead to False Positive Fungal Test (aspergillosis)

* Is Alternative Medicine Really 'Medicine'? 

Anjou:  Excellent interview with Dr Offit about his recent book

* Oncologist urges drug companies to include key information in cancer drug labels

* When patient expectations battle with reality
 
Anjou: Deals with end of life issues in oncology. Not lymphoma specific.

* Immunotherapy Is Beginning To Have A MAJOR Impact For Patients With Cancer And Infectious Diseases 
 

Saturday, July 6, 2013

From various news sources: Oncologypractice.com, The ASCO Post, ClinicalTrials.gov 
* Study of interest: ABT-199 in Subjects With Relapsed or Refractory CLL with 17p Deletion
* Rituximab plus chlorambucil extend event-free survival in MALT lymphoma

*  Primary Mediastinal B-Cell:   It's Déjà Vu All Over Again
    Joseph M. Connors, MD
cites history as reason for caution
"Yogi Berra's pithy remark neatly summarizes my reaction when I read the article, "Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma," by Drs. Dunleavy, Wilson, and colleagues in The New England Journal
of Medicine.1  ...  as strong as these circumstantial pieces of evidence may seem, we need to be careful not to allow hope to triumph over evidence.

Thursday, July 5, 2013

From various news sources:  Sciencebase, NEJM, NY Times, Medical News Today, The Oncology Report, News Medical, Huff post
* Why your personal CAM story is not evidence

* Toward Patient-Centered Drug Development in Oncology 

* Keeping Cancer a Secret
 
   Who do you tell about your cancer? Have you kept quiet about it with certain people?

* What Are Benzodiazepines? What Are The Risks Of Benzodiazepines? - PAL 

   Anjou: Article discusses benzodiazepines, medications used for anxiety, sleep and some may be used as anticonvulsants
* Ice Pops May Confound Tests After Transplant 

* Rituximab plus chlorambucil extend event-free survival in MALT lymphoma 

* Antibody-Drug Conjugates and Cancer Treatment: Making “Smart Bombs” Smarter Scientific American

   Anjou:  Excellent blog post - well written for a lay audience

* Nobody Shaved Their Head for Me  

* Second Draft NICE Guidance For Aggressive Non-Hodgkin Lymphoma Treatment, PIXUVRI® (Pixantrone) 

 

Wednesday, July 3, 2013

From various news sources: PAL, PBS, Oncology Times, Salon.com, KevinMD.com, Psychology Today, Clinical Oncology News, J Nuclear medicine
*  Medication and Consult Organizer - PDF
Print, then fill in. Provide a copy for each physician to assist in your consults. Includes tips on how to avoid common medical errors
* Nanoparticles Show Big Promise in Fight Against Cancer 

* FDA Approvals of  Revlimid for MCL 

* Two Studies Reveal Important Genetic Insights Into The Development of NHL

* Are Vitamins a scam? 

* The tension between oncology and palliative care

* Don’t Be Intimidated in the Doctor’s Office: Six Strategies 

* Cytarabine Improves Combination Therapy for Mantle Cell Lymphoma

* Interim PET in Hodgkin Lymphoma: Would PET-Adapted Clinical Trials Lead to a Paradigm Shift? 

Anjou: Full article with a good bit of review regarding what is known about the use of PET in Hodgkin Lymphoma
 

Monday, July 1, 2013

From various news sources: ASCO Post, PAL, NEJM
* Primary Mediastinal B-Cell Lymphoma: It’s Déjà Vu All Over Again By Joseph M. Connors, MD
* Survival Rates for Patients with Burkitt’s Lymphoma Improve, Especially among Young Adults
* What's a  drug?
GA101 (type II cd20 antibody) OR Rituxan in Untreated Low Tumor Burden Indolent NHL
* Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

 

Sunday, June 30, 2013

From various news sources: NYtimes, KevinMD, CBS, OncLive
* Confronting the reality of uncertainty in medicine

   anjou: Interesting article talks about cases that are difficult to diagnose
* Management of Hodgkin Lymphoma

KarlS: comprehensive.  Includes expert perspective and insights
* Video: Chemotherapy could soon be obsolete with new treatments 

   KarlS:  Expert describes progress in exploiting differences between cancer and normal cells
* Breaking the Seal on Drug Research
 

Saturday, June 29, 2013

From various news sources:
* FDG-PET/CT for assessment of response to Brentuximab Vedotin (Adcetris) treatment in relapsed and refractory Hodgkin Lymphoma
* Risk and outcome of non-Hodgkin lymphoma among classical Hodgkin lymphoma survivors
* Limited role for surveillance PET-CT scanning in patients with diffue large B-cell lymphoma in complete metabolic remission following primary therapy
* For follicular patients can calculate their FLIPI score here
* Dr. Sweetenham: How I Manage Primary Mediastinal Large B-Cell Lymphoma
* Aggressive B-cell lymphomas: how many categories do we need? * Book raises alarms about alternative medicine
* 5 benefits of online patient communities

 

Friday, June 28, 2013

From various news sources:
* Life, Interrupted: Un-kept Resolutions
* Allogeneic Transplantation in Hodgkin Lymphoma
* John Theurer Cancer Center leads multicenter clinical trial for chemotherapy-induced neuropathic pain

   KarlS:  Important area of clinical study - an effective treatment would help address a common unmet need.
* ADA: Insulin Does Not Hike Cancer Risk
* Studying Tumors Differently, in Hopes of Outsmarting Them

   Anjou:  Excellent article exploring the issue of how tumors develop resistance, and that using targeted drugs together, rather than sequentially may be more effective.
* PACT Act May Improve Cancer Care for Medicare Patients Medscape
* New cancer treatment beats chemotherapy without the toxic side effects
 
"If a locked door must be opened, explosives can be used, but normally it is better to use a key."
* Cancer Clinics Closing: Community Oncology 'Near Crisis'

 

Thursday, June 27, 2013

From various news sources:
bullet
Dr. Sharman's CLL & Lymphoma Blog: The doctor is out?
bullet
How to Navigate a Cancer Diagnosis
bullet
No more chemo: Docs say it's not so far-fetched
bullet
Climbing Mountains

Essay that explores "one of the toughest questions of life.  How long do you continue to fight, when death is certain?  When does striving become vain hope which  drains quality and creates only suffering?  What makes struggle worth the pain; when is it time to yield? You've heard about the "asparagus cure", laetrile..etc  now... the  Bicarbonate Maple Syrup Cancer Treatment!
bullet
Sweet and alkaline won’t win the war against cancer
bullet
Research IDs Potential Treatment for Deadly, HIV-Related Blood Cancer

"The USC team shows that a class of drugs called BET bromodomain inhibitors effectively targets primary effusion lymphoma (PEL), a type of cancer  for which those drugs were not expected to be effective."
bullet
Human and Canine Lymphomas Share Molecular Similarities, First Large-Scale Comparison Shows
bullet
Safety Concern Halts Study of Seattle Genetics' Lymphoma Drug
bullet
Sex and Cancer -- Breaking the Taboo
bullet
Ibrutinib Shows High Response Rate in Mantle-Cell Lymphoma
bullet
Antibiotic therapy in non-gastrointestinal MALT lymphoma: a review of the literature
bullet
A Potential Turning Point in Treatment of CLL

Medscape summary of recent New England Journal of Medicine article on use of Ibrutinib in CLL
bullet
Clinical Oncology News: How I Manage Primary Mediastinal Large B-Cell Lymphoma
bullet
Mitti Mithai Viral Cancer Cure Conspiracies

Wonderful cartoon and essay about bogus cancer cures hyped on the net.  The  author says copying is cool, so I'll put the essay here, but use the link and check out the cartoon!
bullet
KevinMD: Genomics and personalized medicine: Is it really different this time?
bullet
Pharmatimes:  Celgene's Revlimid succeeds in lymphoma in Rituxan combo
bullet
Weill Cornell: ASCO Update: Ibrutinib Combined with R-CHOP Shows Positive Results for in patients with CD20-positive, B-cell non-Hodgkin Lymphoma
bullet
Weill Cornell: ASCO Update: Idelalisib Effective in Combination Therapy for Indolent non-Hodgkin Lymphoma http://bit.ly/15ze6b9
bullet
KevinMD:  Help patients find information on the Internet: Tips to surf safely
bullet
KevinMD: The medicine that kept her alive was not in a bottle

(end of life issues)
bullet
The Oncology Report: Idelalisib and rituximab produce responses in 97% with CLL (CAL-101)
bullet
NYTimes:  Employers Test Plans That Cap Health Costs
bullet
Pubmed: (Cancer): Cytarabine, Ki-67, and SOX11 in patients with mantle cell lymphoma receiving rituximab-containing autologous stem cell  transplantation during first remission
bullet
Pubmed (J Clin Onc) Follicular Lymphoma Cells Induce Changes in T-Cell Gene Expression and Function: Potential Impact on Survival and Risk of Transformation
bullet
Pubmed: (Cancer) The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as  a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT

Very Good news!!!  Lets hope it keeps getting better and better!
bullet
PubMed: Improvements in observed and relative survival in follicular grade 1-2 lymphoma over four decades: the Stanford University experience.  
bullet
Mwd News Today: Ibrutinib Shows Surprising Efficacy As Treatment For Chronic Leukemia, Mantle Cell Lymphoma
bullet
MSN Money:  Pharmacyclics could get ibrutinib approval this year: The FDA should make a speedy review of the breakthrough cancer drug a top priority
bullet
US News and World Report: How the Sequester Hurts Cancer Patients: Budget cuts are slicing into clinical trials  CNN Health: New drug may be best treatment for leukemia yet   

Video about Ibrutinib
bullet
Medscape: Ibrutinib: A Step Change in the Treatment of Mantle Cell Lymphoma
bullet
Dr. Sharman's CLL & Lymphoma Blog: Generic Cancer Drugs - aka "Biosimilar"
bullet
Sunrise Rounds: Cancer Office Gossip
bullet
OncLive: Utilization of Brentuximab Vedotin in Hodgkin Lymphoma
bullet
Medscape: Proton Therapy 'Sells Hope': No Clear Benefit for Patients
bullet
Dr. Sharman's CLL & Lymphoma Blog: Ibrutinib for CLL and MCL in New England Journal of Medicine

Thank you Dr Sharman for being part of this important research and for providing a link to the papers and the editorial
 
bullet
Haematologica. 2013 Jun 10.: High cure rates in Burkitt lymphoma and leukemia: NILG study of the German short intensive rituximab-chemotherapy program. http://1.usa.gov/12AKHRQ 
bullet
Oncology TImes: CLL: ‘Potent,‘ Well-Tolerated Activity for Ibrutinib, Irrespective of Deletion 17p http://bit.ly/17kh2hJ

Sunrise Rounds: Why is the doctor ANGRY? http://bit.ly/18GhTqZ 

Dr Len's Cancer blog: Genomics And Personalized Medicine: Is It Really Different This Time? http://bit.ly/11vyhEt 

Dr. Sharman's CLL & Lymphoma Blog Personalized Medicine - turning drug development upside down! http://bit.ly/18GBcTq 

Psychology Today: 12 Tips from 12 Years Sick http://bit.ly/1aKOR8J 

The onc: Are Oncology Studies Really Less Robust? http://bit.ly/Zzc3am 

NPR: Cherishing The Gift Of Friendship Through A Cancer Bout http://n.pr/11cDvpC 

News Medical: Three easy steps for cancer survivorship http://bit.ly/11Hx96w 

NYT: Life, Interrupted: Going Public With Cancer http://nyti.ms/140Xmwl 

Medpage Today: Combo Boosts PFS as Initial Leukemia (CLL)Therapy http://bit.ly/11q3FUM 

Cancer.net: What to Know: ASCO's Guideline on Fertility Preservation http://bit.ly/15aFkak 

Sunrise Rounds: Doc, how about some marijuana? http://bit.ly/12OJouy 

News Medical; Survival rates increased among patients who received blood stem cell transplants: Study http://bit.ly/1az7qwL 

Science-Based Medicine: Patient Participation in Decision-Making http://bit.ly/1599OK6 

Respectful Insolence: Cutting, poisoning, and burning naturally http://bit.ly/11p0nBh 

OncLive: Primary Management of Advanced Hodgkin Lymphoma http://bit.ly/12ZlCxC 

MNT: Intensified, Liposomal Anthracycline-Based Chemo Regimen For Children With Leukemia May Offer High Survival Rates Without Added Heart Toxicity http://bit.ly/1asgweF

NYTimes: Battling Cancer Together http://nyti.ms/11sLPWY 

MailOnline: The mother and daughter diagnosed with the SAME cancer (hodgkins) at exactly the SAME age - even though it's not hereditary http://bit.ly/11lGSte 

MedicalXpress: Non-Hodgkin lymphoma survival doubles since early 1970s http://bit.ly/14Fh6ov 

Science Daily: It's Not Your Imagination: Memory Gets Muddled at Menopause http://bit.ly/ZhsdVL
 
Some women get thrown in to menopause from treatment....is it chemobrain or menopause, combination?

Medscape: After Cancer: Debate About Terminology Beyond Treatment http://bit.ly/16Y1Nvu

NYT: Mothers With Cancer http://nyti.ms/11epTZI 

Huff Post: Medical No Man's Land: A 20-year-old Cancer Patient http://huff.to/16RxgyD 

NYT: What's in Your Green Tea? http://nyti.ms/10OaO17 

Cancer and careers: Working with Chemo Brain http://bit.ly/10RtUrm

Onclive: ONLINE FIRST: In Phase I Study, CLL Patients Appear to Benefit from Isoform-Specific PI3K Inhibitor http://bit.ly/168zCK9 

Dr. Sharman's CLL & Lymphoma Blog: Inotuzumab sinks.... http://bit.ly/10PI108 

Reuters: Pfizer halts study of lymphoma drug unlikely to help survival http://reut.rs/13GKNpE

inotuzumab ozogamicin

Comments: A good example of a "failed" controlled study that provides valuable information. Without the randomized design and the comparator ... the results may have seemed "encouraging" or "deserving of further study." IO may still find its place as an effective lymphoma treatment (such as in consolidation or in indolent lymphoma). Relapsed / refractory aggressive lymphoma ineligible for SCT is a challenging setting and it seems that chemo has an edge over antibody therapy in this population (based on RIT for example) - perhaps because chemo is faster acting?

Science Daily: Radioactive Nanoparticles Target Cancer Cells http://bit.ly/16N4LCr 

Sunrise Rounds: Don’t play the numbers http://bit.ly/12J3CYi 

MNT: Cancer Survivors Suffer Physical & Emotional Impairments Which Often Go Untreated http://bit.ly/1a0imTH 
bullet
Dr. Sharman: How expensive are new drugs? http://bit.ly/10zY11Z
bullet
April 2013: Pharmacyclics Completes Enrollment of Phase III Ibrutinib CLL Study and Phase II Ibrutinib MCL Study  ascopost.com
bullet
Latif and Morris: Monoclonal Antibody Therapy of T-Cell Leukemia and Lymphoma:  http://bit.ly/WimCgm
bullet
Oncology Times: Stage I Follicular Lymphoma: LymphoCare Study Questions Role of Radiation—Many Options, ‘Rigorous’ Staging Key http://bit.ly/O6rWhP
bullet
Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity? http://1.usa.gov/S2hWsi
bullet
Parenthood in Survivors of Hodgkin Lymphoma: An EORTC-GELA General Population Case-Control Study. http://1.usa.gov/RkQTWB
bullet
Doctors Lounge: Watch & Wait OK in Low-Tumor Burden Follicular Lymphoma http://bit.ly/Sl49va
bullet
Watchful Waiting in Low-Tumor Burden Follicular Lymphoma in the Rituximab Era: Results of an F2-Study Database. http://1.usa.gov/P9pAdW 
bullet

Dr. Cheson on expectant management of follicular lymphoma: Waiting is the Hardest Part http://bit.ly/Sm3plQ

bullet
oNLINE FIRST: Stage I Follicular Lymphoma: LympoCare Study Questions Role of oncology Times: Radiation; Many Options, ‘Rigorous’ Staging Key http://bit.ly/NuPdda
bullet
OncLive: Dr. Furman on Trials Examining Ibrutinib's Safety in CLL http://bit.ly/VPeLF7
bullet
Cancer Connect: Cystitis from treatments http://bit.ly/10ndcRH  Tips on how to avoid it etc
bullet
NBC: If you can't pay: How to get insurance to cover specialty drugs http://nbcnews.to/SfsNiu
bullet
Dr. Sharman's CLL & Lymphoma Blog What is R-CHOP?
bullet
Dr. Sharman's CLL & Lymphoma Blog: What is FCR? http://bit.ly/PBQkI6 

An excellent explanation. A good read- even if your battle is not with CLL.
bullet
HemOnc Today: Optimized fertility advice needed for Hodgkin's lymphoma survivors http://bit.ly/U2KmjV
bullet
Dr. Sharman's CLL & Lymphoma Blog: Making sense of all the different lymphomas  http://bit.ly/OfCYNs
bullet
MNT: Improving Cell-Based Immune Therapies For Cancer http://bit.ly/VaFLxN Exciting concept
bullet
ASH Education, 2012:
The many faces of marginal zone lymphoma
by Dr. Zinzani  http://bit.ly/TTcdUk  
bullet
ASH Education, 2012:
Is there a role for "watch and wait" in follicular lymphoma in the rituximab era? by Dr. Brad Kahl
http://bit.ly/U40lNi 
bullet
Medscape: Is R-Benda a New Standard in Lymphoma? http://bit.ly/X5Azh5 
bullet
KevinMD.com: How to get the most out of your oncology appointments http://bit.ly/Wts8Xs
bullet
Dr. Sharman's CLL & Lymphoma Blog:
Richter's Syndrome / Histologic Transformation: Richter's Syndrome / Histologic Transformation http://bit.ly/UQj6al
bullet
Medscape: Fatigue-Busting Programs Work Even in Advanced Cancer http://bit.ly/X6O9gV
bullet
NYT: Living With Cancer: Chemo-Feet (peripheral neuropathies) http://nyti.ms/100QEqw
bullet
Cancer Connect: Prophylactic Vorinostat Cuts Risk of Graft-Versus-Host Disease in Half http://bit.ly/VGbpQJ

ASH abstract: https://ash.confex.com/
bullet
Medscape: A Call to Eliminate 'Chemotherapy Concession' http://bit.ly/RtRuHz
bullet
KevinMD: Are you a thrifty patient? How to get the care you need and save money http://bit.ly/W3P4vu
bullet
KevinMD.Com: How to deliver bad news to patients: 9 tips to do it better http://bit.ly/Uljp9A
bullet
On Healthy Survivorship: Tips for Adult Children of Newly Diagnosed Patients http://bit.ly/X0OJww
bullet
Dr Sharman's CLL and Lymphoma Blog: The Slow (Indolent) Lymphomas http://bit.ly/VqwvmE

Thank you Dr Sharman for this patient friendly explanation!
bullet
Sunrise Rounds: 100% Inconclusive http://bit.ly/XeN9Lu
MSNBC: How to avoid spreading the flu: Stay home for 4 days http://nbcnews.to/WXacGF
bullet
NYT: Juggling Diabetes and Cancer http://nyti.ms/Vfv0YM  excellent article
bullet
Health News Reviews:
3rd annual year-ender on health care Public Relations crap we receive http://bit.ly/UEmQfg 
bullet
KevinMD.Com: Physicians can be better doctors by being patients http://bit.ly/ZPnuuz
bullet
Forbes: Making a Profit from Offering Ineffective Therapies to Cancer Patients http://onforb.es/XaKKkN
bullet
Dr. Sharman's CLL & Lymphoma Blog :
New CLL Prognostic Groups http://bit.ly/Vo0X3u
bullet
Science Daily: New Technique Catalogs Lymphoma-Linked Genetic Variations http://bit.ly/10kVmOM
bullet
NEJM: The Impact of Drug Shortages on Children with Cancer — The Example of Mechlorethamine http://bit.ly/TyYyEz
bullet
Science Daily: Immune System Changes May Drive Aggressiveness of Recurrent Tumors
http://bit.ly/Vj72OE
bullet
Science Based Medicine: Why Do People turn to Alternative Medicine http://bit.ly/U9vHSn
bullet
Onc Times: View from the Other Side of the Stethoscope: False Hope http://bit.ly/Tp5wsf
bullet
CNN: Why I donated my bone marrow http://bit.ly/U8apo8 

Lymphoma patients cannot make donations but can encourage others to do so!
bullet
New Yorker: Cleaning up Science: http://nyr.kr/VZsB30
 
ASCO 2012: Lymphoma and CLL:

CLL/SLL | CNS | Diffuse Large B-cell | Follicular | Hodgkin | Mantle Cell | Marginal Zone | T-cell
 
bullet
ASH 2011 lymphoma and CLL abstracts
bullet
Effectiveness of First-Line Management Strategies for Stage I Follicular Lymphoma: Analysis of the National LymphoCare Study jco.ascopubs.org  http://bit.ly/POvLsJ
bullet
Medscape: Early Follicular Lymphoma -- Need to Revisit Guidelines? http://bit.ly/SViGe0
bullet
Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial http://bit.ly/O2E6nq 
bullet
Annals of Oncology: Follicular lymphoma, A Review article  http://bit.ly/O2FJBz
bullet
News Medical: FDA requests Biovest to conduct second Phase III trial of BV301 for NHL http://bit.ly/NFf7GS
bullet
Medpage Today: Drug (Maraviroc is a CCR5 antagonist) Staves Off Graft-vs-Host Disease http://bit.ly/RQiy3h  
bullet
Medical Express: Exercise may improve quality of life during and after cancer http://bit.ly/PoaoL4
 
In two separate Cochrane systematic reviews, the authors gathered together evidence showing that activities such as walking and cycling can benefit those who are undergoing or have completed treatment for cancer.
bullet
Onc Times: Indolent & Mantle Cell Lymphoma: Bendamustine-Rituximab Superior to R-CHOP, Long-Term Results Confirm http://bit.ly/O3tTMu
bullet
Medscape: Standard of Care for Older Patients With Mantle Cell Lymphoma? http://bit.ly/O5RA3R
bullet
International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: Altered Utility in the Modern Era. [J Clin Oncol. 2012] - PubMed - NCBI http://1.usa.gov/OXVehO
bullet
Helicobacter pylori eradication therapy is effective in the treatment of early-stage H pylori-positive gastric diffuse large B-cell lymphomas.. [Blood. 2012] - PubMed - NCBI  http://1.usa.gov/QX6z4D
bullet
Rituximab Maintenance Effective in Elderly Mantle-Cell Lymphoma Patients - Cancer Network 
http://bit.ly/S3EnrM
bullet
Cancer Research UK: Cannabis, cannabinoids and cancer – the evidence so far http://bit.ly/NuPhtL
bullet
Medscape: CT Overused in Monitoring Pediatric Hodgkin's Lymphoma http://www.medscape.com/viewarticle/768239
 
bullet
Science Codex: Novel drug therapy targets aggressive form of non-Hodgkin's lymphoma http://bit.ly/UtxBf3 

Interesting pre-clinical research on new target MALT-1 that is highly active in ABC-DLBCL - from a very well-respected researcher and team.
bullet
Doctors Lounge: Predictors of QoL ID’d for Long-Term Lymphoma Survivors http://bit.ly/Un97X2
bullet
Cancer Research UK: Alternative cancer treatment claims in the media are damaging and misleading http://bit.ly/TOXxnb 
bullet
Helicobacter pylori: Epidemiology and Routes of Transmission http://bit.ly/113izUs 
bullet
PsychCentral: 12 Depression Busters for Caregivers http://bit.ly/UDSFSR
bullet
Find published articles on
Fertility and Hodgkin lymphoma ncbi.nlm.nih.gov
bullet
Insect bite-like reaction associated with mantle cell lymphoma: a report of two cases and review of the literature. http://www.ncbi.nlm.nih.gov/pubmed/15485536
bullet
Psychcentral: 8 Simple Ideas for Remembering to Take Your Medication http://bit.ly/SFxVqf
bullet
LewisGale Regional Health System:
Evidence based info on herbs and supplements: http://bit.ly/Ui0j9p
 
Be sure to check out the What is the Scientific Evidence link for each item.
bullet
Memorial Sloan Ketterings mobile app on herbs and supplements http://bit.ly/VA3gzO
bullet
MNT: Improving Stem Cell Transplant Outcomes By Harnessing The Immune System http://bit.ly/VlHaTj 

Interesting research with multiple myeloma, another blood cancer-- Hopefully one day, this type of process might help lymphoma patients.
bullet
Science fact or science fiction? Making sense of cancer stories in the media http://bit.ly/OFmzro
bullet
Science Based Medicine: Patients Still Respect Evidence http://bit.ly/PapIQ3
bullet
WSJ: Access to Doctors' Notes Aids Patients' Treatment http://on.wsj.com/T1d5rc 

While patients legally have the right to see their entire medical record, including doctor's notes, the notes aren't automatically included in requests for records and doctors don't make it easy for patients to see them
bullet
KevinMD: How well does your doctor play with others? http://bit.ly/SxTltL
bullet
Respectful Insolence: Are mouse “avatars” useful for predicting human response to chemotherapy and targeted agents in cancer? http://bit.ly/R0DeSu
bullet
Sunrise Rounds: CancerLand, the undiscovered country http://bit.ly/Ql2WAk
bullet
TedTalks: Ben Goldacre: What doctors don't know about the drugs they prescribe http://bit.ly/UQduxa
bullet
NYT: A Cancer Patient’s Best Friend http://nyti.ms/STK1ww

In the short time Oscar has been in my life, he’s had an effect on my relationships. Rather than staring at my bald head, passers-by stop to play with Oscar and to tell me how cute he is. The other tenants in my building now say hello to my dog before greeting me.
bullet
NBC: Cancer doctor reveals the 'very dark side' of hospital errors http://nbcnews.to/QhkWvs
bullet
NYT: Needles or Port? A Cancer Patient Decides
 
“They are tiny and rollers,” the nurse says as his fingertips
trace the veins on my arms. My part in a trial has begun,
but the only “good” vein in the crook of my left arm looks
alarmingly bruised, as do both of my wrists.
bullet
MSN: Why patients don't report medical errors http://nbcnews.to/PoB5j0
bullet
Dr. Sharman's CLL & Lymphoma Blog CLL treatment - avoiding chemotherapy http://bit.ly/QxAwGi
bullet
JCO; Waiting is the hardest part http://bit.ly/UuWvfh 

Commentary by Cheson on news story posted earlier about watch and wait for follicular
bullet
Cancer Connect: Advanced Directives http://bit.ly/NPME5s 

clear explanations of things like living wills, advanced directives etc.
bullet
Sunrise Rounds: food and cancer http://bit.ly/OnA66N
bullet
News Medical: Cancer-related medical costs to more than double in some states in less than eight years http://bit.ly/UsReF7
bullet
Science Daily: Researchers Solve Puzzle of B-Cell Lymphoma Development http://bit.ly/VvgPQ9
bullet
MDC researchers solve puzzle of B-cell lymphoma development http://bit.ly/Q9Y4RY
bullet
Navigating through Chemobrain http://bit.ly/OLpEGb
bullet
KevinMD: 5 ways to help make a cancer diagnosis more manageable http://bit.ly/Q5Ke2Z
bullet
Dr. Sharman's CLL & Lymphoma Blog: How drugs are created / why does it take so long? http://bit.ly/PZF4p8
bullet
Oncology Report: Is Anyone Listening? http://bit.ly/QFdGu0

Talks about how couples communicate when one has cancer. How has it been for you?
bullet
NYT: Needles or Port? A Cancer Patient Decides http://nyti.ms/RzvXxp
bullet
NYT: Poor Pain Control for cancer patients http://nyti.ms/PsDHxl
bullet
Sunrise Rounds: The aggressive chemo fallacy http://bit.ly/Rz2zY8
bullet
KevinMD: Despite the best evidence, oncologists cannot dictate treatment http://bit.ly/UkjCt0

Allowing myself time to step back, however, made me realize it was not me who was in a position to determine what toxicity is “acceptable.” I am not the one who must live with treatment and its impact on daily life. Indeed, only one person has to look at herself every day, fight cancer, and fight to remain true to who she is despite it. It was my patient in front of me, and she did not want PLD. In essence, she did not want to take the risk that her cancer would mean giving up yet one more passion.
bullet
Oncology Times: POINT-COUNTERPOINT: Mantle Cell Lymphoma: Observation vs. Immediate Treatment for Asymptomatic Patients with Low Tumor Burden http://bit.ly/NB0HMf
bullet
The Daily Star: Orangutan's cancer treatment similar to humans http://bit.ly/UfqQyq  (Peanut)
bullet
Scientific American: Killer skills of a neutrophil http://bit.ly/OT8XEv

Nice explanation, helpful in understanding what those blood count labs mean.
bullet
Respectful Insolence: Overselling preclinical results http://bit.ly/NxvDgd
 
bullet
Mayo: Melanoma Up to 2.5 Times Likelier to Strike Transplant, Lymphoma Patients http://bit.ly/O5CcXH

Highlights the importance of regular checks with the dermatologist
bullet
Business and Health: Quality-of-life Program May Help Cancer Patients http://bit.ly/RSv8PP
bullet
NYT The Trials of Cancer Trials http://nyti.ms/QM8AhF

See also Expanded Access a possible option for patients not eligible for trials: lymphomation.org
bullet
MDA: Shifting opponents: From fighting cancer to fighting sepsis http://bit.ly/O1Css4
bullet
NYT: The Widow’s Doctor Visit http://nyti.ms/O0KdOP
bullet
Shrink Rapt: Saying the Right Thing http://bit.ly/Pym80o
bullet
News Medical: New model reveals how immune system functions under conditions of neutropenia http://bit.ly/OGrnIl
bullet
Science Based Medicine: An Acupuncture Meta-Analysis http://bit.ly/PbhT8Z
bullet
Respectful Insolence: Can we finally just say that acupuncture is nothing more than an elaborate placebo? Can we? (2012 edition) http://bit.ly/Pio61s
bullet
Sci Amer: Scientists play a large role in bad medical reporting http://bit.ly/QDQmyA
bullet
KevinMD: How to tell your friends and family that you have cancer http://bit.ly/OEYfBx
bullet
NYT: Coping With Mild Cognitive Impairment http://nyti.ms/RCmg0F
bullet
MSNBC: Should you fire your doctor? http://nbcnews.to/NjblXI
bullet
Medical NEws Today; Junk DNA Not Junk After All http://bit.ly/Qdaq8T
bullet
Science Based Medicine, Video: Fairy Tale Science and Placebo Medicine http://bit.ly/NU5No2
bullet
KevinMD: Experiencing my first Facebook era death http://bit.ly/UCkTOa
bullet
News Medical: Vitamin D supplements {MAY} have unintended lipid consequences http://bit.ly/NfjwnP
bullet
NYT: Not a Cancer Survivor http://nyti.ms/OepRS5
bullet
Cornell: ASH Patient Advocacy Alert: Help Protect Medical Research Funding http://bit.ly/TZDIsf
bullet
Science Daily: Stem-Cell-Protecting Drug Could Prevent the Harmful Side Effects of Radiation Therapy http://bit.ly/P0ANzy
bullet
Dr Len's Cancer Blog: Expert Opinion: A US Perspective On Beating Cancer http://bit.ly/TZCyND
bullet
Respectful Insolence: The Real Way to Prevent Cancer http://bit.ly/RoS4Ab
bullet
The Oncology Report: Biologic Agents for RA Don't Appear to Raise Malignancy Risk - meta-analysis of 63 randomized clinical trials http://bit.ly/Nbe0me
bullet
Weill Cornell: Research Study: Dietary Cholesterol Associated with Increased Cancer Risk, Including NHL http://bit.ly/RIhIAq
bullet
Moffitt Cancer Center on 'chemo brain': on average the deficits are slight and limited to verbal ability and visuo/spatial skills http://bit.ly/RCP7QY
bullet
FHCC: New genetic clues to why most bone marrow transplant patients develop graft-versus-host disease http://bit.ly/Teev1q
bullet
News Medical: Missing link between bone marrow stem cells and human immune system http://bit.ly/RdfPv3
bullet
KevinMD: My doctor isn’t listening to me! How you can help http://bit.ly/UjJ6J1
bullet
KevinMD: How to plan for a long hospital stay http://bit.ly/NIEIhP
bullet
Dr. Sharman's CLL & Lymphoma Blog What is R-CHOP? http://bit.ly/Q9jgX7
bullet
MSNBC: Reducing infection risk:Bagged lettuce or bulk? Experts offer food safety advice
http://nbcnews.to/Ru72oR
bullet
Science Based Medicine: Questioning Whether Psychotherapy and Support Groups Extend the Lives of Cancer Patients http://bit.ly/N3u1uu
bullet
KevinMD: End of life ethics and the importance of doing the right thing http://bit.ly/N3uooQ
bullet
NYTimes: Life, Interrupted: Five Days of Chemo http://nyti.ms/SVUn2e
bullet
KevinMD: Hospice care and palliative care: What’s the difference? http://bit.ly/Owd08t
bullet
Mayo study: Exercise can help cancer patients, but few oncologists suggest it http://bit.ly/SOszyt
bullet
Treanda (bendamustine) approved in Canada http://reut.rs/OGOELa
bullet
WSJ: To Treat the Cancer, Treat the Distress http://on.wsj.com/PnYEw3
bullet
Science Based Medicine: Andrew Weil’s Seasonal Supplements http://bit.ly/SM8R6c
bullet
Cancer drug helps patient despite faltering in trials http://fxn.ws/PcoPG8  
bullet
Sunrise Rounds: Picking your doctor’s team http://bit.ly/Q90DnH
bullet
KevinMD: Test results without physician guidance will cause patient anxiety http://bit.ly/PfCS9y
bullet
ScienceDaily (Aug. 22, 2012) — Particle physicists have developed a new medical technology that combines PET and MRI in one. Benefit: Improved image quality and less radiation. http://bit.ly/Nic392
bullet
NYTimes: Life, Interrupted: Six Ways to Cope With Cancer http://nyti.ms/OxNBxd

"At first, I bristled at the idea of a cancer community. It was enough to have cancer; did I also have to share my experience with a group of strangers? It felt like extra homework"
bullet
DBs Medical Rants: Compassionate paternalism http://bit.ly/PH8tU1
 
"We have, I believe, overdone the shared decision making concept.  Patients cannot really make informed decisions about everything.  We have a professional responsibility to provide our opinions and "argue" with patients about their health care decisions." 
bullet
KevinMD: Helpful things to say to someone who’s sick http://bit.ly/O67463
 
“How are you holding up? Do we need to stop visiting so you can rest?"
bullet
Dr. Sharman's CLL & Lymphoma Blog Campath is going away? http://bit.ly/MNyWiV
bullet
Respectful Insolence: Quackademic medicine versus cancer quackery  http://bit.ly/NFhwGQ   
bullet
The Telegraph: Green tea extract 'eradicates cancer tumours - piggy-backing the extract on proteins that carry iron molecules.   http://bit.ly/SnAtyn
bullet
Cancer Quackery: The Persistent Popularity of Useless, Irrational 'Alternative' Treatments http://bit.ly/PviT9Q
Have to register for site to read but a good article
bullet
Modern Medicine: Clinicopathologic diagnosis minimizes misidentification of lymphoma http://bit.ly/PDUKxa
bullet
NYtimes: Gene Tests in Yeast Aid Work on Cancer http://nyti.ms/PQ8aaX
bullet
KevinMD:  Don’t accept advice from physicians until they understand your values http://bit.ly/NeOeJ4
bullet
KevinMD.com: Googling cancer information: Tips from a cancer survivor  http://bit.ly/Qgb0AH
bullet
USA TOday: My Semicolon Life: Welcome to the cancer club http://usat.ly/MDJTDG
bullet
KevinMD: How I define patient engagement http://bit.ly/NPXNT5
bullet
Hospital discharge planning: Involve the patients http://bit.ly/N7De6i
bullet
Dana Farber: 7 Tips to Remember When Visiting Cancer Patients http://bit.ly/MDJFwq
bullet
KevinMD.com Patient care suffers when nurses are overloaded with work http://bit.ly/NJPkPi
bullet
Medical News Today: Two Approaches To Understanding The Basic Mechanics Of Cancer http://bit.ly/Q7kdLA
bullet
Medscape: Cancer Treatment During Pregnancy Feasible http://bit.ly/Rncz70
bullet
Dr. Sharman's CLL & Lymphoma Blog: Why the B-Cell Receptor Matters / Another possible explanation for Ibrutinib or CAL-101?  http://bit.ly/PtvSWS
bullet
KevinMD: Helping cancer survivors fight neuropathy  http://bit.ly/RlDyQs
bullet
Science Daily: B Cell Survival Holds Key to Chronic Graft Vs. Host Disease http://bit.ly/NIR89A
bullet
UNC: B cell survival holds key to chronic graft vs. host disease http://bit.ly/N675pR
bullet
The Conversation Project http://bit.ly/NpkZ7M
 
"We are all mortal, yet as a society we have been painfully slow in recognizing how many of the people we love are not dying in the way they would choose."
bullet
Stanislaw Burzynski versus regulations protecting human research subjects  http://bit.ly/RjGvAM
bullet
Life, Interrupted: Putting a Positive Spin on Cancer - NYTimes.com http://nyti.ms/MzEbmo
bullet
Medical News Today: Cause Of Burkitt Lymphoma Discovered http://bit.ly/PpWNmn
bullet
Medical News Today: Scientists Develop Model For New Burkitt Lymphoma Treatments  http://bit.ly/OiMVf2
bullet
PsychCentral: Key Questions to Ask When Choosing a Psychotherapist  | World of Psychology http://bit.ly/PkPD6z
bullet
"Background and credentials aren’t the only things to consider when hiring a therapist."
bullet
The Globe: Exercise is powerful cancer medicine http://bit.ly/NAtIDc
bullet
Naturopathic cancer treatments versus reality – Respectful Insolence  http://bit.ly/P9Tgej
bullet
Science Daily:  New Key Element Discovered in Pathogenesis of Burkitt Lymphoma http://bit.ly/NyLvuu
bullet
News Medical: Researchers uncover how pathological cells activate themselves in chronic lymphocytic leukaemia  http://bit.ly/MrIBM5  Science Daily: http://bit.ly/MrIro3
bullet
Bone Marrow Transplant.

A cautionary tale for probiotic use in hematopoietic SCT patients-Lactobacillus acidophilus sepsis in a patient with mantle cell lymphoma undergoing hematopoietic SCT. (no abstract)
bullet
bullet
Cure: Letting Go: Saying Goodbye When a Loved One Says It’s Time http://bit.ly/MZ1h72
bullet
NPR: David Rakoff: 'There Is No Answer As To Why Me' http://n.pr/OaWWe3
bullet
USA Today: My Semicolon Life: What to say to a cancer patient http://usat.ly/MLBQGg
bullet
MSNBC: Cholesterol drugs may lower cancer risk http://nbcnews.to/MISAYH
bullet
What if the Doctor Is Wrong? - WSJ.com http://on.wsj.com/ydUuLG
bullet
Book recommendation from On Healthy Survivorship: Help Me Live http://bit.ly/P8omnu
bullet
NYTimes: Life, Interrupted: Medical Bills, Insurance and Uncertainty http://nyti.ms/MkNPJx
bullet
Dr. Sharman's CLL & Lymphoma Blog: Trisomy 12 in CLL http://bit.ly/MBJ93o
bullet
NEJM: Treatment of Older Patients with Mantle-Cell Lymphoma http://bit.ly/NkrGJ2
bullet
Medical Express: Grapefruit juice lets patients take lower dose of cancer drug http://bit.ly/QLr8kC
 
Good that they are exploring this, but not something for patients to explore on their own without consulting docs as could be harmful!
bullet
Patients in clinical trials of new targeted cancer therapies appear to have lower risk of side-effects http://bit.ly/QLoD1t 
bullet
U Penn: The Daily Pennsylvanian :: Penn partners with Novartis to fight cancer http://bit.ly/PeXUoQ
bullet
Dr. Sharman's CLL & Lymphoma Blog: Genetically Modified T-Cells for CLL (and eventually NHL) http://bit.ly/Nkly1E
bullet
Bloomberg: Novartis Gets Immune-Cell Cancer Therapy in UPenn Pact http://bloom.bg/QFoWLm
bullet
In the Pipeline: Novartis Bankrolls T-Cell Cancer Therapies http://bit.ly/OHk6dG
bullet
KevinMD: Patients who receive test results instantly: Doctors need to be ready http://bit.ly/TbfBs4
bullet
Neurologica blog: Health Information on the Internet http://bit.ly/Q4JgPH

Conclusion: We are still living in the wild west of the internet. The net is becoming a critical resource, and health information is near the top of the list. It is difficult, however, to create and maintain accurate resources of health information. The topics are complex and the information is constantly changing. In my experience the more controversial the topic also the more misinformation there is out there clogging up Google searches.
bullet
USA Today: Column: Lab test access carries unintended consequences http://usat.ly/QvgiwK
bullet
10 surprising dangers of vitamins and supplements Don't assume they're safe because they're 'all natural'
Consumer Reports magazine: September 2012 http://bit.ly/OCRuQ0
bullet
Dr. Sharman's CLL & Lymphoma Blog: How I approach follicular lymphoma  (part 1) - patients with low risk disease http://bit.ly/T0OZtV

(part 2) - patients with higher risk disease  http://bit.ly/MjgQQW
bullet
Oncology Times: View from the Other Side of the Stethoscope: Patient Handout—Managing Primary Care Needs  http://bit.ly/NS3GAg
bullet
LIKE: Accuracy of Medical Information on the Internet | Guest Blog, Scientific American Blog Network http://bit.ly/MC1Y1z

Comment: Excellent conclusions.  

Regarding "Always seek out the counter opinion for anything that seems controversial" I learned this lesson the hard way. It took a few mistakes for it to sink in!
bullet
Cancer Connect: Antidepressant Cymbalta Might Tame Post-Chemotherapy Pain Http://bit.ly/NWTBPV  
bullet
Lifescript: 8 Ways to Fight the Fatigue of Chemotherapy Treatment http://bit.ly/PoEWtP
bullet
Medical xpress: Mayo Clinic completes first genome-wide analysis of peripheral T-cell lymphomas http://bit.ly/NlY5w7

Researchers at Mayo Clinic have completed the world's first genome-wide sequencing analysis of peripheral T-cell lymphomas, unlocking the genetic secrets of this poorly understood and highly aggressive cancer of the immune system. We need better treatments for this type of lymphoma-- hopefully this will help lead to them!
bullet
‘Chemo brain’ frustrating for cancer patients http://bit.ly/MRzNjD
bullet
Dr. Sharman's CLL & Lymphoma Blog: What is BCL-2 and why should we inhibit it? http://bit.ly/R05pj6
bullet
Kevin MD: 5 questions every patient needs to ask http://bit.ly/O7bE4i
bullet
Dr Sharman's CLL and Lymphoma Blog:  CLL: Going nowhere fast or going fast to nowhere? How Growth Kinetics Apply to Clinical Picture http://bit.ly/Ot702S
bullet
Dr. Sharman's CLL & Lymphoma Blog: PCI-32765 (ibrutinib), CAL-101 (GS-1101) Changing the future of CLL http://bit.ly/QqXStq
bullet
NYTimes: When Dr's words aren't Soothing http://nyti.ms/SXM19q
bullet
UC San Diego: CLL Tumor cells' inner workings predict cancer progression Molecular markers help reveal nature of chronic lymphocytic leukemia -- slow or fast http://bit.ly/PSdiu5
bullet
Opposing views: Dating With Cancer: Not an Easy Prospect http://bit.ly/PS6i0a
bullet
Dating after cancer http://bit.ly/Qn7o6A
bullet
When Should You Tell Your New Love Interest That You Have Cancer http://bit.ly/O2XCTY
bullet
Livestrong: DATING AND NEW RELATIONSHIPS http://bit.ly/N1O9ca
bullet
Pubmed: Atypical burkitt's lymphoma transforming from follicular lymphoma http://1.usa.gov/N1NkQx
bullet
News Medical: Lymphoma drug dislodges hidden virus in HIV patients http://bit.ly/OT6Z4V
bullet
Respectful Insolence: New cancer drugs: Fitter, happier, more productive? Or not?  http://bit.ly/PRikHa
bullet
NBC news: Life-threatening illness: To tell or not to tell? Nora Ephron kept quiet on her leukemia; others share to build emotional support http://bit.ly/MIKhjk   What would you do?
bullet
Wendy Harpham, MD blog: What Not to Say to a Cancer Patient http://bit.ly/OnzVDJ  
bullet
Better Health: In Defense Of Doctors: Why We Act Like Jerks, And How To Handle Us When We Do http://bit.ly/NXdmoL
bullet
NYTimes: When Health's at Stake, Waiting Is Hardest Part - http://nyti.ms/O4eP0u   scanxiety, scanic attack...you name it...
bullet
Family Life | Cancer.Net http://bit.ly/MRc4dd
bullet
MSN: Consulting Dr. Google is rarely a good idea. Here's why http://bit.ly/PolH4M
bullet
Medical News Today: Google Is Not A Doctor http://bit.ly/LyeXjc
bullet
U Colorado, Denver: Meta-analysis: Depression -

Interventions improve depression in cancer patients Especially cognitive behavioral therapy and pharmacologic interventions decrease depressive symptoms in cancer patients http://bit.ly/MN0TmD
bullet
Psychology Today: Does Your Oncologist Care About Your Quality of Life? Preference for Quantity over Quality in a National Survey  http://bit.ly/Ly7uR6

In cancer treatment, patients and doctors are often faced with the difficult job of balancing the desire for quantity versus quality of life.
bullet
Science Daily: Potential Key to New Treatment for Mantle Cell Lymphoma (MCL) http://bit.ly/NKIWJX
 
bullet
Cell. 2011  Hallmarks of cancer: the next generation  
bullet
DLBCL - ASCO 2012:  High-dose chemotherapy followed by allogeneic stem cell transplantation in high-risk relapsed and refractory aggressive non-Hodgkin lymphoma: Results of a prospective study of the German high-grade non-Hodgkin lymphoma study group.
bullet
B-R vs. CHOP-R, Cheson - Medscape:
Lymphoma: More a Question of Toxicity Than Efficacy
bullet
Blocking PD  - immune checkpoints
bullet
MZL - Cancer: Prognostic value of the Follicular Lymphoma International Prognostic Index (FLIPI) score in marginal zone lymphoma: An analysis of clinical presentation and outcome in 144 patients
bullet
News Medical: Updated results from two clinical trials of Bruton's ibrutinib for CLL/SLL http://bit.ly/KXCMQp
bullet
MDA blog: What it means to take care of yourself, from one caregiver to another http://bit.ly/KH9RGC
bullet
Brentuximab Vedotin and Panobinostat: New Drugs for Hodgkin's Lymphoma—Can They Make One of Medical Oncology's Chemotherapy Success Stories More Successful? http://jco.ascopubs.org/content/30/18/2171.full 
bullet
Sacremetno Bee: Reduction of Chemotherapy and PET-Guided Radiotherapy in Advanced-Stage Hodgkin Lymphoma: the GHSG HD15 Trial 

Read more here: http://www.sacbee.com/2012/06/14/4564029/reduction-of-chemotherapy-and.html#storylink=cpy and http://bit.ly/MG5NAF
bullet
Leuk Lymph: Intermediate Hodgkin's lymphoma in partial remission after three or four ABVD courses: no benefit of one course of intensive chemotherapy before irradiation. http://1.usa.gov/LW3DBN
bullet
Blood: Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study. http://1.usa.gov/KaSBn0
bullet
MSNBC: Drug costs now a bigger issue in cancer treatment Soaring costs of new medicines, reduced reimbursements and use of generics play a role http://on.msnbc.com/Ks6ulz
bullet
Oncology Times: ONLINE FIRST: White Paper Prediction: With Sustained Efforts, Cancer Can Become Chronic, Manageable Disease in 10 Years http://bit.ly/MbmUMc
bullet
WebMD: AmI cured Yet? http://bit.ly/K7xpOG  Thanks to Dave P
bullet
Am J Hem: Final results of a randomized trial comparing 1, 3 or 6 infusions of rituximab plus 6 cycles CHOP provide valuable preliminary data towards a more cost-effective and safer treatment of advanced follicular lymphoma http://bit.ly/LPOFgH
bullet
Weill Cornell:  New Clinical Trial: GS-1101 (CAL-101) + Rituximab for Previously Treated CLL http://bit.ly/MuzfwS
bullet
NYTimes: Life, Interrupted: Feeling Guilty About Cancer http://nyti.ms/LYoosR
bullet
MSNBC: Woman challenges bone marrow donation law in effort to save daughters' lives http://bit.ly/MBUCZL  What do you think- should the law be changed?
bullet
Power: Considering the Benefits of Randomized Clinical Trials http://bit.ly/MObWPt
bullet
Patient Power: Staying Prepared on Your CLL Journey   http://bit.ly/MBTy8k
bullet
Weill Cornell: New Clinical Trial: Ofatumumab and Bortezomib in Untreated Waldenstrom Macroglobulinemia http://bit.ly/MBZLSf
bullet
MSNBC: In one type of cancer, heavier men may live longer (diffuse NHL) http://on.msnbc.com/L3RPMM
bullet
Discover: A world within a tumour – new study shows just how complex cancer can be http://bit.ly/OmHzPc (Thanks to Helen U)
bullet
Aarhus Univ:
Mindfulness reduces anxiety and depression in cancer patients http://bit.ly/KnQt1g  
bullet
Exercise report
It was all over the news last week that "exercise doesn't help depression."    Here's an analysis of the study which showing that it pays to question what you read in the news! Scientific American: Exercise doesn’t help depression? Let’s take a real look at that study. http://bit.ly/N3A5DV
bullet
Monteray County Herald:
ALL-OUT WAR ON CANCER http://bit.ly/MwZr6x General cancer, not lymphoma specific
bullet
Psych Central:
6 Things Cancer Patients Have Taught Me http://bit.ly/MwZ38e
bullet
ADV HEM:
Novel Therapies for Aggressive B-Cell Lymphoma http://1.usa.gov/LfxG6k
bullet
University of Cambridge:
Everything we think we know – and know we don’t know – about cancer http://bit.ly/JTOOdA
bullet
Cancer Research UK: Ginseng for cancer fatigue? The jury’s still Out http://bit.ly/Mpjms2
bullet
Onc Live: The Treatment Should Not Be Worse Than the Disease  http://bit.ly/KEnQNc
bullet
New Weill Cornell Study: Thalidomide and Lenalidomide + Rituximab (ThRiL) for Previously Treated Waldenstrom Macroglobulinemia http://bit.ly/LuqDHZ
bullet
Medical News Today: Tumors Start To Develop As A Result Of Specific Combinations Of Errors In The Processes That Safeguard Cell Integrity http://bit.ly/LzAZVy
bullet
Forbes: Cancer drug targets- the march of the lemmings http://onforb.es/Nmpnr7
bullet
 Medicaresupplemental: why we haven't cured cancer, cell by cell http://bit.ly/MhB2oY
bullet
Cancer Fighters Thrive: Covering the Cost of Cancer Care  http://bit.ly/KfMJ1M
bullet
 NYTimes: Life, Interrupted: Finding My Cancer Style http://nyti.ms/MM01np
bullet
KevinMD: Can you handle being the first to know your own test results? http://bit.ly/JPT2Dg  Your thoughts on this?
bullet
 USA Today: CaringBridge: 15 years of connecting caregivers http://usat.ly/LbK3x1
bullet
Reuters: Doctors try to make sense of cancer's genetic jumble http://reut.rs/L5FBSb
bullet
bullet
Cancer Research UK: Ginseng for cancer fatigue? The jury’s still out
bullet
Physicians Practice: When the Doctor Becomes the Patient - A cancer diagnosis taught me about life on the patient’s side of the stethoscope
bullet
The Oncologist: “Less is More”: The Role of Purging in Hematopoietic Stem Cell Transplantation
bullet
CLL Topics: A Happy Ending- journal of mini-allo transplant
bullet
Oncology Times: New Insights into Follicular Lymphoma from Sister-to-Sister Transplantation
bullet
DLBCL - Science: New Drug Shows Promise for Advanced Lymphoma

ibrutinib [eye broo' ti nib] is also known as PCI-32765. The drug blocks a protein called Bruton's tyrosine kinase (BTK) that's part of the B-cell-receptor signaling pathway.

Trials: Ibrutinib
bullet
FL indolent - Cancer Network: Inotuzumab Ozogamicin Achieves ‘Markedly Long’ Antitumor Response in Indolent B-Cell NHL (phase II study) 

Trials: Inotuzumab Ozogamicin 
bullet
FL Blood: "mini" allogeneic transplantation with or without Zevalin is potentially curative for relapsed follicular lymphoma: 12-year results.
bullet
HL- Interim FDG-PET Scan in Hodgkin's Lymphoma: Hopes and Caveats  
bullet
HL Oncology Times: ONLINE FIRST: Hodgkin Lymphoma: Novel Agents Can Act as Bridge to Allogeneic Transplant for Selected Patients  
bullet
HL  J Clin Onc: Long-Term Results of CCG 5942:  Randomized Comparison of Chemotherapy With and Without Radiotherapy for Children With Hodgkin's Lymphoma 
bullet
MCL - Lancet: Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial
bullet
MCL - 2012 Vose: Update on diagnosis, risk-stratification, and clinical management
bullet
Best Pract Res Clin Haematol, 2010: Should double cord blood transplants be the preferred choice when a sibling donor is unavailable?

Mismatch at two antigens actually improves the risk of relapse for umbilical cord blood transplant recipients with relatively low risk of severe acute or chronic graft vs host disease. However, umbilical cord blood transplant is associated with an inferior neutrophil recovery rate when compared to other stem cell sources.
bullet
Communications - KevinMD: How to discuss online health information with your physician  
bullet
FL- Cancer:  Racial differences in presentation and management of follicular non-Hodgkin lymphoma in the US
bullet
FL  Larry W. Kwak: Translational Development of Therapeutic Vaccines for Lymphoma
bullet
KevinMD: How to discuss online health information with your physician
bullet
Travel - NCCN: Traveling with Cancer
bullet
Viral link - Science News: Tracking the viral link to lymphoma: Epstein-Barr has genes that can either suppress or promote blood cancer
bullet
transformed lymphoma - ASH Ed.: The incidence, natural history, biology, and treatment of transformed lymphomas
bullet
Tips - Science-Based Medicine: How to Chose a Doctor
bullet
USA Today: Googling bad for your health? Docs debate online health forums
bullet
Fertility - Live Science - Helping young cancer patients protect their fertility
bullet
FL - Oncology Times: Point-Counterpoint: Should All Patients with Follicular Lymphoma Receive Maintenance Rituximab?

Comment: An excellent debate on the question. 

However, my memory of the audience vote was not the same as that reported by Oncology Times, so I wrote one of the speakers and the Chair of the event.  Each confirmed that Oncology Times got the voting part wrong.  ~ Karl Schwartz.
bullet
Statistics – CancerGuide: The Median ISN'T the Message
bullet
Statistics 101 - CancerGuide: Survival Curves
bullet
ASCO Post: Searching for Quality in an Increasingly Complex Health-care Environment
A Conversation with Sean R. Tunis, MD, MSc
bullet
CLL - OncLive: Dr. Wierda Discusses Watchful Waiting in CLL
bullet
Communications - Cure: Honest Discussions Can Help Ease Kids' Anxiety About Cancer
bullet
Communications - KevinMD: Doctors need to be better trained to deliver bad news
bullet
Complications - HemOnc Today: CLL (and NHL) linked to poorer survival in those with malignant melanoma, MCC

 "Trust me, don't forget the sunscreen!"
bullet
Drug Complications - About Lymphoma: What Is Extravasation?
bullet
Financial support - LRF: Patient Transportation Assistance Program to Assist T-Cell Lymphoma Patients
bullet
Hope - ASCO CONNECTION: Beating the Odds

I find interpreting statistics for patients very difficult; not because I don't understand the concept of relative and absolute risks, hazard or odds ratios, or survival rates. It's because in the end, they do not apply at an individual level.
bullet
Stress - Cure: Stressed During Cancer Treatment? Try Meditating-Mindfulness meditation can ease stress during treatment.
bullet
Science Daily: A New Approach to Faster Anticancer Drug Discovery
bullet
Evidence - Cure: Finding Reliable Cancer Information Online--Think before you leap when researching cancer online.
bullet
NEJM - Perspective: Supreme Court Review of the Health Care Reform Law

Gregory D. Curfman, M.D., Brendan S. Abel, B.A., and Renée M. Landers, J.D.

Snips:

"If the Court determines that review is appropriate, it will next consider whether Congress has the authority to require most U.S. citizens to purchase health insurance or pay a penalty."

"Challengers argue, however, that the mandate to purchase a product from a private entity is unprecedented and constitutes an intrusion on individual liberty."
bullet
Aggressive NHL: Leukemia (2011): oral mTOR inhibitor everolimus in relapsed aggressive lymphoma (including transformed)

Comment: It's anticipated that such agents will be most effective as part of combination therapy. We may soon see a pilot study evaluating this oral agent in combination with CHOP or CHOP-R as initial therapy for aggressive lymphoma ... based on its clinical activity as a single agent in the relapse setting. (Temsirolimus is an IV version of this agent that targets the mTOR pathway.)

Studies evaluating Everolimus / RAD001 (oral) -
bullet
T-cell - Rev. Bras. Hematol. Hemoter: T-Cell Lymphomas in South America and Europe
bullet
Rituxan - Rheumatology: Non-infectious pulmonary toxicity of rituximab: a systematic review

A very rare side effect-- But, highlights the importance of telling your doc about any respiratory symptoms.
bullet
SCT - Best Practice and Research in Clinical Haematology: Autologous or allogeneic transplantation in B- and T-cell lymphomas
bullet
SCT - OncLive: Nonmalignant Late Effects Pose Heavy Burden After Hematopoietic Cell Transplant

As always, we must weigh benefits against risks. We know many who might no longer be with us had they not had a transplant. Hopefully, with more research, ways will be found to reduce these risks or, at least, ways to improve follow-up care.
bullet
FL - LRF: A Conversation About Follicular Lymphoma With Dr. Sonali M. Smith
bullet
GVHD - News Medical: Researchers identify molecule that helps decrease acute GVHD severity
bullet
Respectful Insolence: Fighting the "acid" of negative (e)motions?
bullet
Supplements - KevinMD: Unregulated supplements is a tragedy in waiting
bullet
Vitamins - MD Anderson: Stop the Multivitamin Madness
bullet
Vitamin C - Cure: Jury Still out on Vitamin C's Effect on Cancer
bullet
Elderly - Best Practice and Research in Clinical Haematology: Therapeutic strategies in elderly and very elderly patients
bullet
WM - YouTube: Dr. Ansell Describes Waldenström Macroglobulinemia
bullet
KevinMD.com: When it comes to cancer, do not just focus on survival
bullet
NYTimes: Answers in Medicine Sometimes Lie in Luck
bullet
NYTimes: Pay Only for Drugs That Help You
bullet
Tumor Biology - Cancer Research UK: On the origin of tumours
bullet
Tumor Biology - USA Today: Scientists are reporting what could be very bad news for efforts to customize cancer treatment based on each person's genes.  
bullet

Is it reputable?  - a checklist for judging online information PDF

bullet
CLL - Two reports on same study: Chronic Lymphocytic Leukemia - Aggressive Drug Combo Restores Quality Of Life  and  http://bit.ly/xJitXk
bullet
FL - Blood: Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. 

Short of expectations.
bullet
MALT - Gut: Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan

"The excellent long-term outcome of gastric MALT lymphoma after H pylori eradication was confirmed by this large-scale follow-up study."
bullet
Pregnancy - Weill-Cornell: Lymphoma in Pregnancy
bullet
Caregiver - PsychCentral: Caregiving: Taking Care of Your Spouse & Yourself

“Even though Denholm, Ph.D, LMHC, is a medical psychotherapist, she felt incredibly unprepared for her role and found little direction for navigating the many stresses and challenges of being a caregiver.”
bullet
Treatment Tips - Oncolink: Home Safety for Patients Receiving Chemotherapy

Handling Body Waste, Handling Trash or Laundry, Handling Spills, Sexual Contact, Safety for My Family
bullet
CLL - OncLive: New Model Helps Guide Treatment Options in CLL

"While the watch-and-wait method is frequently employed in patients with chronic lymphocytic leukemia (CLL), there are a number of prognostic factors that can help identify those at a high risk for disease progression who may benefit from early intervention."
bullet
CNS lymphoma - MRCC: Primary CNS Lymphoma Treatment (PDQ®)
bullet
Diagnosis - Medscape: Difficulties in Diagnosing Cancer: UK Study /
bullet
DLBCL- OncLive: New Directions in Relapsed / Refractory Diffuse Large B-cell Lymphoma  

"the Bruton’s tyrosine kinase inhibitor PCI-32765 was tested in 8 patients with relapsed or refractory ABC DLBCL. The results showed that 2 patients achieved complete response for 11+ and 5 months, respectively; 3 patients achieved stable disease for 4, 2, and 2 months, respectively; and 3 patients had progressive disease. The drug was generally well tolerated across the patient population."

See for more on this kinase inhibitors
bullet
FL - EU J of Nuclear Med and Molecular Imaging: FDG PET/CT predictive role in follicular lymphoma

“Of the different predictive factors, only FDG PET result significantly correlated with patient outcome (p = 0.0002). PET/CT performance at the end of treatment was as follows: 100% sensitivity, 99% specificity, 89% positive predictive value and 100% negative predictive value.”
bullet
Hodgkin - Blood: A phase II study of rituximab-ABVD in classical Hodgkin lymphoma.

"In classical Hodgkin lymphoma (cHL), circulating clonotypic malignant cells express CD20, potentially explaining the observed activity of rituximab. This multicenter phase II study investigated the combination of rituximab-ABVD for stage II-IV untreated cHL."
bullet
Fertility - Weill Cornell: Fertility and Lymphoma
bullet
T-cell, ASH Education Program Book, 2011:
Therapies for Peripheral T-Cell Lymphomas Kerry J. Savage 
"...Encouragingly, there have been several new therapies emerging with activity in PTCLs and exciting novel combinations under consideration that will hopefully move the field forward and improve outcome in this challenging group of diseases."
bullet
Evidence - Respectful Insolence: Dr. Stanislaw Burzynski strikes again 
bullet
Evidence - Science Based Medicine: Dr. Oz revisited

"All truth passes through three stages. First, it is ridiculed. Second, it is violently opposed. Third, it is accepted as being self-evident."

… When cranks invoke Schopenhauer the implication behind their parroting the above quote is that they have The TRUTH
.
bullet
Treatment Tips - Oncolink: Home Safety for Patients Receiving Chemotherapy

Handling Body Waste, Handling Trash or Laundry, Handling Spills, Sexual Contact, Safety for My Family
bullet
SCT - NCI - all about stem cells and stem cell rescue

Each slide has a graphic with narration. Ready for printing.
bullet
CLL Topics Updates: FC + Campath for Chemo-Naive Patients
bullet
Follow up is key -
Oncology Times: Second Thoughts from Sekeres: A Pyrrhic Victory in the War Against Cancer: What We Should Demand from Clinical Trials

"Among the piles of journals that invade our offices weekly, advancing on the sanctity of clean desk space like kudzu, occasionally—very occasionally—an article pops out that upends the conclusions we have always drawn from clinical trials
bullet
FL, early stage - Strahlentherapie Und Onkologie: Radiotherapy in stage I-III follicular non-Hodgkin lymphoma: Retrospective analysis of a series of 50 patients

RT is a curative option in the treatment of limited stage FL. If RT of microscopically uninvolved area is necessary, a reduction in the radiation dose should be carefully weighed against the risk of in-field recurrences.
bullet
Hodgkin - Haematologica: Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin lymphoma
bullet
MCL, relapsed - Haematologica: A multicenter phase II trial (SAKK 36/06) of single-agent Everolimus(RAD001) in patients with relapsed or refractory mantle cell lymphoma.
bullet
NHL, relapsed - Annals of Hematology: Bendamustine with or without rituximab for the treatment of heavily pretreated NHL patients A multicenter retrospective study
bullet
Oncology Times: Lymphoma Highlights from ASH: Important News about Hodgkin Lymphoma, and an Unexpected Negative Transplant Study in DLBCL
bullet
Pixantrone - Medscape: Pixantrone Progresses Toward Approval in the European Union

"We are encouraged by the progression-free survival noted in the PIX301 study and the opportunity this agent provides in treating this difficult-to-treat group of patients," Dr. Coiffier said
bullet
PMLBCL - The Oncologist: R-CHOP with or Without Radiotherapy in Primary Mediastinal Large B-Cell Lymphoma: The Emerging Standard of Care
bullet
SCT - Oncology Times: Haplo Transplant Valid Option for Patients without Conventional Donors
bullet
T-cell - J Clinical Onc: Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy

Also see - Clinical trials with Romidepsin
bullet
Transformation - BJH: Incidence, risk factors and outcome of histological transformation in follicular lymphoma  
bullet
T-cell therapy - Blood: CD20-specific adoptive immunotherapy for lymphoma  (similar to CAR 19)
bullet
WM study - Weill-Cornell Med Ctr: Waldenstrom’s Macroglobulinemia Clinical Database Study
bullet
MCL - Haematolgica: A multicenter phase II trial (SAKK 36/06) of single-agent Everolimus (RAD001) in refractory mantle cell lymphoma.

See  Everolimus clinical trials
bullet
CLL - CancerConnect.com: Combination of Campath and Fludarabine Provides Benefit in CLL

NOTE: But the standard treatment against which this protocol was tested is now Fludarabine with Rituxan.
bullet
FL - Nature Bone Marrow Transplantation: Long-term outcome after SCT in patients with recurrent follicular lymphoma
bullet
Nutrition - Medical News Today: How much do nutritional interventions help malnourished cancer patients?
bullet
Pregnancy - Medscape: Hematologic Cancers in Pregnancy Pose Substantial Risks
bullet
SCT - Medical News Today: Blood Cancer Patients To Benefit From Stem Cell Research Breakthrough

"These findings provide a practical, clinical strategy for lowering the risk of death following an unrelated-donor blood stem cell transplant. It builds on the gold-standard which already exists for transplants and could be easily incorporated into the current framework transplant centers use when trying to find the best match."
bullet
WM study - Weill-Cornell Med Ctr: Waldenstrom’s Macroglobulinemia Clinical Database Study

“Participants in this study give their permission for the investigators to collect their clinical information for research purposes. In addition, the researchers will store participants’ blood, urine, check swab, bone marrow and/or tumor tissue samples for research studies to be performed now and in the future. In some cases, participants may be asked by their physician to provide additional samples.”
bullet
FL Video - Dr. Kahl interview: Results of the RESORT Trial for Follicular Lymphoma:
Questions for Patients and Their Physicians


Interview by Patient Power - in association with Patients Against Lymphoma

NOTE:  Excellent description of the study by Dr. Kahl ... However, we anticipate that his closing comment on evidence of a lack of resistance to Rituxan will be controversial.
bullet
MCL Video - Dr. Peter Martin interview
Kinase Inhibitors Offer New Hope for Mantle Cell Lymphoma


by Patient Power in Association with Patients Against Lymphoma
bullet
Medscape video: Dietary Supplements and Mortality Rates in Women: A Cautionary Tale
bullet
Bad science - NYTimes:
How Bright Promise in Cancer Testing Fell Apart
bullet
Off-label drugs - WSJ: Dilemma: When One Drug Treats Two Diseases

Balanced perspective provided here ... but the author appears to have confused off-label use of drugs with use of experimental drugs ... only the latter require company permission for use outside of a trial in the US. 
bullet
Where's the full report? - Medscape, login required - Dr. Cheson video: Do Unpublished Data Need an Expiration Date?
bullet
CAM - Medpage Today: No Cancer Help from Supplements (omega-3 and B vitamins) for Heart Patients
bullet
Cancer Research Institute: Antibodies to intracellular cancer antigens combined with chemotherapy enhance anti-cancer immunity  (pre-clinical)
bullet
Career - NCCS - Working It Out - Your Employment Rights As A Cancer Survivor

Employment Challenges and Cancer Survivors
How to Avoid Job Discrimination
How Employment Discrimination Laws
Protect Cancer Survivors
Know Your Legal Rights
Talk It Out Before You Sue
bullet
Fake drugs - WSJ: Fake Cancer Drug Found in U.S.
bullet
Misdiagnosis - KevinMD.com: 5 ways to avoid a misdiagnosis
bullet
Be The Match - Patients Connect Facebook Page

People can join the Be The Match Registry® – the world’s largest listing of potential marrow donors and donated cord blood units – contribute financially and volunteer.
bullet
NIH: Clinical Trials and You
bullet
aggressive NHL - Am J Hematology: NEAM followed by autologous stem cell transplantation for patients with chemosensitive aggressive NHL
bullet
aggressive NHL - Pubmed: Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study. 
bullet
DLBCL - Swiss Medical Weekly: Diagnosis and treatment of diffuse large B-cell lymphoma
bullet
MCL - Haematolgica: A multicenter phase II trial (SAKK 36/06) of single-agent Everolimus (RAD001) in refractory mantle cell lymphoma.

Single agent everolimus is well tolerated and has anti-lymphoma activity in relapsed or refractory mantle cell lymphoma. Further studies of everolimus either in combination with chemotherapy or as single agent for maintenance treatment are warranted.

See  Everolimus clinical trials
bullet
SCT - Oncology Times: New Data Emphasize Importance of Alerting Patients Undergoing HCT of Long-Term Risks
bullet
SCT - Oncology Times: Stem Cell Transplants: Overall Survival Same with Unrelated-Donor PBSCs and BMSCs http://bit.ly/wqeSYc
bullet
T-cell - Press Release: Allos Therapeutics reports interim data of Folotyn combination therapy
bullet
T-cell therapy - Blood: CD20-specific adoptive immunotherapy for lymphoma  (similar to CAR 19)

“Recent clinical trial data demonstrate that modification of T cells with chimeric antigen receptors (CAR) is a promising strategy … Four patients were enrolled, and 3 received T cell infusions following cyclophosphamide lymphodepletion. Treatment was well tolerated, although one patient developed transient infusional symptoms. Two patients without evaluable disease remained progression-free for 12 and 24 months.”
bullet
The Dirt on Coming Clean: Perverse Effects of Disclosing Conflicts of Interest

"Most important, it assumes that estimators know what to do with the information that is disclosed. There are grounds for skepticism regarding this assumption. "
bullet
Costs - KevinMD.com: A look behind the growing cost of cancer drugs
bullet
Pregnancy - Medical Press: Complications of blood cancers make termination advisable at early stages of pregnancy

“The authors advise that, in the absence of a durable remission of at least 2 years, avoidance of pregnancy is advisable in patients with acute leukaemia or lymphoma because the disease is most likely to recur during that period.”
bullet
Pregnancy - Medscape: Chemotherapy During Pregnancy Appears Safe for Offspring
bullet
Radiotherapy, treating injury - Medscape:
Hyperbaric O2 Helps Most Chronic Radiation Injuries: Study
bullet
SMZL - CancerNetwork: Splenic Marginal Zone Lymphoma: Current Knowledge and Future Directions
bullet
Starting with cpg in situ vaccine:

ASCO Merit Award -, Joshua Brody, MD: Immuno-transplant For Mantle Cell Lymphoma: Phase I/II Study Preliminary Results.
bullet
Btk-inhibitors - Nature Reviews Drug Discovery: Trial watch: BTK inhibitor shows positive results in B cell malignancies
bullet
DLBCL, relapsed - ASH 2011: Bexxar - BEAM Vs. Rituximab - BEAM and Autologous Stem Cell Transplantation for Relapsed DLBCL: No Difference in Progression-Free (PFS) or Overall Survival (OS)

Discussion: http://forums.lymphoma.com/ 
bullet
FL- Annals of Oncology: A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by Zevalin in untreated intermediate/high-risk follicular lymphoma
bullet
FL- Patient Power: Results of the RESORT trial for follicular lymphoma: questions for patients and their physicians 

Discussion: http://forums.lymphoma.com
bullet
FL- BJH: Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times

Contains survival stats that can be challenging to read ... but important and encouraging findings for grade 3b - specifically

"In contrast to grade 1–3A, grade 3B did not relapse beyond 5 years of follow-up in our population-based cohort. This study supports the hypothesis that grade 3B might be an aggressive neoplasm, but if it is treated aggressively, some patients are probably cured."
bullet
Hodgkin - FDA Briefing Document: Oncologic Drugs Advisory Committee Meeting
July 14, 2011 | BLA 125388 for (Adcetris) brentuximab vedotin
Proposed Indication: Treatment of Relapsed or Refractory Hodgkin Lymphoma
bullet
Hodgkin - Haematologica. PET imaging response at time of autologous stem cell transplantation predict outcome of patients with relapsed and/or refractory Hodgkin Lymphoma responding to prior salvage therapy.
bullet
Hodgkin - Medwire News: Chemotherapy alone improves long-term survival in Hodgkin's lymphoma

From Discussion: "We found that the rate of long-term survival is higher with ABVD alone than with treatment that includes subtotal nodal radiation therapy, particularly when subtotal nodal radiation therapy is combined with two cycles of ABVD therapy. As postulated by the study hypothesis, the advantage that is seen with chemotherapy alone is due to the fact that there are fewer deaths from causes other than progressive Hodgkin's lymphoma or acute treatment-related toxic effects. Furthermore, we have addressed the question of whether chemotherapy alone has curative potential for these patients,19 since the rate of 12-year freedom from disease progression that we observed with ABVD alone was 87%.

The major limitation associated with our results is that the subtotal nodal radiation therapy that was used in the radiation-therapy group is outdated, and the extent of radiation therapy is very likely to have contributed to the excess deaths. "
bullet
T-cell - J Clinical Oncology: Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy http://bit.ly/yUzGtL
bullet
MCL - Oncology Times: FDA Approves Supplemental New Drug Application for Velcade (Bortezomib) for Multiple Myeloma and Mantle Cell Lymphoma

"The FDA has approved an update to the label for Velcade (bortezomib) to include the subcutaneous method of administration in its approved indications

…. Although both methods showed similar safety profiles, in the subcutaneous arm of the trial only 6% of patients experienced peripheral neuropathy of grade 3 or higher, compared with 16% in the intravenous group. In the subcutaneous group, 38% of patients experienced neuropathy of all grades, compared with 53% of patients in the intravenous group."
bullet
SMZL - CancerNetwork: Splenic Marginal Zone Lymphoma: Current Knowledge and Future Directions
bullet
T-cell - Cure Today: Romidepsin effective for refractory peripheral T-cell lymphoma

The researchers documented objective responses in 33 patients (25%), including 19 (15%) who had complete responses.
bullet
radiotherapy, treating injury - Medscape: Hyperbaric O2 Helps Most Chronic Radiation Injuries: Study

A positive outcome occurred in 94% of patients with osteoradionecrosis of the jaw (n = 43), 76% of patients with cutaneous radionecrosis that caused open wounds (n = 58), 82% of patients with laryngeal radionecrosis (n = 27), 89% of patients with radiation cystitis (n = 44), 63% of patients with gastrointestinal radionecrosis (n = 73), and 100% of patients who were treated in conjunction with oral surgery in a previously irradiated jaw (n = 166). Source
bullet
New approved drug - Oncolink: Brentuximab Vedotin aka Adcetris
bullet
Expert perspective on Lymphoma research - Oncology Times Key, Dr. Cheson - Lymphoma Takeaways from ASH
bullet
T-cell, cutaneous - review - Oncology Times: Photopheresis in the treatment of cutaneous T-cell lymphoma: current status

CTCL - Extracorporeal photopheresis (ECP), an immunomodulating procedure involving treatment of blood with a photoactive agent, was given regulatory approval by FDA as a medical device for the treatment of cutaneous T-cell lymphoma (CTCL) in 1988 [1]. It is one of many treatment options for CTCL.
bullet
T-cell therapy - Oncology Times: Investigational T-Cell Therapy for CLL Shows the Progress in Immunotherapy

“It worked much better than we thought it would,” senior author Carl H. June, MD, Director of Translational Research and Professor of Pathology and Laboratory Medicine at the Abramson Cancer Center, said. “We saw at least a 1,000-fold increase in the number of modified T cells in each of the patients. Drugs don't do that. In addition to an extensive capacity for self-replication, the infused T cells are serial killers. On average, each infused T cell led to the killing of thousands of tumor cells—and overall, destroyed at least two pounds of tumor in each patient.”
bullet
WM - Acta Hem: Familial (inherited) Aggregation of Waldenström Macroglobulinemia
 
bullet
Zevalin, media report - Spectrum says its Zevalin drug led to higher survival rates in certain lymphoma patients
bullet
Medical News Today: Blood-Forming Stem Cells' Growth Identified

“The research has implications for bone marrow and umbilical cord blood transplants, Dr. Morrison said. … Doing so will make it possible to expand blood-forming stem cells prior to transplantation into patients, thereby increasing the safety and effectiveness of this widely used clinical procedure."
bullet
Podcast - Cancer.net: How to choose and Oncologist
bullet
Starting with cpg in situ vaccine:

ASCO Merit Award -, Joshua Brody, MD: Immuno-transplant For Mantle Cell Lymphoma: Phase I/II Study Preliminary Results.

A two step process. The first step is to induce tumor-reactive t-cells with cpg vaccine; the second to implant the tumor-reactive t-cells in patients after chemotherapy - a concept first tried in MCL. Encouraging results reported here.
bullet
Fertility resource - Myoncofertility.org  
bullet
Financial - Cancer Support Community:
Coping with the cost of cancer care.
bullet
Hope - Harpham, Wendy S. MD - Oncology Times: VIEW FROM THE OTHER SIDE OF THE STETHOSCOPE: Real Good News  

“When you order a scan, do you ever wonder what kind of news your patient hopes for? If you assume every patient hopes for “good” news, you'd be right most of the time. But not always. I, for one, don't spend time and energy hoping for good news. To understand why, let's look at hope in the setting of patient evaluations.”
bullet
Living - KevinMD.com: Incorporating 12-step program concepts into cancer survivorship
bullet
Living - KevinMD: A reminder that families suffer together
bullet
Treatment support - Cure Today: Consider Dental Issues Before Beginning Cancer Treatment
bullet
Insurance - KevinMD: The problem of insurance gaps in cancer patients
bullet
Financial - Cure: Resources to Ease the Financial Burden of Cancer
bullet
Living - Psych Central: 9 Ways to Take Care of Yourself When You Have Depression
bullet
Living - MDA: Letting People Know (you have cancer)
bullet
Living - ESMO: Anxiety and Depression in Cancer patients

An excellent presentation on anxiety and depression in cancer patients. Audio would not load, but can go through slides. Talks about cancers that can present with depression (lymphoma is one of them) and medications that can cause symptoms
bullet
Teamwork - CLL topics Update: Controversies in Communication
bullet
Teamwork - Kevin MD: Doctors who give cash to patients for running late
bullet
DLBCL - Cancer: Limited-stage diffuse large B-cell lymphoma treated with abbreviated systemic therapy and different types of consolidation radiotherapy
bullet
FL - expert perspective - Medscape, Dr. Cheson: Reason to RESORT to Rituximab Maintenance?
bullet
Hodgkin - expert Perspective - Medscape, Dr. Cheson: Radiation Therapy vs Chemo in Hodgkin Lymphoma Patients
bullet
Hodgkin - ASCO: Favorable Early-stage Hodgkin Lymphoma and HD.6: The Take-Home and Don’t–Take-Home Messages
bullet
RIT - expert perspective - Medscape, Dr. Cheson: Radioimmunotherapy: How Strong an Option Is It?
bullet
MZL, nodal, review article - CancerNetwork.com: Nodal Marginal Zone B-Cell Lymphoma: A Diagnostic and Therapeutic Dilemma
bullet
SCT - Annals of Hematology: Allogeneic stem cell transplantation in patients with DLBCL relapsed after autologous stem cell transplantation
bullet
T-cell - Univ Hospitals Case Medical Ctr: UH Case Medical Center publishes study on novel treatment for Cutaneous T-Cell lymphoma 

"By adding O6-benzylguanine, we can effectively lower the dosage of the topical treatment, carmustine, and render it less toxic on healthy cells but more effective at killing cancer cells," says Dr. Cooper. "This combination treatment has had excellent initial clinical results and we are following it up with additional ongoing studies."

Related Study of Interest - O6-Benzylguanine and Topical Carmustine in Early-Stage (IA-IIA) Cutaneous T-Cell Lymphoma:
bullet
Transformed lymphoma - BJH (correspondence): Improving survival in patients with transformed B cell non Hodgkin lymphoma: consolidation with Zevalin-BEAM and autologous stem cell transplantation
bullet
Acupuncture - J Altern Complement Med. 2008 - The Status and Future of Acupuncture Clinical Research
bullet
Second Pathology Evaluations: WSJ: Informed Patient: Diagnostic Errors Highlight Need for Second Opinions
bullet
CAM - Is there any merit in the concept that to restore health you have to "Alkalinize your blood  to fight cancer?

Respectful Insolence: Acid Base or Woo

Respectful Insolence: Acid Base or Woo, revisited
bullet
CLL Topics Updates: How to Treat Elderly CLL Patients
bullet
Advocacy, expert perspective - Medscape: Clinical Trial Woes: Dr. Bruce Cheson on Where Are the Drugs?
bullet
PBS: Cancer Treatment: Are Personalized Molecular Profiles in Our Future?
bullet
Patient Power: Physician Turned Patient: My Quest for the Best CLL Treatment
bullet
News Medical: Study investigates immune response in cancer
bullet
Cure: Why Banks Need Your Tissue for Research
bullet
Alt Med - Sloane Kettering: Complementary vs. Alternative Cancer Therapies
bullet
BoingBoing: Three common mistakes in medical journalism
bullet
Causes of cancer - Cure Today: Connecting the Dots: Why It's So Hard to Pin Down Environmental Causes of Cancer
bullet
Resveratrol - In the Pipeline: A Resveratrol Research Scandal. Oh, Joy
bullet
allo SCT - Perspective - Current role of allogeneic stem cell transplantation in follicular lymphoma
bullet
Zevalin - Cancer: Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia.

snip: "incidence of sMDS/AML, which nevertheless was comparable to the incidence observed in a matched group of patients who received chemotherapy-based conditioning.”
bullet
Sustainability - NYTimes: It Costs More, but Is It Worth More?

snip: “So a second option is “coverage with evidence development.” In this approach, Medicare would pay for proton beam treatment … only if the patients were enrolled in a randomized trial that would compare the outcomes of their treatment to those from surgery, other kinds of radiation or active surveillance. Medicare has used this approach sparingly, but it should be applied to more cases like this one.”
bullet
Celebrities with lymphoma - Reuters: Black Sabbath guitarist diagnosed with lymphoma
bullet
End of Life - Denialism Blog: How Do you Want to Die?

Speaks frankly about end of life issues, if reading about these issues upsets you please don't open.

Also: How Doctors Die
bullet
Family Practice News: Pregnant Women With Lymphoma Can Have Good Outcomes
bullet
Fertility - Springer: Cancer and fertility -- young women speak up
bullet
Nutrition - ACS: Updated American Cancer Society nutrition guidelines stress need for supportive environment
bullet
Nutrition - Oncology Times: ACS Updates Nutrition and Physical Activity Guidelines

snip: “The guidelines are really about educating people about what they can do on their own to reduce the risk of cancer, but are also designed to spur action for change -- to make it easier for people to get a banana instead of a candy bar,”
bullet
Teamwork - NYTimes: Project Puts Records in the Patients’ Hands
bullet
Teamwork - MDA: Advance Care Planning: A Patient and Provider Partnership
bullet
Hodgkin- Patient Power: Expanding New Treatment Option to Frontline Treatment for Hodgkin Lymphoma
bullet
Hodgkin- The Oncology Report: New Scoring System Devised for Youth With Hodgkin's Lymphoma
bullet
SCT - Patient Power: Keeping Transplant Patients Safe: Behind the Scenes with an Infectious Disease Specialist
bullet
Patient Power: Fighting Cancer in Your 20s: Lessons Learned

Rose Egge never thought she would be facing a cancer diagnosis at 25 years  old. ... Now, Rose helps other young adults cope with a cancer diagnosis through her foundation, Thrive Through Cancer.
bullet
MCL - LLS November 2, 2011 - Mantle Cell Lymphoma

archived video and transplant for those who may have missed the presentation
bullet
MCL - Blood: Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database.

Author's comment: "Future trials should focus on novel agents rather than comparing efficacy of current approaches."
bullet
Cancer biology - Johns Hopkins: Cancer Cells feed on Sugar-free diet
bullet
Walter and Eliza Hall Institute: Research shows cells influence their own destiny
bullet
Blood - Targeting CXCR4 with cell-penetrating pepducins in lymphoma and lymphocytic leukemia

Targeting the microenvironment could improve sensitivity to treatment. 
bullet
Fertility - Patient Power: Oncofertility: Fertility Preservation for Cancer Patients
bullet
CLL - Patient Power: Dr. Steven Rosen on Breakthroughs in Chronic Lymphocytic Leukemia from ASH 2011
bullet
Hodgkin - Patient Power: Dr. Ajay Gopal on Robust Treatment Options Keep Hope Alive
bullet
Elderly - Cancer Chemo and Pharmacology: Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma
bullet
HCV Infection and Cryoglobulinemia
Antiviral Therapy in HCV-Positive NHL: Pathogenetic Implications 

A systematic review of subsequent studies reported that 75% of HCV-infected patients with B-NHL treated with pegylated interferon-α (pIFN-α) plus ribavirin (RBV) achieved a complete hematological response (CHR), whereas no such response was obtained in matched HCV-uninfected B-NHL patients. Our own experience refers to a retrospective analysis ...”

See also
MJH, 2010:
Hepatitis C Virus Infection and Lymphoma
bullet
Histone Deacetylase (HDAC) Inhibitors: Potential in Cancer Therapy
bullet
Hodgkin: PubMed: PET/CT surveillance in patients with Hodgkin lymphoma in first remission is associated with low positive predictive value and high costs.
 
Full text: haematologica.org
bullet
SCT - AM J Hematology: Autologous stem cell transplant is feasible in very elderly patients with lymphoma and limited comorbidities
bullet
Allo SCT - Biol Blood Marrow Transplant. 2011 - HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation.

HLA-C antigen-mismatched unrelated PBSC donors were associated with worse outcomes compared with 8/8 HLA-matched donors. 
bullet
T-cell: Pubmed: Efficacy and safety of the third-generation Fotemustine for the treatment of chemo-refractory T-cell lymphomas.
bullet
Science Based Medicine: Why Do We Really Need Clinical Trials?

"Given the incredible number of complex, interacting factors involved in the development of each particular disease, it shouldn’t surprise us when even a reasonable hypothesis with limited support from observational trials and other lower level evidence turns out to be false."
bullet
Medscape (login required): Dr. Cheson - Great New Drugs Will Be Harder to Come By

"So, it's sort of a conundrum. The more effective regimens we develop, the higher the bar, and the more difficult it is for new drugs to come down the pike."
bullet
ASH review  - Cheson and Leonard - Medscape:
Has Rituximab Met Its Match in Lymphoma ... and other topics?
bullet
Preclinical models - NPR: Perhaps Scientists Like Lab Mice TOO Much
bullet
CLL Topics Update: "Doc, how long do I have" Discusses prognostic factors in CLL
bullet
General Health - US Preventative Service Task Force: Vitamin D With or Without Calcium Supplementation for Prevention of Cancer and Fractures An Updated Meta-Analysis

“ Evidence is not sufficiently robust to draw conclusions regarding the benefits or harms of vitamin D supplementation for the prevention of cancer.”
bullet
Living - Cancer Connect: Showing Love in the Face of Loss  

the peaks and valleys of my emotions eventually started to level out somewhat. When my child’s birthday or Christmas arrived, I had to brace myself and just concentrate on breathing.
bullet
Living - Crazy Sexy Cancer: 10 Things I Learned from People Who Survive Cancer
bullet
Living - Psych Central: When Cancer Patients also grapple with depression
bullet
Medical Errors - KevinMD.com How patients can avoid medical errors
bullet
Prevention - MDA: Diet and Cancer  

... diet is thought to account for about 30% of cancers in Western countries.
bullet
Safety - Science Based Medicine: Reducing the Risk of Adverse Drug Events

“The elderly are seven times as likely as younger people to have adverse drug events. ... Forty percent of people over 65 take 5-9 medications, and 18% take 10 or more. Combinations of medications can cause unexpected problems.”
bullet
Financial - Cure: Medical Debt: An Unspoken Side Effect of Cancer Care
bullet
CLL - Medscape (login required):
New Class of Drug May Vanquish CLL

Also see Navitoclax - Lancet, Wilson et al a Targeted High Affinity Inhibitor of BCL-2 (ABT-263), in Lymphoid Malignancies - full text
bullet
CLL - Patient Power: Dr. Steven Rosen on Breakthroughs in Chronic Lymphocytic Leukemia from ASH 2011
bullet
Hodgkin - Patient Power: Dr. Ajay Gopal on Robust Treatment Options Keep Hope Alive
bullet
MZL - ASH 2011: Patients with Limited Stage Extranodal Marginal Zone Lymphoma Have Excellent Survival regardless of Choice of Therapy Type or Observation
bullet
T-cell, cutaneous - PubMed: Photodynamic Therapy with methyl-aminolaevulinic acid (MAL) for Mycosis Fungoides
bullet
Caregivers - Oncology Times: Gender Differences Can Make a Difference in Caregiving

“Overall, the belief is that women facing a crisis find comfort in discussing their fears, while men take solace in action.”
bullet
Disparities - Cancer: Survival disparities by Medicaid status An analysis of 8 cancers
bullet
General Health - NY Times: The Fat Trap

There have been studies that suggest obesity may raise risk for lymphoma and other cancers. Excellent article on why it's difficult to maintain weight loss
bullet
Skin care - The Examiner: Tips for skin care during cancer treatments
bullet
News Medical: Scientists discover a way to keep normal and cancer cells alive in the lab
bullet
Weill Cornell, Dr. Martin: Obinutuzumab (GA101), a New Generation Rituximab
bullet
CLL: Patient Power: Update on Kinase Inhibitors for CLL: Where Are We Now?
bullet
NPR: The War on Cancer turns 40
bullet
NPR: If it’s not a war on cancer, what is it? 
bullet
CLL Topics: A Well Designed PCI-32765 Clinical Trial – just about to open
bullet
Dr. Len's Cancer Blog: We Can Find You A Space In The Mall Parking Lot, Ma'am, But Your CT Scan Will Have To Wait
bullet
Hodgkin - Cure: Brighter Horizons for Hodgkin Lymphoma Patients
bullet
Quackwatch: about Mercola 
Respectful Insolence: http://bit.ly/sCKysu
bullet
NEJM: Selling Bone Marrow — Flynn v. Holder
bullet
Medscape: NCI's Varmus Changes the Metaphor: There Is No War on 'Cancer'
bullet
Optimizing Doctor Visits - PDF

Print on both sides of page to create a free
tri-fold brochure
bullet
PAL Perspective: 
Let's Standardize Reporting of Clinical Trial Outcomes
bullet

Update to Factors Influencing Treatment Decisions - Regarding the Clinical Context  
 

bullet
Aggressive B-Cell Lymphomas: A Review of New and Old Entities in the WHO Classification
bullet
AIDs-related: AIDsMEDs: Rituxan Prolongs HIV-Related Lymphoma Survival   abstract
bullet
Allo SCT - Weill Cornell, Dr. Besien: ASH 2011: Major Advances in Allogeneic Stem Cell Transplant Offer New Hope For Patients with Hematologic Malignancies
bullet
Bone marrow biopsy - Medscape: Powered Device Hailed as Advance for Bone Marrow Biopsy
bullet
Childhood, general: Brit J Cancer: Survival from childhood cancer in northern England, 1968-2005.
bullet
CLL - ASH Education Book Dec 2011: Alemtuzumab Use In Relapsed and Refractory CLL/SLL
bullet
CLL- ASH Education Book Dec 2011: Nurture versus Nature: The Microenvironment in Chronic Lymphocytic Leukemia
bullet
CLL- ASH Education Book Dec 2011: Using the Biology of CLL to Choose Treatment
bullet
CLL- ASH Education Book Dec 2011: The Treatment of Relapsed Refractory CLL/SLL
bullet
CLL - Medscape, Dr. Cheson - ASH review: A Dickensian CLL Story
bullet
Diagnosis - Annals of Oncology: Expert second-opinion pathology review of lymphoma in the era of the WHO classification
bullet
DLBCL - Annals of Oncology: R-CHOEP-14 improves overall survival in young high-risk patients with DLBCL compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group
bullet
DLBCL - ASH Education Book 2011:  Relapsed/Refractory Diffuse Large B-Cell
bullet
FL - Weill Cornell: ASH: What is the role of rituximab maintenance in patients with low tumor burden follicular lymphoma?
bullet
Georgia Health Sciences University: Scientists may be able to double efficacy of radiation therapy
bullet
Health - Medical News Today: Vitamin D For Cardiovascular Disease, Cancer, And Bone Fracture Protection? Evidence Is Lacking
bullet
HIV-related NHL - Cancer: Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated NHL
bullet
Hodgkin - ASH Education Book Dec 2011: Optimal Therapy of Advanced Hodgkin Lymphoma
bullet
Hodgkin - ASH Education Book Dec 2011: PET in the Management of Hodgkin Lymphoma
bullet
Hodgkin - Hematolgica: Second line salvage chemotherapy for transplant-eligible patients with Hodgkin lymphoma resistant to platinum-containing first-line salvage chemotherapy.
bullet
Hodgkin - Late Effects in the Era of Modern Therapy for Hodgkin Lymphoma
bullet
Hodgkin - PubMed: Management of children with high-risk Hodgkin lymphoma
bullet
Indolent - Medscape: Bendamustine Plus Rituximab Could Replace R-CHOP in Indolent Lymphomas
bullet
Indolent - Monthly Prescribing Reference: Bendamustine Plus Rituximab Provides Superior Progression-Free Survival Benefit to Patients With Relapsed Follicular, Indolent, or Mantle Cell Lymphomas vs. Fludarabine Plus Rituximab
bullet
Indolent - Oncology Times: Bendamustine + rituximab offers new standard first-line treatment option for lymphoma
bullet
JNCI: Autologous stem cell transplantation does not improve os in patients with follicular lymphoma  (for newly dx'd pts)
bullet
MCL - Annals of Oncology: Autologous SCT in patients with MCL beyond 65 years of age: a study from the European Group
bullet
MCL - Cancer: Post-treatment (not interim) PET scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD

Also see http://1.usa.gov/trRECZ
bullet
MCL - Pub Med: Indolent mantle cell leukemia: a clinic-pathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis
bullet
MCL - Weill Cornell, Dr. Martin: Update from ASH 2011: New treatments for mantle cell lymphoma are on the horizon
bullet
MCL -Weill Cornell, Dr. Martin: Update from ASH 2011: Rituximab improves survival in patients with mantle cell lymphoma
bullet
PMBCL - PubMed: Randomized Clinical Trial to Assess the Efficacy of Radiotherapy in Primary Mediastinal Large B-Lymphoma.
bullet
Risk factors - CancerConnect: Still No Clear Evidence That Vitamin D Reduces Cancer Risk
bullet
T-Cell - AHS Education Book Dec 2011: Therapies for Peripheral T-Cell Lymphomas
bullet
T-cell - Cancer: Increasing incidence of enteropathy-associated T-cell lymphoma in  US, 1973-2008.
bullet
T-Cell - Weill Cornell, Dr. Ruan: ASH 2011: New Treatment for T-Cell Lymphoma
bullet
Trends - Annals of Oncology: Diverging trends in incidence and mortality, and improved survival of NHL, in the Netherlands, 1989–2007
bullet
WM - Medpage Today: ASH: Fludarabine Works Best in Rare Lymphoma Trial (Waldenstrom's)
bullet
Zevalin - Medscape: Renewed Interest in Ibritumomab for NHL
bullet
Communications - Vanity Fair: Miss Manners And the Big C
bullet
Communications - USA Today: Online access to notes on patients gets mixed reaction
bullet
Depression - About Lymphoma: Depression in Blood Cancer Patients
bullet
EOL: Washington Post: When terminally ill patients ask how long they have, doctors find it hard to say
bullet
Health - Medscape: Vitamin D and Calcium Supplementation Reduces Fracture Risk 
bullet
QOL - About Lymphoma: Holiday Gift Ideas for the Blood Cancer Patient
bullet
Neuropathy - Medical News Today: What Are The Signs And Symptoms Of Neuropathy?
bullet
Survivorship - Cancer Connect: You’ve Been Diagnosed with Cancer. Now What?
bullet
Survivorship - Cure: The Positive Power of Pets
bullet
Survivorship - Health.com: Study: Cancer Survivors Have Higher Risk of Melanoma
bullet
NYTimes: Computer Scientists Helping to Cure Cancer
bullet
News Medical: GE Healthcare, UCSF collaborate for cord blood project
bullet
CLL - Patient Power: Reflections and Major Developments in CLL from ASH 2011
bullet
NCCN: Asking questions about your cancer video
bullet
NCCN: Video Defining quality in cancer treatment video
bullet
CLL - Medscape: Massive Hunt Finds New Mutations That Drive CLL
bullet
FL - ASH: 2707 Eleven-Year Follow-up of Idiotype Vaccine and DA-EPOCH-Rituximab in Untreated MCL: Correlation with Immune response
bullet
Science Daily: Immune System in Leukemia Patients Repaired Following Chemotherapy
bullet
Preclinical - Prognosis E-news: Targeting tumor resistance mechanism

“All tumors develop resistance to anti-cancer drugs at least partly because their normal tumor suppressor proteins are kicked out of the nucleus.”
bullet
ASCO: Childhood cancer survivors' exposure to chemotherapy, radiation does not increase risk of birth defects in their children
bullet
END OF LIFE ISSUES: KevinMD.com: Saying no to your oncologist is sometimes the right thing to do
bullet
QOL - Medscape: First Study Ever of Long-Term Problems After HCT   (free login required for access.)

“Hematopoietic cell transplant (HCT) offers the only potential for a cure for many hematological cancers; however, although the cancer may be cured by the transplant, the recipients remain at risk for psychological and chronic health conditions.”
bullet
Communications - Salon: How to talk to someone with cancer As the holidays approach, here's what your friends with cancer need to hear -- and never want you to say
bullet
CLL Topic Updates: CAL-101: Latest Update at ASH-2011
bullet
CLL Topics Update: PCI-32765: ASH2011 Update
bullet
Science-Real science vs. fake science:
How can you tell them apart?
bullet
Take as Directed: Pseudoscience Sunday  

David Kroll Phd, friend and advisor to PAL pointed us to several interesting stories today.
bullet
Respectful Insolence: Dr. Burzynski and the cult of personality of the "brave maverick cancer doctor"
bullet
b-cell lymphoma - Medscape: Genetically Engineered T Cells Show Promise in B Cell Malignancies
bullet
CLL - Patient Power: Reflections and Major Developments in CLL from ASH 2011

Dr. Keatings explains why he is more excited than ever before about prospects for progress against CLL
bullet
CLL, relapsed - News Medical: Celgene announces interim results of REVLIMID study on CLL
bullet
CLL, treated with Fludarabine - News Medical: Treatment with leukemia (CLL) patients' own cells may prevent infections after chemotherapy

Question from the front lines: How long do the infused t-cells persist … is the protection from infection long lasting?
bullet
DLBCL, relapsed- Company Press release: Blinatumomab Produces Durable Responses in Patients with Relapsed DLBCL
bullet
Medscape Education: The Role of Hematopoietic Stem Cell Transplant in Follicular Lymphoma
Julie M. Vose, MD; Edward A. Faber, Jr., DO, MS
bullet
FL, Rituxan maintenance – ASH 2011 -
abstract generating high interest:
Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for (previously untreated) Low Tumor Burden Follicular Lymphoma

Results favors Retreat as Needed


Perspectives on:  http://prn.to/vmK5nA  | http://bit.ly/tBhxTM | http://bit.ly/vCABbb
bullet
FL - MPR: Fractionated 90Y-Ibritumomab Tiuxetan Effective as First-Line Therapy for Relapsed Follicular Lymphoma
bullet
FL , origins of - AACR: Study of Two Sisters Sheds Light on Lymphoma Evolution  Also see

“this case gave scientists the unique opportunity to understand the genetic abnormalities that led to follicular lymphoma in both cases.”
bullet
GVHD, SCT - News Medical: Breakthroughs in hematopoietic cell transplantation to be presented at 53rd ASH meeting   | See also

“study reveals that peripheral blood stem cell (PBSC) transplants from unrelated donors are associated with higher rates of chronic graft-versus-host-disease (GVHD) and have no survival advantage when compared to transplants using stem cells taken from the bone marrow.” 
bullet
HL, first treated - Business Week: Study finds that Early Hodgkin Lymphoma Patients Can Skip Radiation Therapy  

Also in NEJM
bullet
HL- HemOncToday: Six cycles of Besc produced 94% CR in Hodgkin’s lymphoma
bullet
HL, QOL - Psycho-Oncology: Posttraumatic stress disorder (PTSD) in survivors of Hodgkin's
lymphoma: prevalence of PTSD and partial PTSD compared with sibling controls
bullet
HL, refractory - Monthly Prescribing Reference: Patients with Relapsed/Refractory Hodgkin's Lymphoma Benefit from VTEPA Salvage Regimen
bullet
HL, relapsed - MPR: Resminostat Has Potential to Offer Substantial Clinical Benefit to Patients with Relapsed or Refractory Hodgkin's Lymphoma
bullet
HL, relapsed - MRP: Patients with Relapsed/Refractory Hodgkin's Lymphoma Benefit from VTEPA Regimen
bullet
HL, survival - Medscape: Long-Term Data Support Chemo Alone in Hodgkin's Lymphoma
bullet
MCL - MPR: R-BAC Effective In Patients With MCL Not Eligible for Intensive Chemotherapy or Autologous Transplant
bullet
MZL - ASH 2011 - Patients with Limited Stage Extranodal Marginal Zone Lymphoma Have Excellent Overall Survival Regardless of Choice of Therapy Type or Observation 
bullet
RIT - Weill Cornell: ASH Conference: Perspective on Radioimmunotherapy as Part of First Line Therapy for Low Grade Lymphoma
bullet
SCT - ASH press release: New methods to improve recovery, survival strategies for patients undergoing transplantation  

Also Medpage Today
bullet
T-cell lymphoma - Marketwatch: Phase II Study of ISTODAX(R) in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: 46% of patients experienced disease control for at least 90 days
bullet
T-cell lymphoma - MPR: Oral Lenalidomide May Have Utility as Maintenance Therapy in Patients with Relapsed/Advanced Cutaneous T-Cell Lymphoma
bullet
Queen's University: New disinfection technique could revolutionize hospital room cleaning
bullet
ACS:  annual report on progress against cancer
bullet
Disability Rights Legal Center: prescription drug assistance
bullet
Science Daily: Important Study Facts Often Missing In Media Reports About Medical Research
bullet
Cancer Research UK: The causes of cancer you can control
bullet
RemedyMD to Launch New Registries at 2011 ASH Annual Meeting Next-Generation Hematology Registries Enable Researchers to Harmonize Data From Diverse Sources and Recognize Undiscovered Patterns
bullet
diagnostics -AM J Hematology: The diagnostic value of biopsy of small peripheral lymph nodes in patients with suspected lymphoma
bullet
Dogs - MNdaily.com: New studies help extend the lives of dogs with cancer
bullet
HL - Blood: Progress in Hodgkin lymphoma: a population-based study on patients diagnosed in Sweden 1973-2009
bullet
MCL - BJH: Rituximab plus HyperCVAD alternating with high dose cytarabine and Methotrexate for the initial treatment of patients with mantle cell lymphoma
bullet
Pixantrone - Boston.com: FDA plans April decision on Cell Therapeutics drug
bullet
Rituxan - Canada Newswire: Ontario funds life-saving treatment for patients with Follicular Lymphoma
bullet
WM - Cancer: Temporal and geographic variations of Waldenstrom's incidence
bullet
Medscape: ASH Preview: A Look at What’s Hot
bullet
ASH reports by ASH

Such as:

SCT - Studies Investigate New Methodologies to Improve Recovery and Survival Strategies for Patients Undergoing Hematopoietic Cell Transplantation

“Although PBSCs from related donors have demonstrated clinical benefits, our trial demonstrates that when these stem cells originate from unrelated donors they are not superior to bone marrow stem cells in terms of patient survival, and they increase the risk for chronic GVHD,” said lead author Claudio Anasetti, MD, Chair of the Department of Blood & Marrow Transplant at Moffitt Cancer Center in Tampa, Fla. “More effective strategies to prevent GVHD are needed to improve outcomes for all patients receiving unrelated donor transplants.”
bullet
Medscape: What's Hot at ASH
bullet
Scientific American: 2011 Nobel Laureate Ralph Steinman Explains Discovery of Cells Used for Cancer Treatment
bullet
The Scientist: Cancer Immunotherapy Pioneer Dies
 
bullet
MSKCC: Excellent videos on Stem Cell Transplants
About transplants (stem cell rescue)
Transplant innovations
bullet
Med News Today: Vitamin D benefits: hope or Hype?
bullet
WSJ: It’s Fine to Compensate Bone-Marrow Donors, Court Says
bullet
Free Thought Blogs: A look at the Burzynski clinic’s publications
bullet
Depression - About.com: Depression in Blood Cancer Patients
bullet
Cancernet: Cancer Rehabilitation

Cancer rehabilitation helps a person with cancer obtain the best physical, social, psychological, and work-related functioning during and after cancer treatment.
bullet
KevinMD: Cancer rehab dramatically improves cancer care
bullet
MSNBC - Cautionary tale: If you don’t hear back about a test result.
bullet
NCI Bulletin: Unexpected Complications: Treating Cancer during Pregnancy
bullet
Neurologica Blog: You too can be a Snake Oil Salesman 

“Next come up with a marketing angle, some target demographic or condition you want to claim to help. Name your product something that suggests it will help with the identified condition. Then simply claim that your product “may” help, or that it will boost the immune system or support the body’s ability to heal from or deal with the condition.”
bullet
Sign On San Diego: Exercise gives cancer patients healthy boost
bullet
U Of Kentucky: Study shows hospice caregivers need routine care interventions
bullet
Coffee - NYTimes: Really? The Claim: Coffee Can Prevent Some Medications from Working
bullet
City Of Hope: New T cell therapy may rid lymphoma patients of cancer
bullet
Health Canal: Researchers Reveal Deletions and Mutations of the FBXO11 gene in B-Cells Contribute to the Development of the Most Common Type of Lymphoma
bullet
NYU: New potential therapeutic target identified for Diffuse Large B-Cell Lymphoma
bullet
Weil Cornell: Weill Cornell Researcher: A Personalized Approach for Targeting Cancer Tumors
bullet
Velcade - Biotech News: Takeda Pulls FDA Application for Expanded Use of Cancer Drug Velcade
bullet
Gastroenterology and Endoscopy News: Lymphoma in Children With IBD Remains ‘Very Rare’ Some Say Risk for Complications From Not Treating IBD Greater Than Risk for Lymphoma
bullet
Aggressive lymphoma - Medscape: Intense Chemo Best for Aggressive Lymphoma
bullet
AIDS/Lymphoma - About.com: The Link Between HIV/AIDS and Blood Cancers
bullet
DLBCL - Lancet Oncology: Prevention of CNS relapse in DLBCL
bullet
Follicular Grades - BJH: Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times
bullet
GvHD - News Medical: Immune system stimulant used as suppressor to treat chronic graft-versus-host disease
bullet
GvHD - The Oncology Report: Low-Dose IL-2 Safe, Effective in Active Chronic GVHD
bullet
GvHD - Medical News Today: New Approach To Graft-Versus-Host Disease Treatment Results In Sustained Improvement For Some Patients
bullet
MCL and Minimal Residual Disease (MRD) - Hematologica: Detection of MRD following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909
bullet
Stem cells - Advances in Hematology: Long-Term Outcome after Autologous Stem Cell Transplantation with Adequate Peripheral Blood Stem Cell Mobilization Using Plerixafor and G-CSF in Poor Mobilizer Lymphoma and Myeloma Patients
bullet
Rituxan - Annals of Hematology: Identification of patients with indolent B cell lymphoma sensitive to rituximab monotherapy
bullet
Blood: The “kiss of death” for follicular lymphoma cells
bullet
Blood: MicroRNA profiles of t(14;18)–negative follicular lymphoma support a late germinal center B-cell phenotype
bullet
Blood: Distribution, function, and prognostic value of cytotoxic T lymphocytes in follicular lymphoma: a 3-D tissue-imaging study
bullet
Cancer Research UK: Hope or false hope? (Article on Burzynski Clinic)
bullet
Classifications - Ash Education: The 2008 WHO classification of lymphomas: implications for clinical practice and translational research
bullet
DLBCL -Medical News Today: Aggressive Lymphoma - Intensive Chemotherapy Significantly Improves Survival And Recurrence In Younger Patients
bullet
Hodgkin’s - Annals of Oncology: Reduced incidence of second solid tumors in survivors of childhood Hodgkin's lymphoma treated without radiation therapy
bullet
MCL - Drugs: Current Status of Targeted Therapies 
bullet
MCL - Hematalogica: Salvage treatment with Lenalidomide and Dexamethasone in relapsed/refractory mantle cell lymphoma
bullet
Side effects - Swiss Med Weekly: Prevalence of symptoms, with a focus on fatigue, and changes of symptoms in outpatients receiving cancer chemotherapy
bullet
Zevalin - News Medical: Zevalin Treatment for NHL becomes simpler with removal of bioscan requirement
bullet
BBC - Cancer survival: Macmillan hails major improvement in surviving different cancers
bullet
Cure: Lifting the Fog (article on chemo brain)
bullet
KevinMD: Grief takes no holidays
bullet
KevinMD: Living with chronic illness during the holiday season
bullet
MDA: Tips for getting through the holidays
bullet
Medical News Today: 'Healthy For The Holidays' 10 Tips For Cancer Survivors
bullet
MSNBC: A cancer survivor's thanks
bullet
CLL Topic Updates: “Incurable, Invisible and Inconclusive”
bullet
Medical News Today: Neurological Impairment Associated With Chemotherapy
bullet
Terra Sigillata: FDA Withdraws Avastin Approval in Breast Cancer - important discussion of endpoints that may also apply to lymphoma studies
bullet
Anaplastic large cell lymphoma - Clinical Oncology News: Study Shows Brentuximab Also Effective in Kids
bullet
Burkitt - AM J Hematol: Intensive short-term chemotherapy regimen induces high remission rate (over 90%) and event-free survival both in children and adult patients with advanced sporadic Burkitt lymphoma/leukemia
bullet
CLL - Modern Pathology: Therapy-related myeloid neoplasms following FCR in patients with CLL/SLL
bullet
Cord blood - Medical News Today: Hemacord - First Cord Blood Product Approved By FDA
bullet
Elderly - BJH: Analysis of very elderly (=80 years) with NHL: impact of functional status and co-morbidities on outcome
bullet
Follicular - Czuczman - Oncology Times: Asymptomatic Follicular Lymphoma: Is ‘Watch and Wait’ Now Passé with the Advent of Rituximab? (Perspective)
bullet
Immunization - Blood: Rituximab blocks protective serological response to influenza A(H1N1) 2009 vaccination in lymphoma patients during or within six months after treatment.
bullet
Pain - Annals Onc: Management of cancer pain: ESMO Clinical Practice Guidelines
bullet
MCL- Bone Marrow Transplant: Potential prolongation of PFS in mantle cell lymphoma after R-HyperCVAD: auto-SCT consolidation or rituximab maintenance.
bullet
T-cell - J Dermatology: Radiation therapy in the management of unilesional primary cutaneous T-cell lymphomas.
bullet
T cell/histiocyte-rich large B-cell lymphoma - J Hematology:  an update on its biology and classification
bullet
Cancer Research UK: Expert Opinion: Professor Fran Balkwill - Discussion on the tumor microenvironment
bullet
Environmental Health News: Research links pesticides - The results strengthen an argument for an environmental link to increased risk for human NHL that is linked to higher levels of organochlorine pollutants.
bullet
EORTC 2011: Genomic profiling for personalized medicine
bullet
USA Today: More targeted treatments key to progress in war on cancer
bullet
USC: Researchers confirm new cancer-causing virus Common cytomegalovirus has central role in salivary gland cancer and possibly other malignancies (MALT) 
bullet
European J Cancer Care: Working while receiving chemotherapy: a survey of patients' experiences
bullet
Healthy Survivorship: Resource on Life after Treatment
bullet
ASCO: Cancer Survivorship - Free Booklet
 
“Your life may be forever changed by cancer. Some people talk about appreciating life more and gaining a greater acceptance of self after their cancer treatment ends. Others become anxious about their health and unsure of how to cope with life’s demands. In some ways, moving from the period of “active treatment” into survivorship is one of the most complex aspects of the cancer experience because it is different for every person."
bullet
Huffington Post: Things to Never Do When Someone Tells You They Have Cancer
bullet
KevinMD: Useful tips when looking for a new doctor
bullet
KSDK.com: Does a family history of NHL put me at greater risk?
bullet
Medscape: Neurofeedback Improves 'Chemo Brain' in Cancer Patients
bullet
Medscape: Consensus Panel From the 2011 Pan Pacific Lymphoma Conference – requires registration and login
bullet
Medscape: Mindfulness Training Can Improve Symptoms, Mood After HSCT
bullet
NYT: THE ETHICIST-The Topic of Cancer – “My boyfriend of one year has been given a diagnosis of terminal cancer”
bullet
Oncology Times - VIEW FROM THE OTHER SIDE OF THE STETHOSCOPE: Managing Uncertainty (Part 2): Serenity
bullet
Oncology Times: A certain uncertainty

Harpham, Wendy S. MD -  Marveling at my remission, Jane asks, Wendy, don't you wish you knew if you were cured? NO! I respond immediately. No? My friend is shocked.  Actually my answer makes perfect sense, since there are only two ways to know if my cancer is gone for good. If the lymphoma recurs, I'll know I wasn't cured. If my cancer is in remission when I die of something else, I'll know I was.
bullet
PsychCentral: 8 Tips to Console a Grieving Friend
bullet
Reuters: Cancer doctors score low on pain management: study
bullet
Burkitts: Medical News Today: Burkitt's Lymphoma Generally Rare But Common In Children In Equatorial Africa
bullet
DLBCL - JCO: Study Gives Slight Edge to R-DHAP for B-Cell Lymphoma Subtype- From Journal of Clinical Oncology
bullet
DLBCL - J Cancer Research, Clinical Onc: How to determine post-RCHOP therapy for risk-tailored adult patients with diffuse large B-cell lymphoma, addition of maintenance rituximab or observation: multicenter experience
bullet
DLBCL- Leuk Lymphoma: Pilot trial of yttrium-90 ((90)Y)-ibritumomab tiuxetan (Zevalin) consolidation following R-CHOP chemotherapy in patients with limited-stage, bulky DLBCL
bullet
Hodgkin's - Blood: Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome
bullet
Hodgkin's - JCO: More Is Not Necessarily Better When Treating Hodgkin's Lymphoma, Joseph M. Connors
bullet
Hodgkin's- JCO: Long-Term Follow-Up Analysis of ABVD versus Stanford V versus MOPP/EBV/CAD in Newly Diagnosed Advanced-Stage Hodgkin's
bullet
Hodgkins- JCO: Eight Cycles of Escalated-Dose BEACOPP Compared With Four Cycles of Escalated-Dose BEACOPP Followed by Four Cycles of Baseline-Dose BEACOPP With or Without Radiotherapy
bullet
Follicular - ASH 2011: CHOP + Rituxan versus
CHOP - Bexxar
bullet
MCL - Blood: Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma
bullet
T-Cell - JCO: Use of Zidovudine and Interferon Alfa With Chemotherapy Improves Survival in Both Acute and Lymphoma Subtypes of Adult T-Cell Leukemia/Lymphoma
bullet
USC: USC microbiologists identify two molecules that kill lymphoma cells in mice.
bullet
Live Science: The Truth About Herbal Supplements for Stress
bullet
Medical News Today: Vaccine Could Prevent Mononucleosis And Cancers Linked To Epstein-Barr Virus
bullet
Medical Press: 'If Hamlet give the first or second hit': The development of Burkitt's lymphoma
bullet
MedPage Today: AACR-FCPR: A Decade of Progress in Cancer Prevention
bullet
BBC: Skin transformed for cancer fight
bullet
BBC: Light 'promising' in cancer fight
bullet
Blood: Editorial: Lymphoma spread? Target CD47-SIRPα! http://bit.ly/uFJJyg abstract
bullet
LA TIMES: Promising cancer therapy is based on epigenetics

John's Hopkins report
bullet
Exercise - Medscape: Treatment for Cancer Patients Should Include It
bullet
Hot flashes - Oncology Times: How Do I Treat it  in Cancer Survivors?
bullet
Immunity - Nobelprize.org: The Body's Secret Army
bullet
Cure: At Diagnosis: Medical Decisions
bullet
Cancer Legal Resource Ctr: Personal Records file - a good idea for all to have, even when we plan on being here a long time
bullet
Cure: Six Side Effects You May Not Expect During Cancer
bullet
Labtests Online: understanding lab tests
bullet
MSNBC: If you're sitting down, you may be increasing your cancer risk
bullet
Science-Based Medicine: Alpha Brain – What’s Wrong with the Supplement Industry
bullet
MSNBC: Is a doctor reading your X-rays? Maybe not Outsourcing radiology can lead to confusion, missed diagnoses and death
bullet
KevinMD: 5 tips to evaluate medical websites
bullet
Clinical Oncology News: Heightened Risk for Lymphomas Found in Celiac Patients Six-fold increased risk should be taken seriously, expert advises
bullet
Medpage: More Links for Obesity, Lymphoma
bullet
Healthnews: Another day, another slew of misleading media messages on observational study http://bit.ly/u4kG3w
bullet
BoingBoing: Three common mistakes in medical journalism
bullet
Respectful Insolence: Oh, no, antiperspirants cause breast cancer! Well, not really...
bullet
Weill Cornell Medical Center: Lymphoma in the News: Cigarette Smoking Associated with Hodgkin Lymphoma  
bullet
Mutations of Mortality: CLL patients refractory to FCR and alemtuzumab (Campath)
bullet
Discover Magazine: From unknown cancer gene to potential cancer drug
bullet
Dana Farber: Research makes it possible to predict how cancers will respond to chemo
bullet
Cell: The Eph-Receptor A7 Is a Soluble Tumor Suppressor for Follicular Lymphoma
bullet
JAMA: Regimen may improve cell transplantation outcomes for older adults with blood, bone marrow cancers http://bit.ly/vDTSGc
bullet
Medical News Today: Genomic Data Leads To New Treatment For Follicular Lymphoma
bullet
Medical Press: Biomarker detects graft-versus-host-disease in cancer patients after bone marrow transplant http://bit.ly/nK6cxO
bullet
CLL Topics Updates: (Almost) Everything You Need to Know About CLL
bullet
CLL - Blood: Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia
bullet
DLBCL - Weill Cornell: PYRAMID: A Personalized Medicine Study in Lymphoma
bullet
Follicular - JCNI: Rituximab Maintenance for the treatment of patients with follicular lymphoma: Systemic Review and Meta-analysis of Randomized Trials
bullet
Hodgkins - Blood: Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group
bullet
Hodgkin's - NEJM correspondence: ABVD versus BEACOPP for Hodgkin's Lymphoma
bullet
Indolent lymphoma - J Clinical Onc: Phase II/III Study of R-CHOP-21 Versus R-CHOP-14 for Untreated Indolent B-Cell NHL: JCOG 0203 Trial
bullet
Infection - Medscape: Protect Outpatient Oncology Patients From Infections
bullet
Lymphoma - AJ Hematology: A multicenter phase II study of darinaparsin in relapsed or refractory Hodgkin-s and non-Hodgkin's lymphoma
bullet
Pediatric Blood and Cancer: Gonadal function and parenthood 20 years after treatment for childhood lymphoma: A cross-sectional study
bullet
US News: Finding Hope in Cancer
bullet
Huffington Post: Are You a Cancer Survivor With "Chemo Brain?" You May Qualify for Accommodations at Work
bullet
NCCN: Paying for cancer treatment
bullet
NCCN: Video: Help with depression during cancer treatment
bullet
NEJM publishes 'The 2010 Dietary Guidelines -- The Best Recipe for Health?
bullet
MSNBC: Cancer patients find help, comfort with 'navigator'
bullet
Cancer Research UK: What should you eat while you’re being treated for cancer?
bullet
PRnewswire: Cleaning for Cancer Launches Series of Surveys to Uncover Unmet Needs in Supportive Services for Cancer Patients
bullet
Psych Central: Using Mindfulness To Alter Your Mood
bullet
Science Based Medicine: Constipation Myths and Facts
bullet
Medical News Today: Planning For Life Beyond A Cancer Diagnosis
bullet
WSJ: Informed Patient: A New Push to Prevent Infections in Cancer Patients
bullet
AOL Healthy Living: '50/50' And Cancer: Can Humor Help Us Heal?
bullet
HemOnc Today: Nutrition and cancer: No magic bullet, but an important aspect of treatment, prevention
bullet
Clinical Oncology: Management of Oral Mucositis in Cancer Patients
bullet
Respectful Insolence: Alternative medicine: The illusion of control
bullet
Mutations of Mortality: CLL - A randomized trial of FA v F.
bullet
Cancer Causes and Control: Sunlight exposure, vitamin D, and risk of non-Hodgkin lymphoma in the Nursesʼ Health Study Sunlight exposure, vitamin D, and risk of NHL in the Nursesʼ Health Study
bullet
CLL TOPIC UPDATES: SOS: Save Our Stem Cells
bullet
KevinMD: Physicians should embrace patient engagement
bullet
Modern Medicine: Denser rituximab no extra help in B-cell lymphoma
bullet
BJCP: Model-based design of rituximab dosage optimisation in follicular lymphoma
bullet
CLL: Mutations of Mortality: CD38 as a Marker in CLL  
bullet
LLS: Archived event and transcript available for September 14, 2011 - NHL: Understanding Your Treatment Options
bullet
Mediterr J Hematol Infect Dis. 2010: Hepatitis C Virus Infection and Lymphoma  (subtypes treated with antiviral therapy)
bullet
PsychCentral:

10 things NOT to say to a depressed person

10 Things You SHOULD Say  
bullet
J Clin Onc: Post-Traumatic Stress Symptoms in Long-Term NHL Survivors: Does Time Heal?
bullet
NYTIMES: A Cancer patient finds little solace in cancer statistics
bullet
NYTIMES: Life as a cancer outlier
bullet
Dr. Wendy Harpham Easy to Forgive
bullet
KevinMD.com: What does explanation of benefits mean?
bullet
MSNBC: Many CA survivors dx'd with Post Traumatic Stress Disorder
 
bullet
Patient Power: An Expert's Perspective: The Changing Landscape of CLL http://bit.ly/poqXwz
bullet
Follicular - Univ. Rochester: Scientists Look to Immune System to Handle Follicular Lymphoma
bullet
Follicular - PubMed: Early steps of follicular lymphoma pathogenesis.
bullet
Medscape: Pitfalls in Lymphoma Pathology
bullet
MZL - Hematology 2008: Marginal Zone Lymphomas: Management of Nodal, Splenic, and MALT NHL http://bit.ly/qp83Hj 
bullet
Hodgkin's -JCO: BEACOPP regimens in Patients With Advanced-Stage Hodgkin's Lymphoma: Final Analysis
http://1.usa.gov/rfHy0c
bullet
Hodgkin's - JCO: ABVD Versus Stanford V Versus MOPP/EBV/CAD in Patients With Newly Diagnosed Advanced- Stage Hodgkin's Lymphoma:  http://1.usa.gov/oV9X2S
bullet
T-cell lymphoma - Am J Hem: Cutaneous T-cell lymphoma: 2011 update on diagnosis, risk-stratification, and management. http://1.usa.gov/nakfo0
bullet
Ann Arbor.com: Cancer researchers drive progress forward, need adequate funding to sustain momentum
bullet
Health News Review Blog: Health care conflict of interest roundup - 3 newsworthy items
bullet
Mutations of Mortality: How to reduce the cost of cancer drugs
bullet
KevinMD: Three major cognitive errors physicians make
bullet
In the Pipeline: Too Many Cancer Drugs? Too Few? About Right?
bullet
CLL - Medical News Today: Chronic Lymphocytic Leukemia Patients' Lives Extended By New Combination Treatment
bullet
Hodgkins: Lymphocyte-Depleted Classical Hodgkin's Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group
bullet
Hodgkins - ASCO: Meta-Analysis of the Association between Smoking and Incidence of Hodgkin's Lymphoma
bullet
Hodgkins: Oncology Stat: PET Scans Key to Less Radiation for Hodgkin's Lymphoma?  Also: http://bit.ly/nKlJCT
bullet
MCL – Cancer, 2010: Durable Responses with the Metronomic (low daily dose) RT-PEPC in Elderly Patients with Recurrent Mantle Cell Lymphoma
bullet
Rituxan - JCO, 2010: Hypogammaglobulinemia - the impact of rituximab maintenance on immune competence
bullet
Neuropathic Pain - Med News Today: (company press release) KRN5500 Demonstrated Significant Decrease In The Intensity Of Neuropathic Pain In Patients With Cancer
bullet
Science Based Medicine: Vitamins and Mortality
bullet
Archives of Internal Medicine: LESS IS MORE Dietary Supplements and Mortality Rate in Older Women The Iowa Women's Health Study
bullet
Oncology Times: Institute of Medicine Workshop Stresses Benefits of Patient-Centered Cancer Treatment Planning
bullet
NY Times: When a doctor becomes a patient
bullet
U Maryland Med Ctr: Sleep Hygiene: Helpful Hints to Help You Sleep
bullet
MailOnline (UK) The sisters who were both diagnosed with cancer within 48 hours of each other... but have now beaten the disease
bullet
NEWS: In Sickness and in Health — Does a Cancer Diagnosis Up Divorce Risk?
bullet
NY Times: Caregiving’s Hidden Benefits
bullet
Science Daily: Cochrane Collaboration Urges Free Access to ALL Data from ALL Clinical Trials
bullet
Scientific American: Molecules to Medicine: Clinical trials for Beginners
bullet
Science Based Medicine: The wrong way to open up clinical trials.
bullet
CLL - In the Pipeline: Interview with Derek Lowe with Paul Howard of the Manhattan Institute on the results of that immunotherapy leukemia (CLL) trial (and on some broader topics around the current state of drug discovery).
bullet
NPR transcript and audio: Shortages Lead Doctors To Ration Critical Drugs
bullet
Ted- Ideas worth Spreading: Battling bad science
bullet
Burkitts: Annals of Oncology: Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis
bullet
CLL: PubMed: Single-agent rituximab in treatment-refractory or poor prognosis patients
bullet
Cutaneous T Cell - Brit J Dermatology: Low-Dose Total Skin Electron Beam Therapy as a Debulking Agent: An open-label prospective phase II study
bullet
DLBCL - Weill Cornell: Update on DLBCL
bullet
Hodgkins: Cohort study evaluates risk of secondary malignancy following chemotherapy treatment for Hodgkin's lymphoma - Highlights the need for regular follow-up care.
bullet
Follicular - NCCN: Guidelines Emphasize Patient Preference as Key to Selection of Maintenance Therapy in Follicular Lymphoma
bullet
Follicular  - Oncology Times: Is ‘Watch and Wait’ Still a Reasonable Strategy for Patients with Asymptomatic, Low-Tumor-Burden Advanced-Stage Disease?
bullet
Neutropenia - Br J Cancer. 2009 September: Prevention of febrile neutropenia: use of prophylactic antibiotics
bullet
Neutropenia - Support Care Cancer. 2010 May: Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?
bullet
Velcade - Biotech News: Takeda Pulls FDA Application for Expanded Use of Cancer Drug Velcade
bullet
Dr. Len's Cancer Blog: Steve Jobs
bullet
DB's Medical Rants: The proper amount of medical care
bullet
NY Times: How to Steer Toward the Path of Least Treatment (general)
bullet
Science Daily: Older Cancer Survivor Population to Increase Substantially
bullet
Respectful Insolence: Steve Jobs, neuroendocrine tumors, and alternative medicine
bullet
Skeptoid- Critical Analysis of Pop Phenomenon: Boost Your Immune System (or Not) -Is "boosting your immune system" for real? Is that possible, and can you really buy it in a bottle?
bullet
Skeptoid- Critical Analysis of Pop Phenomenon: A Lesson in Treating Illness
bullet
Quackwatch: Why You Should Stay Away from Insulin Potentiation Therapy
bullet
Medical News Today: Cancer Patients Can Benefit From Early Detection of Heart Damage Using Echocardiography
bullet
Cure Today: Tell what you're taking (supplements)
bullet
Quackwatch: Questionable Cancer Therapies - A place to look up alternative therapies that may be suggested by well meaning friends/family or stumbled upon on the web
bullet
Rude Introduction to Epidemiology: Every other day, there is report that x, y, or even z causes cancer
bullet
Cure: Managing treatment related diarrhea
bullet
USA.gov - Pre-existing condition insurance plans
bullet
Flu shots?  University Of Michigan: What you need to know
bullet
MSNBC: Cancer Kiss-off: Getting dumped after diagnosis
bullet
"I'm Gonna Love You Through It" - Martina McBride
bullet
MD Anderson: Tips for Coping Through a Long Hospital Stay
bullet
KevinMD: A day in the life of a hospice professional
bullet
NY Times: Navigating the Net Wisely in a Health Crisis
bullet
NeedyMeds.org: Pharmaceutical Patient Assistance programs for lymphoma medications
bullet
NeedyMeds.org and the Lymphoma Research Foundation announce a new source of information on Lymphoma medications and the financial help available for those living with the disease
bullet
CNN: Doctors, listen to your patients - Some thoughts from Abraham Verghese MD, author of a wonderful novel- "Cutting for Stone."
bullet
Live Science: Health Value of Omega 3 Fatty Acids questioned
bullet
Science Daily: Pre-Clinical Research may Prove Promising for the Treatment of Blood Cancer
bullet
Walter and Eliza Hall Institute: Discovery helps explain why chemo causes drop in platelet numbers
bullet
BBC: Cancer cost 'crisis' warning from oncologists
bullet
Weill-Cornell-lymphoma: Oral Chemotherapy Bill Signed into Law in New York State
bullet
NCCN - Video: Talking to patients with a new cancer diagnosis
bullet
Patient Power: Personalized Oncology- Where are we now?
bullet
University of Leicester: Public ignorant about key messages concerning diet and cancer
bullet
Neurologic blog: Well it worked for me
bullet
Mail ONline: Don't give out cancer drugs if it's just to extend life?
bullet
KevinMD: Learning the hard way that there is an art to medicine
bullet
Pharmagossip: Use of cancer drugs questioned - Health News - NHS Choices
bullet
Pharmagossip: NICE blames pharma R&D model for spiraling cancer drug costs
bullet
Science Daily: Drug Companies Must Report Clinical Trial Results, Even When They Won't Lead to a Product, Experts Urge
bullet
UCDAVIS: Drug companies must report clinical trial results, even when they won't lead to a product
bullet
Respectful Insolence: Abraham Cherrix still battling Hodgkin's Five Years Later
bullet
Mother risk: Cancer in Pregnancy: Non-Hodgkin's Lymphoma and Pregnancy
bullet
Medscape: Love the Caregiver as Much as the Patient
bullet
ASCO Expert Corner: The Role of a Tumor Board in Cancer Treatment
bullet
Medscape: Chemotherapy Safe to Give During Pregnancy
bullet
NCCN: Financial Assistance for People with cancer
bullet
The Spokesman Review: Diagnosed with lymphoma, photographer turned lens on himself
bullet
Lymphomation: Tools and Tips from Lymphomation
bullet
ASCO: Anti-nausea drugs: Oncology Clinical Practice Guideline Update
bullet
MALT - MedWire: ‘Excellent’ outcomes after H. pylori eradication for gastric MALT
bullet
Pregnancy - ECCO: Chemo during pregnancy does NOT seem to cause developmental problems in children
bullet
NY Presby-Weill Cornell: Two Important Studies Take Us One Step Closer to Personalized Lymphoma Therapy
bullet
Blood: BeEAM (Be = Bendamustine) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients
bullet
Cancer Care: Update on Lymphoma from the 2011 ASCO Annual Meeting
 
<
bullet
CLL Topic Updates: Bendamustine and Rituxan- relapsed/refractory CLL Bendamustine
bullet
PubMed: Utility of PET scans in mantle cell lymphoma
bullet
PubMed: Physical activity for patients undergoing an allogeneic hematopoietic stem cell transplantation: benefits of a moderate exercise intervention.
bullet
DLBCL- PubMed: Subclassification Has a Prognostic Impact for Response to Salvage Therapy in Relapsed/Refractory DLBCL
bullet
University of Michigan Health System: 10 ways to make better decisions about cancer care -- how to improve communication about risk
bullet
Cure Magazine: Managing Cancer-Related Diarrhea
bullet
KevinMD: How to ask for help when chronic pain or illness strikes
bullet
The Oncologist: Cancer Disparities in the Context of Medicaid Insurance
bullet
WSJ: Getting Lab Results Directly to Patients
bullet
On Healthy Survivorship: Give Food or Money? Discusses an interesting financial aid site
bullet
Dr. Len's Cancer Blog: We Can Treat The Cancer, But Can We Care For The Survivors?
bullet
Rockefeller University Press: Tumor environment keeps tumor-fighting T cells away
bullet
John's Hopkins: Protein 'switches' could turn cancer cells into tiny chemotherapy factories
bullet
Burkitt - Blood: Adult Burkitt leukemia and lymphoma
bullet
CNSL - The Lancet: Prevention of CNS relapse in diffuse large B-cell lymphoma
bullet
CLL - NCCN: Advances in CLL Therapy Offer Prolonged Survival; Toxicities Continue to Plague Elderly Patients
bullet
DLBCL - The Lancet: CHOP-like therapy with or without rituximab in young patients with good-prognosis DLBCL: 6-year results - (MInT) Group
bullet
DLBCL - BJH: Biweekly R-COMP-14 in elderly patients with poor-risk DLBCL and moderate to high ‘life threat’ impact cardiopathy
bullet
DLBCL - Blood: How I treat patients with
bullet
DLBCL - CA: Improving Outcomes
bullet
HODGKIN'S--J Clin Oncol: Lymphocyte-Depleted Classical Hodgkin's Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group.
bullet
HODGKIN'S-- Blood: Phase II study of PVAG in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma
bullet
HODGKINS & ALCL - FDA Approves Brentuximab Vedotin for Hodgkin and Anaplastic Large-Cell Lymphoma
bullet
Indolent lymphoma - Ntl Elec Library for Med: Phase II/III study of R-CHOP-21 vs. R-CHOP-14
bullet
MALT - MedWire:
‘Excellent’ outcomes after H. pylori eradication for gastric MALT
bullet
MALT - Alimentary Pharmacology and Therapeutics: Common misconceptions in the management of H. pylori-associated gastric MALT
bullet
Marginal Zone - Annals of Hematology: Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy
bullet
NCI: Scientists find approach to enhance and prolong immune attack against tumor cells
bullet
PTCL - Leukemia: Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect
bullet
Science Daily: Costly Blood Clots More Common Than Expected Among Cancer Patients
bullet
MSNBC: Many stem cell 'therapies' offer heartbreak
bullet
Respectful Insolence: Quacks do better than medicine!
bullet
Medical News Today: When To Administer Food And Drugs Together
bullet
Examiner.com: Blood Cancer Research Is The Super Highway To Curing Cancer
bullet
Cure Magazine: Açaí Berry’s Effect on Cancer?
bullet
Cure Magazine: Supplement Research in Cancer Lacking
bullet
Cure Magazine: Supplements During Cancer: Help or Hype?
bullet
Scientific American: Drugs from the Crucible of Nature
bullet
Cornell-lymphoma.com: Understanding the Importance of Clinical Trials - Wickerham, Mitchell, Leonard webcast
bullet
Science Daily: Newest Cancer Therapies Multi-Task to Eliminate Tumors
bullet
Cornell-lymphoma.com: Understanding the Importance of Clinical Trials
bullet
Clinical trial: Phase 2 Safety and Efficacy Study of CAL-101 (GS-1101) in Relapsed or Refractory Hodgkin Lymphoma
bullet
Science Daily: Public May Not Be Aware of Important Uncertainties About Drug Benefits and Harms
bullet
KevinMD: Essential tips for medical journalists
bullet
Science Based Medicine: Boost Your Immune System -- What does that mean?
bullet
Terry Hamblin: Is There a Malignant Stem Cell at the Root of CLL?
bullet
Science Quest: Can scientists win the war against cancer?
bullet
Respectful Insolence: Chemotherapy doesn’t work?
bullet
NCCN: How to Maintain Bone health
bullet
Medpage Today: Zofran - Anti-Nausea Drug - Linked to Arrhythmias (irregular heartbeat)
bullet
The Oncologist: Battling the Hematological Malignancies: The 200 Years' War
bullet
Archives of Pathology: Detecting Minimal Residual Disease in Hematologic Disorders
bullet
Market Watch: NCCN Guidelines Emphasize Patient Preference as Key to Selection of Maintenance Therapy in Follicular Lymphoma
bullet
Nature Leukemia: Allo transplant following a reduced-intensity Conditioning regimen in relapsed/refractory peripheral T-cell lymphomas
 
bullet
PAL: Learn about different types of lymphoma treatments
bullet
Blood: Ofatumumab is active in patients with Fludarabine-refractory CLL irrespective of prior Rituxan
bullet
NY Times: An Immune System Trained to Kill Cancer (CLL)
bullet
PubMed: Initial treatment with R-CHOP vs R-miniCEOP for elderly pts with diffuse large b-cell lymphoma
bullet
Medical News Today: Chemotherapy-Induced Neuropathic Pain; The Pain Of Surviving Cancer
bullet
PubMed: Pathology review of outside material: when does it help and when can it hurt?
bullet
CBS NEWS: A bit of lymphoma awareness info
bullet
Cancer Legal Resource Center: Legal Issues in the work place for women with cancer

Part 1
and
  Part 2
bullet
ESMO: A guide for patients with advanced cancer:  Getting the most out of your oncologist
bullet
Medical News Today: Cancer Prevention Tips By Age
bullet
ABC News: NHL Kills Nearly 20,000 a Year -- If you have symptoms of depression, talk with your doctor
bullet
Medical News Today: Why Are Patients Reluctant To Reveal Depressive Symptoms To Their Family Doctor?
bullet
Medical news today: Fish Oil Supplements Can Undermine Chemotherapy effectiveness
bullet
LA Times: U.S. requires health insurers to publicly justify big rate hikes
bullet
Chicago Blood Cancer Foundation: First International  Lymphoma Awareness Forum (radio broadcast) 9/12/11
bullet
Mutations of mortality: Why experts do better (Commentary on CLL Study posted earlier)
bullet
CLL Topic Updates: Does Your Doctor’s Expertise Matter?
bullet
Science Based Medicine: Commentary on BMJ article on Comparative Drug Research
bullet
Medical News Today: New Drugs Should Be Compared To Current Treatments Before Approval
bullet
Science News: Harmless Soil-Dwelling Bacteria Successfully Kill Cancer
bullet
BBC: Cancer drug resistance clue found-may be possible to extend the usefulness of cancer drugs
bullet
Globes Israeli Business Arena: Curetech lymphoma trial succeeds (phase 2, diffuse)
bullet
Nature: A phase II trial of the oral mTOR inhibitor Everolimus in relapsed aggressive lymphoma
bullet
Current Hematologic Malignancy Reports:
PET in T-Cell Lymphoma
bullet
European J Nuclear Med and Molecular Imaging: Early interim 18F-FDG PET in Hodgkin’s lymphoma: evaluation on 304 patients
bullet
JCO: Is There a Role for Bortezomib Combinations in the Management of Patients With Follicular Lymphoma? (Velcade)
bullet
Cornell-lymphoma.com: Upcoming Cancer Care Workshop: Update on Diffuse Large B-cell Lymphoma
bullet
News Medical: Pulitzer photojournalist with lymphoma films his experiences
bullet
Cancer: Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer
 
bullet
Pubmed: Sexual well-being among survivors of NHL
bullet
NY Times: Need Sleep? Stay Out of the Hospital
bullet
NCCN: Taking Charge of Follow Up Care
bullet
CaringBridge: If you haven't seen it, Caringbridge is a great way to keep in touch with family and friends during treatment
bullet
NY Times: When Doctors Become Patients
bullet
PAL updates:
bullet
Lymphoma Studies sponsored by CALGB cooperative group - now called the ALLIANCE
bullet
Cancer-related fatigue - a patient's perspective
bullet
Understanding the lymphatic system
bullet
Treatment support
bullet
Advancing the Informed and Routine Consideration of Clinical Trials
bullet
Treatment-Related Questions for Your Doctor
bullet
Is it Ethical to Require a Tissue Biopsy of Participants in Clinical Trials?
bullet
Words of encouragement for lymphoma patients
bullet
Watchful waiting for indolent lymphomas
bullet
Exercise - just "do it!"
bullet
How indolent Lymphomas are Monitored
bullet
Comments on Programming T-cells to Kill Malignant B-Lymphocytes
bullet
To Port or Not to Port - and related drug administration questions
bullet
PET scan - clinical use
"very little is certain and agreed upon." 
bullet
NPR Radio interview: Delivering Viruses To Try And Kill Tumors
bullet
Cure:
New solutions to boost enrollment are breaking barriers that keep cancer patients out of clinical trials
bullet
Cure:
Abysmal' participation in cancer trials  
bullet
Press release:
Phase 1b/2 Study of TRU-016 in Combination with Rituxan and Bendamustine in Relapsed - Indolent Lymphoma
bullet
NY Times:
Ingredients of Shady Origins, Posing as Supplements
bullet
Cancer.gov:
Investigating Nature's Mysteries for Drug development
bullet
Terra Sigillata:
The best objective herbal medicine information for less than $100 per year
bullet
Oncology Times:
Old vs. New Drug Combinations for Optimal Frontline Therapy for Untreated, Symptomatic CLL
bullet
KevinMD:
The trouble with Dr. Google
bullet
Oncology Times:
MUSINGS OF A CANCER DOCTOR:
The Cost of Drugs
bullet
NY Times:
Cancer Fighting Words
bullet
John W. Sweetenham:
The Role of Radiolabeled Monoclonal Antibodies as Part of the Conditioning Regimen for Stem Cell Transplants (autografts)
bullet
JNCI:
Should Antioxidants Be Avoided During Chemo and Radiation Therapy?
bullet
Pubmed - Leuk Lymphoma:
The Impact of High- Dose Chemotherapy, Autologous Stem Cell Transplantation and Conventional Chemotherapy on Quality of life of Long Term Survivors with Follicular Lymphoma.
bullet
Systematic Review and Meta-Analysis:
Front-line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma
bullet
Pubmed - Leuk Lymphoma:
Improved outcome for very elderly patients with diffuse large B-cell lymphoma in the immunochemotherapy era
bullet
Pub Med:
Maintenance rituximab following chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network.
bullet
Annals of Hematology:
Replacement of conventional doxorubicin by pegylated liposomal doxorubicin is a safe and effective alternative in the treatment of NHL patients with cardiac risk factors
bullet
Blood:
Adding Rituxan to chemo alone as first-line therapy improves over-all survival in elderly patients with Mantle Cell lymphoma
bullet
Blood:
Treating limited stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome
bullet
Pharmalive:
Study Demonstrates Effectiveness of Extracorporeal Photopheresis in Early-Stage Cutaneous T-Cell Lymphoma
bullet
Thomas Jefferson Hospital:
New half-match bone marrow transplant procedure yields promising outcomes http://bit.ly/pG2zuL
bullet
ASH press release:
First injection of cultured red blood cells in human donor
bullet
Cancer:
Disease-specific expertise and survival: Lessons from chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
bullet
NCI:
Cancer Research Now: Natural Products Branch (video)
bullet
Dr Farnsworth:
The Science of Herbs (video)
bullet
PBS NewsHour Video:
Drug Shortages Force Tough Choices for Patients, Doctors
bullet
Medscape:
New Way to Predict the Right Drug for the Right Patient (video)
bullet
MSNBC:
Roundup kills weeds, but does it harm us?
bullet
Cancerandcareers:
Cancer and work
bullet
Cancerandcareers:
Cancer as Inspiration for Career Changes
bullet
ACS:
How to find a support group
bullet
Cancer and Careers:
Resources for Men working with cancer
bullet
MSNBC:
Single and seriously ill - care circles fill in for family
bullet
MSNBC:
Does Gov. Perry's use of an unproven stem cell 'treatment' send wrong message?
bullet
MSNBC:
High price tag for treatment with new cancer drug for anaplastic large cell lymphoma 
bullet
The Week:
The 'amazing' cancer treatment that costs $100,000 A slew of new drugs are powerfully effective at fighting cancer.   
bullet
NY Times:
An Insurance Maze for U.S. Doctors  
bullet
ACS:
Earthquakes, hurricanes, floods, oh my--
Coping With Cancer After a Natural Disaster
bullet
KevinMD.Com:
Are doctors to blame for long waiting room times?   
bullet
Cancer Research UK:  
UK Government releases new cancer patients’ waiting time stats   
bullet
KevinMD:
The entire approach to food based on nutrients is wrong  
bullet
Oncology Times:
Speak Up: 8 Words & Phrases to Ban in Oncology!
bullet
Oncology Times:
Lymphoma Expert Calls for more Focus in Clinical 
bullet
Respectful Insolence:

The complexity of cancer, Part 1

Part 2: Enter the quacks
bullet
Respectful Insolence:
If we can put a man on the moon, why can't we cure cancer?
bullet
CancerNetwork:
Electronic Health Record System Gets Government’s Stamp of Approval
bullet
Medical News Today:
KRN5500 For Chemotherapy-Induced Neuropathic Pain Gets Fast Track Designation By FDA
 
bullet
Medical News Today:
On Trail Of A Treatment For Cancer Of The Immune System
bullet
EmpowHER:
Adcetris Targets CD30 Cells in Hodgkin's Lymphoma
bullet
NCCN:
Ability to Create Better, Safer Medicines Brings Hope to Many With Cancer
bullet
Medical News Today:
Cancer Viral Therapy Attacks Tumors And Does Not Harm Healthy Tissue
bullet
7th Space Interactive:
Subtype Distribution of Lymphomas in Southwest China:  (for our readers in China)
bullet
Lerner Research Institute:
Researchers find new hope for treatment of chronic leukemia
bullet
Youtube:
Learn about the importance of a specific subtype diagnosis in adults with NHL in this video, led by Dr. John Sweetenham.
bullet
ASCO POST:
Combined Therapy Produces Good Outcomes in Primary Testicular Diffuse Large B-cell Lymphoma
bullet
ODAC:
Recommends Accelerated Approval for Brentuximab
bullet
CURE:
New drug for two types of lymphoma  
bullet
NCCN: 
Updated patient info on NHL  
bullet
PubMED:
Interim (mid-treatment) PET Not Justified In DLBCL During First Line Immuno-Chemotherapy
 
bullet
AM J Hematology:
Follicular lymphoma: 2011 update on diagnosis and management
bullet
Cochrane:
Comparison of chemotherapy including escalated BEACOPP vs chemotherapy including ABVD for patients with early unfavorable or advanced stage Hodgkin lymphoma